Sarcopenia in COPD : functional and metabolic implications by Franssen, F.M.E.
  
 
Sarcopenia in COPD : functional and metabolic
implications
Citation for published version (APA):
Franssen, F. M. E. (2009). Sarcopenia in COPD : functional and metabolic implications. Maastricht:
Universitaire Pers Maastricht.
Document status and date:
Published: 01/01/2009
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
 
 
 
 
Sarcopenia in COPD  
  
 
Thesis Frits Franssen_08.pdf   1 21-11-2008   10:21:48
functional and metabolic implications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© F. Franssen, Maastricht 2009  
 
ISBN: 978-90-9023821-0 
 
 
Layout: Tiny Wouters 
Cover: Mascha Hellenbrand 
Production: Datawyse | Universitaire Pers Maastricht 
 
 
 
 
 
 
 
 
The studies presented in this thesis were performed at the Nutrition and Toxicology 
Research Institute Maastricht (NUTRIM), which participates in the Graduate School 
VLAG (Nutrition, Food Sciences, Agro-Biotechnology and Health Sciences), accredited 
by the Royal Netherlands Academy of Arts and Sciences (KNAW) and at CIRO Horn. 
 
 
Printing of this thesis was financially supported by AstraZeneca, Boehringer Ingelheim, 
Chiesi, Danone Research – Centre for Specialised Nutrition, GlaxoSmithKline, 
Grünenthal, Novartis, Nycomed and Pfizer.  
Thesis Frits Franssen_08.pdf   2 21-11-2008   10:21:48
  
Sarcopenia in COPD  
  
 
 
 
PROEFSCHRIFT 
 
ter verkrijging van de graad van doctor 
aan de Universiteit Maastricht, 
op gezag van de Rector Magnificus, Prof. mr. G.P.M.F. Mols 
volgens het besluit van het College van Decanen, 
in het openbaar te verdedigen 
op vrijdag 30 januari 2009 om 14.00 uur 
 
 
door 
 
 
Frits Maria Elisabeth Franssen 
 
Thesis Frits Franssen_08.pdf   3 21-11-2008   10:21:48
functional and metabolic implications 
Promotores: 
 
Prof. dr. ir. A.M.W.J. Schols 
Prof. dr. E.F.M. Wouters 
 
 
Beoordelingscommissie: 
 
Prof. dr. ir. R.P. Mensink (voorzitter) 
Prof. dr. S.D. Anker (Campus Virchow-Klinikum, Berlijn, Duitsland) 
Prof. dr. M.P. Van Dieijen-Visser 
Prof. dr. M.I. Polkey (Royal Brompton Hospital, London, Verenigd 
Koninkrijk) 
Prof. dr. C.D.A. Stehouwer 
Thesis Frits Franssen_08.pdf   4 21-11-2008   10:21:48
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Voor Mara en Marijn 
Thesis Frits Franssen_08.pdf   5 21-11-2008   10:21:48
Table of contents 
Chapter 1 General introduction 9 
 
PART 1 Physiological implications of sarcopenia  27 
 in COPD  
 
Chapter 2 The contribution of starvation, deconditioning and  29 
 aging to the observed alterations in peripheral  
 skeletal muscle in chronic organ diseases.  
 A systematic review 
 
Chapter 3 Arm mechanical efficiency and arm exercise 61 
 capacity are relatively preserved in chronic  
 obstructive pulmonary disease 
 
Chapter 4 Limb muscle dysfunction in chronic obstructive  81 
 pulmonary disease: effects of muscle wasting  
 and exercise training 
 
Chapter 5 Effects of whole-body exercise training on body 101 
 composition and functional capacity in normal- 
 weight patients with chronic obstructive  
 pulmonary disease 
 
Chapter 6 Summary and discussion on part 1 121 
 
PART 2 Substrate metabolism in relation to  137 
 sarcopenia in COPD 
 
Chapter 7 Increased postabsorptive and exercise-induced  139 
 whole-body glucose production in patients with  
 chronic obstructive pulmonary disease 
 
Chapter 8 Whole-body resting and exercise-induced lipolysis  163 
 in sarcopenic patients with chronic obstructive  
 pulmonary disease 
 
Chapter 9 Greater whole-body myofibrillar protein breakdown  179 
 in cachectic patients with chronic obstructive  
 pulmonary disease 
Thesis Frits Franssen_08.pdf   6 21-11-2008   10:21:49
Chapter 10 Perspective: chronic obstructive pulmonary 195 
 disease and obesity: more than adipose tissue  
 mass matters 
 
  Samenvatting 221 
 
 List of publications 235 
 
 Dankwoord 239 
 
 Curriculum vitae 245 
Thesis Frits Franssen_08.pdf   7 21-11-2008   10:21:49
 Thesis Frits Franssen_08.pdf   8 21-11-2008   10:21:49
   
9
 
 
 
 
 
Chapter 1  
General introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis Frits Franssen_08.pdf   9 21-11-2008   10:21:49
Thesis Frits Franssen_08.pdf   10 21-11-2008   10:21:49
 General introduction ⏐11 
General introduction 
Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is defined as a 
disease characterized by progressive airflow limitation that is not 
fully reversible1. The airflow limitation is caused by a combination of 
small airway obstruction (obstructive bronchiolitis) and destruction of 
lung parenchyma (emphysema). Typical presenting symptoms of 
patients with COPD are exertional dyspnoea and exercise intolerance. 
As defined by the Global initiative for chronic Obstructive Lung 
Disease (GOLD) criteria1, conventional staging of severity of COPD is 
based on the degree of chronic airflow limitation measured by the 
forced expiratory volume in one second (FEV1). Cigarette smoking is 
the most important risk factor for the development and progression 
of COPD. It has been estimated that 80-90% of all patients with 
COPD have a history of tobacco smoking2, although less than 25% of 
all smokers develop the disease3. Other identified risk factors for 
COPD are indoor and outdoor air pollutants4, occupational exposures, 
genetic predisposition, female gender5 and cured meat 
consumption6. The current estimated worldwide prevalence of COPD 
GOLD stage II and higher is around 10%7. In 2001, COPD was the 
fifth leading cause of death around the world and it is projected that 
it will be the third leading cause by 20208.  
 
In the classical view of the disease, COPD was considered a 
respiratory disease only, based on the presence of chronic airflow 
limitation9. In the last decades however, important manifestations 
beyond the lungs were described. These extra-pulmonary 
manifestations are also referred to as the systemic effects of COPD10 
and are included in the most recent GOLD definition of the disease1. 
These effects include weight loss and nutritional abnormalities11, 
skeletal muscle dysfunction12, increased risk of cardiovascular 
disease13, hormonal and metabolic disturbances14, osteoporosis15 and 
anxiety and depression16. The new understanding of COPD has 
important clinical implications. In addition to traditional 
pharmacological therapy focused on treating chronic airflow 
limitation, management of COPD now requires a more holistic 
approach. Pulmonary rehabilitation programs aimed at reversing 
some of the extra-pulmonary manifestations of advanced COPD have 
been developed. Significant improvements in exercise tolerance17, 
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nutritional status18 and health-related quality of life19 were achieved 
by pulmonary rehabilitation and this type of non-pharmacological 
therapy is now considered one of the essential components of 
disease management.  
 
While the list of systemic effects of COPD is still growing, the drivers 
of these manifestations are only partially understood. Systemic 
inflammation is recognized as one of the key mechanisms behind 
many of the extra-pulmonary manifestations. In addition to an 
amplified inflammatory response of the respiratory tract to cigarette 
smoke and other irritants, a low-grade persistent abnormal 
inflammatory response is present in the systemic circulation of 
patients with COPD. This reaction is characterized by enhanced 
numbers of leukocytes in the circulation and increased circulating 
concentrations of acute-phase proteins, such as C-reactive protein 
(CRP) and fibrinogen along with acute-phase cytokines like tumour 
necrosis factor-α (TNF-α) and interleukin-6 (IL-6)20. The origin of this 
low-grade systemic inflammation is unclear, although there are 
several possible mechanisms. The lack of correlation between 
inflammatory markers in respiratory samples and values in blood in 
COPD patients, suggests that the systemic inflammatory response is 
not a result of “spilling over” of pulmonary inflammation into the 
systemic compartment21. There is evidence showing that cigarette 
smoking itself can cause systemic inflammation, which persists long 
after quitting22. Also, other organs may contribute to continuous 
systemic inflammation in COPD. Increased plasma TNF-α levels were 
observed after submaximal exercise in patients with severe COPD, 
suggesting that exercising muscle is a possible site of origin23. In 
addition, there’s a growing scientific interest in bone marrow and fat 
mass as potential sources of pro-inflammatory mediators in COPD. 
Although it has recently been suggested that COPD should be 
considered a “chronic systemic inflammatory syndrome”24, there are 
several other potential mechanisms contributing to the systemic 
manifestations of the disease. These include semi-starvation, 
deconditioning, aging and chronic gas exchange abnormalities.   
Body composition in COPD 
Low body weight and involuntary weight loss are well-recognized 
findings in patients with COPD, affecting 10-20% of patients with 
mild to moderate disease25 and around 37% of patients with severe 
COPD26. Traditionally, weight loss was considered an inevitable 
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epiphenomenon of the progression of the disease. In the last 
decades however, it became clear that low body mass index in COPD 
is related to increased mortality risk27, independent of disease 
severity28. In addition, it was shown that low body weight can be 
reversed by nutritional supplementation integrated in pulmonary 
rehabilitation29. Most importantly, weight gain was associated with 
decreased mortality risk in patients with severe COPD29. 
In addition to loss of body weight, which reflects an imbalance 
between dietary intake and energy expenditure, alterations in body 
composition are commonly observed in COPD. In the two 
compartment model, body mass is divided in fat mass (FM) and fat-
free mass (FFM). FFM is further divided in an intracellular 
compartment, reflecting muscle mass and other metabolizing tissues, 
and an extracellular compartment. FFM is commonly used as an 
indirect measure for muscle mass in patients with COPD and there 
are several techniques available to assess FFM in clinical practice30. 
Loss of FFM was observed in a substantial proportion of patients with 
COPD and was not always accompanied by weight loss. The 
prevalence of pulmonary cachexia, defined as weight loss with a 
disproportional loss of FFM, varied between 11% in moderate to 
severe COPD out-patients25 and 26% in severe patients eligible for 
pulmonary rehabilitation. In addition, hidden depletion of FFM was 
observed in 10-15% of normal-weight COPD patients31,32. The latter 
subgroup of patients is also referred to as the sarcopenic phenotype 
of COPD, referring to the age-related decline in muscle mass in the 
elderly33. The loss of FFM is a significant clinical and societal problem 
in patients with COPD, independent of body weight. It contributes to 
skeletal muscle weakness34, exercise intolerance35 and reduced 
health-related quality life (HRQOL)36. The clinical relevance of the 
sarcopenic phenotype was further emphasized by studies showing a 
greater degree of physical impairment and a worse HRQOL in 
normal-weight COPD patients with low FFM compared to underweight 
patients with a relatively preserved FFM32,36. In addition, it was 
shown that FFM-index is an even more important determinant of 
prognosis in moderate-to-severe COPD than BMI31,37. 
Skeletal muscle dysfunction in COPD 
Exercise intolerance is one of the most frequent symptoms in 
patients with COPD. Traditionally, abnormal lung mechanics, 
impaired gas exchange and destruction of pulmonary vasculature 
were considered the pathophysiologic mechanisms behind the 
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reduced ability to sustain exercise in COPD. As part of the current 
concept of COPD as a multi-organ-system disease, there now is clear 
evidence that dysfunction of skeletal muscles contributes to exercise 
intolerance. Reduced quadriceps muscle strength was observed in a 
majority of COPD patients38 and was associated with impaired 
walking distance and maximal oxygen consumption during cycle 
ergometry39. In addition, reduced limb muscle endurance may 
contribute to muscle weakness and exercise intolerance in COPD40. 
Finally, it was suggested that disturbances in muscle energy 
metabolism and decreased work economy in COPD41 contribute to 
increased total daily expenditure42. This might contribute to energy 
imbalance and in the longer-term result in weight loss in these 
patients. 
 
The pathophysiology of skeletal muscle dysfunction in COPD is 
complex and not yet completely understood. Several structural 
alterations were described in skeletal muscle of COPD patients, 
including reduced muscle mass43 and a shift from fibre type I to II in 
vastus lateralis muscle44. Furthermore, reduced activities of oxidative 
enzymes (citrate synthase, succinate dehydrogenase and 3-
hydroxyacyl-CoA dehydrogenase) were consistently detected in 
quadriceps muscle biopsies of moderate-to-severe COPD patients in 
comparison to controls45,46. 
Metabolic alterations in COPD 
The observed structural and functional changes in skeletal muscle of 
patients with COPD indicate a reduced oxidative capacity and 
suggest alterations in cellular energy metabolism in these patients. 
In muscle biopsies obtained in COPD patients at rest, increased 
levels of inosine monophosphate (IMP) and decreased ratios of 
adenosine triphosphate (ATP) to adenosine monophosphate (AMP) 
and phosphocreatine to creatine were observed in comparison to 
controls47, suggesting a compromised muscular energy status in 
these patients. Insufficient energy supply was also demonstrated 
during exercise in COPD in studies using 31P nuclear magnetic 
resonance spectroscopy, which is a technique that allows non-
invasive quantification of energy metabolism in vivo. Increased and 
progressive phosphocreatine depletion and enhanced acidification 
were observed during forearm muscle exercise in COPD patients 
compared to controls48. While skeletal muscle glycolytic enzymatic 
activities are unaffected in COPD, the observed early increase in 
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blood lactic acid during exercise in COPD is related to reduced 
skeletal muscle oxidative capacity49.  
 
Despite marked disturbances in energy metabolism in COPD, limited 
studies investigated intermediary glucose metabolism in this disease 
and available data are inconclusive. Jakobsson et al.50 reported 
normal fasting plasma glucose and insulin levels in a small group of 
advanced normal-weight COPD patients with chronic hypoxia. 
Hjalmarsen et al.51 observed normal fasting glucose, insulin, 
glucagon, cortisol and adrenaline levels in normal-weight 
normoxemic patients, hypoxemic patients and hypoxemic patients on 
long-term oxygen therapy (LTOT), in comparison to controls. 
However, hypoxemic patients on LTOT were characterized by 
impaired glucose tolerance following an oral glucose tolerance test, 
which led to the conclusion that glucose metabolism is altered in 
severely hypoxemic COPD patients. An important point of criticism 
towards this study is the fact that 50% of the LTOT patients and 
none of the other subjects were using oral corticosteroids at the time 
of the test, which are known for their ability to induce 
hyperglycemia. In another study by Jakobsson et al.52 resting post-
prandial hyperglycemia was described in COPD patients with chronic 
respiratory failure receiving LTOT at home in comparison to 
normoxemic patients, suggesting altered glucose metabolism. 
Finally, Goldstein et al.53 described an increased carbohydrate 
oxidation in hypermetabolic malnourished patients with emphysema 
and normoglycemia in comparison to underweight controls. The 
combined results of the available studies suggest some disturbances 
in intermediary glucose metabolism in subgroups of COPD patients 
with hypoxemia or underweight. However, all previous studies 
investigated glucose metabolism by measuring glucose 
concentrations, representing only the result of the balance between 
whole-body glucose production, i.e. gluconeogenesis and 
glycogenolysis and glucose tissue uptake. Glucose kinetics have not 
been studied in COPD.  
 
Although it is well-recognized that fat oxidative capacity is reduced in 
COPD, potential disturbances in intermediary lipid metabolism are 
yet unknown. Triglycerides stored in the adipocytes form the main 
energy reserve of the body. Following hormonal stimulation, 
trigycerides are hydrolyzed to their components free fatty acids 
(FFA) and glycerol and these are released into the systemic 
circulation. This process is called lipolysis and is mainly stimulated by 
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catecholamines. During β-adrenergic stimulation with isoprenaline, 
the increase in plasma FFA was significantly reduced in COPD 
patients with a sarcopenic phenotype, compared to controls with 
comparable BMI but significantly lower fat mass54. Furthermore, the 
increase in energy expenditure during β-adrenergic stimulation was 
blunted in the sarcopenic patients54. These results suggest that an 
impaired whole-body lipolytic rate may play a role in the 
pathophysiology of the sarcopenic phenotype in COPD, characterized 
by relatively or absolutely increased fat stores. In other chronic 
conditions, disturbances in adipocyte lipolysis have been associated 
with alterations in body fat mass. In human obesity, impaired 
adipose tissue lipolytic response is recognized as an important factor 
in the development and maintenance of increased fat mass55,56, while 
increased lipolysis is one of the possible mechanisms behind cachexia 
in cancer patients57.  
 
Insulin plays a central role in the regulation of intermediary 
metabolism. It controls the level of blood glucose by its inhibitory 
effect on glucose production, affecting both glycogenolysis and 
gluconeogenesis58. In addition, insulin increases the rate of glucose 
uptake from the blood into skeletal muscle cells and adipocytes by 
increasing the number of glucose transporter proteins 4 (GLUT4) at 
the plasma membrane. Insulin resistance is defined as a state in 
which a given concentration of insulin is associated with a subnormal 
glucose response59. It is a central component of the metabolic 
syndrome, which is a common basis of cardiovascular disease and 
reduced insulin sensitivity commonly occurs in chronic disease, such 
as chronic heart failure60 and chronic liver disease61. Some recent 
studies suggested that resistance of glucose metabolism to insulin 
action is present in a number of patients with COPD as well62,63. 
Possible underlying mechanisms and clinical consequences of insulin 
resistance in COPD are currently unknown. In addition to effects on 
intermediairy glucose metabolism, insulin is considered the most 
important inhibitor of lipolysis64 and it is a growth factor for many 
cells.  
Based on the divergent physiological effects of insulin in humans, it 
is hypothesized that disturbances in insulin function are related to 
several of the systemic manifestations of COPD, including nutritional 
depletion, alterations in muscle energy metabolism and increased 
cardiovascular mortality. Indeed, available evidence suggests altered 
insulin concentrations in patients with COPD63,65, but the clinical 
importance is yet unknown.   
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Despite recent advances in the identification and understanding of 
the extra-pulmonary manifestations of COPD, numerous questions 
remain unanswered. The distribution of skeletal muscle dysfunction 
and exercise intolerance between lower and upper limbs is yet 
unknown, since most studies focused on the lower extremities. 
Information on upper limb performance may contribute to the 
understanding of the etiology of skeletal muscle dysfunction, 
disturbed energy metabolism and functional limitation in COPD. 
Furthermore, better characterization of lower and upper extremity 
functioning will enable development or optimization of non-
pharmacological and pharmacological therapeutic strategies in these 
patients.  
Also, the relationship between body composition and various aspects 
of muscle function, such as strength, endurance and mechanical 
efficiency is only partially understood. It is essential to gain insight 
into the mechanisms behind muscular dysfunction in order to 
develop specific exercise training and other anabolic interventions.  
Potential adaptations in glucose metabolism, lipolytic rate and insulin 
homeostasis are currently unexplored in COPD. These might 
contribute to or result from disturbances in body composition, 
skeletal muscle function and energy metabolism or various other 
systemic manifestations of the disease. The clinical consequences of 
alterations in intermediary metabolism remain to be unravelled as 
well.    
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Aims of the thesis 
In order to increase our understanding of the etiology of skeletal 
muscle dysfunction and develop specific interventions aimed at 
restoring muscle function, the first aim of this thesis was to study the 
distribution of skeletal muscle dysfunction between lower and upper 
extremities in patients with COPD. Historically, most studies focused 
on skeletal muscle dysfunction of the lower limbs, while limited 
information is available about muscle performance of the upper limbs 
in these patients. A low FFM and disturbances in muscle energy 
metabolism contribute to skeletal muscle dysfunction in COPD 
patients and heterogeneity in the distribution of these factors 
between different muscle groups may result in clinically important 
locoregional differences in muscle function. Therefore, various 
features of skeletal muscle function, including strength, endurance 
and mechanical efficiency, were assessed and the relationship with 
alterations in FFM was studied in detail in these patients. 
The impact of disturbances in muscle energy metabolism and skeletal 
muscle function on intermediary metabolism in COPD is yet 
unknown. Furthermore, alterations in glucose metabolism, lipolytic 
rate and myofibrillar protein turnover may contribute to a shift in 
body composition towards low FFM in patients with COPD. Therefore, 
investigation of substrate metabolism using stable isotope tracer 
methodology in relation to alterations in body composition in patients 
with COPD was the second aim of this thesis.  
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Outline of the thesis  
The thesis is divided in two parts. First, the results of the studies 
focused on skeletal muscle function and exercise capacity are 
presented (chapter 2-5), followed by a summary and discussion on 
this subject (chapter 6). Secondly, the studies on metabolic 
alterations in COPD are presented (chapter 7-10). 
Physiological implications of sarcopenia in COPD 
Similarities in skeletal muscle function, morphology and energy 
metabolism in patients with COPD, chronic heart failure and chronic 
renal failure were systematically reviewed in chapter 2. Impaired 
skeletal muscle function, reduced oxidative capacity and a shift 
towards more glycolytic muscle fibre types are well-recognized 
features of these chronic conditions. Also, the contribution of semi-
starvation, deconditioning and the aging process to the observed 
alterations in chronic disease conditions was investigated in this 
chapter.  
Chapter 3 and 4 of the thesis focused on potential differences in leg 
and arm muscle function and exercise capacity in COPD patients and 
controls.  
Increased energy expenditure related to physical activity had been 
reported in patients with COPD. In accordance with this observation, 
reduced mechanical efficiency of lower extremity exercise had been 
observed. In chapter 3, mechanical efficiency and peak exercise 
capacity of upper limb exercise were compared to those of lower limb 
exercise. The results indicate that in contrast to the lower 
extremities, mechanical efficiency and exercise capacity of the upper 
extremities are relatively preserved in COPD.  
Impaired quadriceps muscle strength and endurance had been 
consistently reported in COPD, while conflicting information was 
available on the function of other peripheral muscle groups. 
Therefore, chapter 4 focused on the comparison of quadriceps and 
biceps muscle function in COPD patients and controls. Furthermore, 
the influence of FFM and the effects of whole-body exercise training 
on quadriceps and biceps muscle strength and endurance were 
studied in this chapter. The results of chapter 4 suggest that loss of 
muscle strength is equally distributed between quadriceps and biceps 
muscle in COPD and is mainly determined by the amount of FFM.  
FFM is related to functional capacity in COPD. Moreover, reduced FFM 
is associated with increased mortality risk. Most studies investigated 
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alterations in body composition and potential effects of anabolic 
interventions on exercise tolerance and survival in malnourished 
COPD patients. In chapter 5, the anabolic effects of whole-body 
exercise training were studied in normal-weight COPD GOLD III-IV 
patients. Also, the relationship between changes in body composition 
and improvements in muscle function and exercise capacity were 
analysed. The results indicate that exercise training per se is able to 
induce an anabolic response in these patients, that is only partly 
related to functional improvements. 
Substrate metabolism in relation to sarcopenia in COPD 
Reduced skeletal muscle oxidative capacity and chronic hypoxemia 
may affect intermediary glucose metabolism in COPD. In chapter 7, 
whole-body resting and exercise-induced glucose kinetics were 
measured in COPD patients and controls using stable isotope tracer 
methodology. Since body composition and glucose metabolism are 
interrelated, potential differences in whole-body glucose production 
between normal-weight and underweight patients were explored. In 
addition, insulin sensitivity was estimated using the homeostatic 
modelling technique. The results indicate that glucose production is 
increased in COPD, especially in underweight patients. In normal-
weight patients with preserved FFM, alterations in insulin sensitivity 
are found. 
A blunted lipolytic and thermogenic response to β-adrenergic 
stimulation had been observed in sarcopenic COPD patients and 
might contribute to a relative preservation of fat mass in the 
sarcopenic phenotype. Chapter 8 focused on possible differences in 
whole-body resting and exercise-induced lipolytic rate between 
patients with normal body weight and preserved fat mass, 
underweight patients and matched healthy controls. The results of 
this chapter show that the contribution of an altered lipolytic rate to 
the sarcopenic phenotype is unlikely, although the regulation of 
lipolysis seems altered in COPD subgroups. 
Disturbances in skeletal muscle protein metabolism may also 
contribute to loss of FFM in cachectic or sarcopenic patients with 
COPD. Chapter 9 investigated potential differences in myofibrillar 
and whole-body protein breakdown between COPD patients and 
controls with a normal body weight and FFM and COPD patients with 
a low body weight and FFM. The study shows that cachexia in COPD 
is associated with increased myofibrillar protein breakdown, while 
whole-body protein turnover is not different between groups.     
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In this thesis, physiological and metabolic implications of a 
sarcopenic COPD phenotype are  described. These patients are 
characterised by loss of FFM in the presence of a normal body 
weight, resulting in a relative or absolute increase in fat mass. There 
is growing evidence suggesting that abundance of fat mass is related 
to a systemic inflammatory state and metabolic disturbances. In 
chapter 10 the relationship between COPD and obesity was 
reviewed. In addition, it is hypothesized that alterations in adipose 
tissue function in early stage COPD patients with abundant fat mass 
may contribute to systemic inflammation, loss of FFM and insulin 
resistance in COPD.  
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Abstract 
Muscle weakness and early fatigue are common symptoms of chronic organ diseases, 
like chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF) and 
chronic renal failure (CRF). It is becoming more and more clear that symptom 
intensities and exercise intolerance are related to muscle wasting and intrinsic 
alterations in peripheral skeletal muscle in these patient populations, while 
correlations with parameters of organ functioning are poor. Also, changes in muscle 
structure and function in COPD, CHF and CRF show much resemblance. 
Semistarvation, reduced physical activity and aging are external factors possibly 
confounding a direct relationship between the primary organ impairments and 
alterations in peripheral skeletal muscle and exercise capacity. Reducing the catabolic 
effects of the various contributing factors might improve muscle function and health 
status in chronic disease. In this review, we present a systematic overview of human 
studies on alterations in skeletal muscle function, morphology and energy metabolism 
in COPD, CHF, CRF and we compare the results with comparable studies in anorexia 
nervosa, disuse or inactivity and aging. Unravelling the relative contributions of these 
external factors to the observed alterations in the various diseases may contribute to 
targeted intervention strategies to improve muscle function in selected groups of 
patients. 
Thesis Frits Franssen_08.pdf   30 21-11-2008   10:21:50
 Muscular alterations in chronic organ diseases⏐31 
Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by 
exertional dyspnoea and impaired exercise capacity. Research has 
shown that these symptoms are not only caused by airflow 
obstruction and loss of alveolar tissue. Skeletal muscle weakness 
contributes substantially to the complaints of patients with COPD. 
This skeletal muscle dysfunction can be related to loss of muscle 
mass and to observed intrinsic alterations in skeletal muscles of 
patients with COPD. Although the primary organ impairment in 
patients with chronic heart failure (CHF) is clearly different from that 
in COPD, the effects of this disease on muscle function and exercise 
capacity show much resemblance, as was reviewed by Gosker et al.1. 
Muscle weakness and fatigue have also long been recognized as 
presenting symptoms in patients with chronic renal failure (CRF). The 
number of studies investigating alterations in muscular function and 
structure in patients with CRF however is limited.  
Besides disease related mediators such as inflammation, hypoxemia 
and acidosis, skeletal muscle function in these diseases may also be 
affected by external factors, closely related to the process of the 
disease and potentially confounding the relationship between the 
organ impairment and skeletal muscle and exercise performance. 
Reduction of physical activity, (semi)starvation and age-related 
changes in body composition and function are examples of these 
comorbid factors. The effects of these factors on human skeletal 
muscle and exercise capacity have been subject of many studies in 
the past. 
Since muscle wasting is related to symptom intensity, functional 
capacity and quality of life, treating the wasting process has been 
associated with beneficial effects for the patients. At present, various 
strategies are available to promote anabolism, including exercise 
training, nutritional suppletion and pharmacological anabolic 
stimulation. To determine the best individual treatment, more insight 
is needed into the relative contributions of identified factors that may 
decrease anabolism or increase catabolism. 
In this review, we present an overview of clinical studies that have 
investigated alterations in peripheral skeletal muscle function, 
muscle morphology and energy metabolism in chronic obstructive 
pulmonary disease, chronic heart failure and chronic renal failure. In 
order to get more insight in the pathophysiology of muscle 
dysfunction in these diseases, the results of these studies are 
compared with findings from human studies on alterations in skeletal 
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muscle which occur during anorexia nervosa, disuse and 
deconditioning and sarcopenia. The contribution of these secondary 
conditions will be discussed, as well as controversies in the results of 
various studies. The results of studies on the defined comorbid 
factors will be presented first. Also, future fields of research and 
clinical implications will be highlighted. 
Methods 
General 
Only peer reviewed publications from the medical literature were 
included. MEDLINE database was searched for relevant original 
articles and reviews. Also, references from included articles were 
studied. Only results from studies in humans were analysed. 
Muscle function 
Skeletal muscle strength and fatigue were used as measures for 
skeletal muscle function. Both studies in which muscle function was 
determined by voluntary contractions as well as studies that used 
electrical stimulation to evoke muscle contractions were included. 
Both isometric as well as isokinetic test protocols have been used in 
order to study muscular endurance. 
Muscle morphology and energy metabolism 
Results of biopsy studies were analysed in order to assess 
morphologic alterations in skeletal muscle. Changes in the number, 
size and distribution of the different muscle fibre types are presented 
(Table 2.1). Also, skeletal muscle capillarization is an important 
factor for normal muscle function. Since there are many 
morphometrical methods to assess the capillary bed, it is difficult to 
interpret the results of the different studies. The capillary density 
(the number of capillaries per mm2) (CD) and capillaries per fibre 
ratio (C/F ratio) are global indices of capillarization. Other indices of 
capillarity are the number of capillary contacts per muscle fibre (CC) 
and the number of capillary contacts per muscle fibre in relation to 
the type and area of muscle fibre (CCFTA). 
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Muscle energy metabolism 
Studies in which the activities of enzymes involved in muscle energy 
metabolism were investigated in muscle biopsies are summarized 
(Table 2.2). Citrate synthase (CS), succinate dehydrogenase (SDH), 
cytochrome-c oxidase (COX) and β-hydroxyacyl CoA-dehydrogenase 
(HAD) were used as measures for oxidative metabolism. The 
activities of phosphofructokinase (PFK), lactate dehydrogenase 
(LDH), hexokinase (HK) and myokinase (MK) were used as indicators 
for glycolytic muscle metabolism. 
31P Magnetic resonance spectroscopy 
Results from studies using 31P magnetic resonance spectroscopy (31P 
MRS) are discussed and presented in Tables 2.3-2.5. With 31P MRS 
direct and noninvasive measurement of bioenergetics in skeletal 
muscle is possible at rest, during exercise and during recovery from 
exercise. Particularly in dynamic experiments metabolic abnor-
malities can be characterized2. The principal signals detected by the 
apparatus in the tissues are the high energy phosphates, including 
phosphocreatine (PCr), inorganic phosphate (Pi) and the ATP 
spectrum, and intracellular pH. Many different indices of muscle 
energy status are used. The ratio PCr/(PCr+Pi) and ATP 
concentration however are most frequently used. When this ratio is 
high, so is the energy status. Depletion of phosphocreatine results in 
lowering of the ratio. Changes in the PCr/Pi or PCr/(PCr+Pi) are 
dependent on aerobic metabolic rate and decreases indicate a lower 
use of aerobic metabolism. The recovery rate of phosphocreatine 
following submaximal exercise is a measure for mitochondrial 
capacity2. 
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Results 
Anorexia nervosa 
Muscle function 
Anorexia nervosa (AN) is a pertinent model in which to study the 
effects of chronic semistarvation on skeletal muscle, without any 
confounding inflammatory process. During early stages of the 
disease the reduced intake of carbohydrates and fats leads to a 
negative energy balance and a depletion of mainly fat mass. As 
undernutrition continues, protein-energy malnutrition and loss of 
skeletal muscle mass occur3.  
Muscle dysfunction occurs in patients with anorexia nervosa3,4, with 
proximal muscle weakness being an important complaint3,5,6. The 
loss of upper limb muscle mass and function tends to be equal to or 
greater than that of the lower limb7,8. McLoughlin et al.3 reported 
that in female patients with severe self-induced weight loss, the 
mean voluntary contraction of the quadriceps muscle was 
significantly lower compared to healthy controls. Also, in the patient 
group, the force was significantly less than the predicted values for 
body weight. This might indicate that besides loss of muscle mass, 
other changes occur in the muscles of patients with AN. Russell et 
al.4 tested the isometric endurance of the adductor pollicis muscle 
with continuous electrical stimulation of the ulnar nerve and found a 
markedly increased fatigue in patients with anorexia nervosa 
compared to controls, which returned to normal after four weeks of 
oral refeeding.  
Muscle morphology 
Table 2.1 summarizes several studies on the effects of anorexia 
nervosa on skeletal muscle fibre. The primary muscle pathology in 
anorexia nervosa is characterized by muscle fibre atrophy3,9-11 with 
especially type II fibres being affected. The relative proportions of 
type I, type IIA and type IIB muscle fibres in anorexia nervosa seem 
to be within the normal limits3,9,10, although both increased10 as well 
as decreased9 proportions of type I muscle fibres have also been 
reported.  
Only one study investigated muscle capillarization in patients with 
AN10 but found no change. 
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Muscle energy metabolism 
Alterations in activities of enzymes involved in muscular metabolism 
are summarized in Table 2.2. Decreased activities of enzymes 
involved in glycolytic and mitochondrial pathways have been 
reported in muscle biopsies from patients with anorexia nervosa10,11, 
with glycolytic capacity being affected the most10.  
We only found one study using 31P magnetic resonance spectroscopy 
to investigate the changes in muscle metabolism in malnourished 
patients. Thompson et al.12 found significantly lower PCr/ATP and 
Pi/ATP ratios, but no change in Pi/PCr in patients compared to 
controls. Among the studied subjects however were elderly patients 
and persons with AIDS. 
Inactivity 
Muscle function 
The effects of reduced physical activity and disuse on skeletal muscle 
have extensively been investigated in several experimental 
approaches in both animals as well as humans. These models include 
immobilization by casting, prolonged bed rest, non-weight bearing 
and limb suspension, and (simulated) microgravity. All these 
situations result in numerous adaptive changes in skeletal muscle 
and in muscular dysfunction. It is however difficult to compare the 
results of the various models on skeletal muscle, since the degree of 
atrophy is influenced by, among other factors, duration of 
immobilisation, length at which a muscle is immobilized, degree of 
disuse compared to normal usage and muscle pre-existing fibre type 
distribution13. 
The loss of muscle strength after a period without weight-bearing14,15 
or after immobilization16 is marked, and is a result of reduced motor 
neuron activity and muscle wasting. The amount of muscular atrophy 
is most pronounced during the early part of immobilization17. Muscles 
with the greatest decrease in utilisation are preferentially affected7,18. 
Upper limb muscles seem to experience fewer loss of muscle 
strength compared with lower limb muscles19. Moreover, extensor 
muscle groups experience greater decrease in strength than do the 
corresponding flexor muscles15,19-21. From this, it can be concluded 
that antigravity muscles that cross a single joint and contain a large 
proportion of slow fibres (soleus, vastus medialis) are most 
vulnerable to immobilisation-induced atrophy, followed by muscles 
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that cross multiple joints (erector spinae, rectus femoris, 
gastrocnemius)13.  
Four weeks of simulated microgravity resulted in a significant 
increase in fatigability of ankle plantar and dorsal flexors, with the 
first being more affected by this period of bed rest21, again indicating 
that antigravity muscles are preferentially affected in this condition. 
The decrease in muscle endurance is less pronounced during 
voluntary sustained contraction than during electrically-sustained 
contraction, indicating a role for neural adaptions in the process of 
immobilization16. However, in a case study, Duchateau et al.22 
reported that fatigability of triceps surae muscle was not affected 
after five weeks of bed rest.  
Muscle morphology 
Table 2.1 summarises several studies on the effects of reduced 
activity on skeletal muscle fibres. Loss of muscle mass and muscular 
atrophy are the most evident consequences of muscle disuse, with 
type I and type II fibres both being subject to atrophy20,23-25. Slow-
twitch fibres however seem to be more susceptible to disuse than 
fast-twitch fibres13,18. According to several studies, the percentage of 
muscle fibres expressing myosin heavy chain (MHC) type I is found 
to be decreased during inactivity and detraining13,24,26,27, whereas the 
percentage of fibres expressing MHC type II was increased. Others 
however did not confirm this change in muscle fibre 
distribution20,23,25. 
The results of studies on the influence of reduced physical activity on 
muscle capillarization are conflicting. Saltin et al.28 reported a 
significant fall in capillary density during an 8-12 days period of bed 
rest. In the same study fibre size fell even more, resulting in an 
increase in the number of capillaries per muscle fibre and a reduction 
in diffusion distance. Hikida et al.23 investigated alterations in 
capillarization in biopsies from vastus lateralis muscle and soleus 
muscle before and after 30 days of six degrees head-down bed rest 
and reported a significant decrease in capillary to fibre ratio in soleus 
muscle, but not in vastus lateralis muscle. Klausen et al.24 reported a 
decrease in capillary to fibre ratio and in the number of capillaries 
contacts per fibre (CC) during eight weeks of detraining after eight 
weeks of training. Fibre area per CC was unchanged in this study. 
Finally, Hather et al.20 did not find a significant change in capillary to 
fibre ratio and the number of capillaries surrounding the different 
fibre types after 6 weeks of left unilateral lower limb suspension. 
Capillary density increased by 15% and the number of capillaries per 
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unit of type I and IIA fibre also increased significantly, as a result of 
fibre atrophy. 
Muscle energy metabolism 
Changes in activities of enzymes involved in energy metabolism as a 
result of decreased activity are shown in Table 2.2. There is 
convincing evidence of a reduction in muscle oxidative capacity, 
while glycolytic enzymes activities are maintained23,24,29,30. 
Besides one case study31, the influence of immobilization on muscle 
metabolism using magnetic resonance spectroscopy has not been 
systematically investigated. 
Aging 
Muscle function 
A decrease in lean body mass, mainly muscle mass, and an 
accumulation of intra-abdominal fat mass are both characteristics of 
the aging process and are referred to as sarcopenia32. The age-
related loss in muscle strength has been recognized for a long time. 
Until the mid-40s, muscle function is generally thought to be 
preserved, after which there is a deterioration of lean tissue and 
strength by about 5% per decade33,34. The loss of function is more 
pronounced in the lower than in the upper extremity, but it remains 
unclear if this is a result of an inherent biological difference, or a 
confounding effect of a greater change in habitual physical activity of 
the leg compared with the arm muscle groups. 
Most studies on age-related effects on skeletal muscle function have 
focused on muscle strength rather than endurance. Available human 
studies however seem to indicate that muscle endurance is 
maintained during the normal aging proces34-36. 
Muscle morphology 
Besides the loss of muscle mass with aging other intrinsic 
differences, including reduced activity of motor neurons37, are 
present in muscles of older compared to younger persons, which 
might affect muscle function. The results of several studies on the 
effects of aging on skeletal muscle fibre are summarized in Table 
2.1. With advancing age, both the number and the size of muscle 
fibres seem to be affected37-40. The decrease in total number of 
muscle fibres involves both fibre types41 and might be greater in type 
II muscle fibres. The muscular atrophy affects both types of muscle 
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fibres, with a preferential loss of fast-twitch fibre size28,34,40-47. Some 
studies suggest that within the group of type II fibres, especially 
type IIX fibres are subject to atrophy with aging45,46. In contrast to 
these results, Aniansson et al.48 reported a significant increase in 
type I and mainly type II fibre areas in vastus lateralis muscle, with 
biceps brachii muscle showing the same tendencies. This was 
interpreted as a compensatory adaption for the loss of motor units 
with aging. With respect to changes in muscle fibre distribution with 
aging both increase in the percentage of type I fibres34,43,44,49,50 as 
well as no age-related redistribution41,42,45-48,51-53 or even a decreased 
proportion of type I fibres54 have been reported. In accordance with 
the greater age-related loss of muscle function in the lower extremity 
extremity compared with the upper extremity, several studies found 
the morphologic and histopathological alterations in biopsies from 
the biceps brachii muscle to be less than in those from vastus 
lateralis muscle28,45,46. 
In 1979 Larsson et al.34 stated that besides the decline in type II 
fibre area, also age and fat free mass were independent variables 
correlating with the decrease in isometric and dynamic muscle 
strength during aging. They suggested that besides the alterations in 
muscle fibres other factors, such as reduced blood flow and 
metabolic abnormalities, would be responsible for this decrease.  
The effect of increasing age on muscle capillarization is still disputed. 
Although some authors stated that muscle capillarization is not 
altered45,46,53, other studies don’t support this point of view47,54. 
Frontera et al.54 found a significant reduction in capillary-to-fibre 
ratio in a 12 year follow up of 12 healthy men with an initial age of 
65 years. They stated that this might be due to the decline in 
proportion of type I fibres of these men, which are known to have a 
higher capillary-to-fibre ratio compared with type II fibres. The 
reduction in capillary-to-fibre ratio was confirmed by Coggan et al.47, 
who examined muscle biopsies from 20 older and 20 younger 
subjects. In this study capillary density and the number of capillaries 
in contact with each muscle fibre were also all significantly lower in 
older than in younger subjects. 
Muscle energy metabolism 
Changes in muscle energy metabolism with aging are reported in 
Table 2.2. Some studies reported a trend towards a reduction in the 
activity of oxidative and glycolytic systems44,47,48,52, although others 
could not confirm this45,46,51. Aniansson et al.46 reported higher 
activities of oxidative enzymes in the vastus lateralis muscle 
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compared to the biceps brachii muscle, whereas glycolytic enzymatic 
activities were higher in the latter muscle. This could partly be 
explained by the relative preservation of muscle fibre size in the 
upper extremity. 
Taylor et al.55 found no differences in high energy phosphates and pH 
at rest, during handgrip exercise and during recovery from exercise 
in a 31P MRS study comparing muscle energetics of healthy 
volunteers of different age groups. This suggests that the aging 
process does not affect the muscle’s metabolic capacity. 
Chronic organ disease 
Muscle function  
Many patients with COPD experience weakness of peripheral skeletal 
muscles56-58 and loss of muscle mass. Bernard et al.7 reported that in 
COPD the relative reduction in isokinetic quadriceps strength was 
greater than that of the muscles of the shoulder girdle. Also, 
Gosselink et al.56 found that the isometric quadriceps force, 
expressed as a percentage of predicted, was lower compared with 
handgrip strength. Although the methods for determining strength of 
upper and lower limbs differed in these studies, the results indicate 
that in COPD muscle function of the upper limb might be relatively 
preserved. 
The results of studies on muscular endurance capacity in patients 
with COPD are conflicting. Zarrata-Hartmann et al.59 reported that 
the isometric endurance of vastus lateralis muscle was normal in a 
group of chronic hypoxemic patients. In the same study however, 
static endurance of adductor pollicis muscle (mainly oxidative 
metabolism) and diaphragm were reduced in patients compared to 
normals. Short term oxygen breathing had a beneficial effect on 
endurance in adductor pollicis muscle. Newell et al.60 found no 
difference in static endurance of elbow flexors between patients with 
COPD and controls. Serres et al.61 found an impaired endurance of 
vastus lateralis muscle during repeated dynamic contractions in 
patients with COPD, compared with normal subjects. Only one 
study58 evaluated dynamic endurance of the upper and lower 
extremities in COPD and found that endurance of the muscles of the 
upper arm was preserved in comparison to the quadriceps muscle.  
Results of studies on muscle weakness in patients with CHF show a 
generalized loss of peripheral muscle strength compared to normal 
subjects57,62,63. Muscle endurance is also negatively affected in heart 
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failure63,64. Minotti et al.64 and Sunnerhagen et al.63 reported a 
reduction in both isometric as well as isokinetic quadriceps 
endurance in CHF, compared to controls. Buller et al.65 found that 
isometric muscle endurance and strength of the adductor pollicis 
muscle, in contrast to the quadriceps muscle, were preserved in CHF. 
Within a population of patients with chronic heart failure, cachectic 
patients showed a greater loss of muscle strength and endurance 
than noncachectic patients66. In the same study strength per unit of 
muscle cross sectional area was also reduced in cachectic patients 
compared with noncachectic patients66, indicating that besides loss of 
muscle mass, other factors might contribute to muscle weakness in 
the patients. Other studies however reported normal strength/muscle 
size ratios in CHF64,65. 
Commonly, patients with chronic renal failure present with muscle 
weakness, complaining of difficulty with rising from a chair or easy 
fatigability. The muscle weakness in these patients is more 
pronounced in the lower than in the upper limbs and is particularly 
present in the proximal muscles67,68. In these patients the quadriceps 
muscle and other muscle groups were found to be weaker, compared 
to healthy controls69-72. Fahal et al.70 reported that within a group of 
patients with CRF, malnourished persons showed a significant 
reduction in quadriceps strength and maximal relaxation rate 
compared to well-nourished patients70. Also, isometric quadriceps 
strength per kilogram body weight tended to be lower in patients 
compared to controls. To our knowledge there are no studies in 
patients with CRF relating muscle strength and endurance to skeletal 
muscle mass. Data on muscle endurance in chronic renal failure are 
rare. One study reported an increase in fatigability of biceps brachii 
muscle in patients with CRF72.  
Muscle morphology 
It is now generally clear that in peripheral skeletal muscles of 
patients with COPD a fibre type redistribution occurs, resulting in an 
increased percentage of fast-twitch fibres and a reduction of the 
proportion in type I or slow-twitch fibres (Table 2.1). Especially the 
relative number of type IIX fibres seems to be increased in these 
patients. Moreover, muscle fibre sizes are reduced in patients with 
COPD73. The degree in which both fibres types are affected by 
atrophy has to be further investigated.  
Studies of peripheral muscle biopsies in patients with chronic heart 
failure show similar results as found in patients with COPD. Here also 
a shift from type I to type II, predominantly IIX, muscle fibres 
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occurs. This alteration in fibre types is accompanied by a reduction in 
fibre size, which might affect all fibre types62 or preferentially type 
II74 or only type IIX75 fibre cross sectional areas. 
Results of biopsy studies in patients with chronic renal failure fail to 
show convincing alterations in fibre type distribution as described in 
patients with COPD and CHF. According to Clyne et al.76 the 
proportion of type IIA fibres is increased and the percentage of type 
IIX fibres is reduced in chronic renal failure, with no change in the 
relative number of type I fibres. Kempeneers et al.71 reported a 
preponderance of type II muscle fibres in vastus lateralis biopsies of 
renal transplant recipients after an endurance training programme of 
24 weeks. This might indicate myopathic changes in these patients 
with a replacement of type I with type II fibres. According to several 
studies, fast twitch muscle fibre area seems to be reduced in patients 
with chronic renal failure. 
Whittom et al.73 demonstrated that capillary to fibre ratio in the 
vastus lateralis muscle of patients with COPD was similar to that in 
normal subjects. In the same study, the number of capillary contacts 
per muscle fibre was lower for type I and type IIA fibres. There was 
no difference in the number of capillary contacts per unit of muscle 
fibre area between patients and controls. In contrast to these results, 
Jobin et al.77 reported a reduction in capillary density and capillary-
to-fibres ratio in patients with COPD. 
In patients with chronic heart failure, an increased74, normal62,78,79 
and decreased80 capillary density have all been reported. Sullivan et 
al.75 reported a reduction in the number of capillaries adjacent to 
type I and type IIA muscle fibres in patients with CHF, compared to 
controls. Capillary to fibre ratio however was unchanged, because 
the muscle fibres in patients tended to be smaller than in controls. 
The latter was confirmed by Mancini et al.74. Schaufelberger et al.78,79 
found a reduction in capillary-to-fibre ratio in patients with CHF. The 
number of capillary contacts per muscle fibre and per muscle fibre 
area were not different in patients from controls. 
To our knowledge, no studies on potential alterations in skeletal 
muscle capillarization in patients with chronic renal failure are 
available. 
Muscle energy metabolism 
The results of various studies on muscle energy metabolism in COPD 
are summarized in Table 2.2. There is accumulating evidence of 
increased activities of glycolytic enzymes and a reduction in aerobic 
metabolism in peripheral skeletal muscles of patients with COPD in 
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comparison to normal subjects81-84. Sauleda et al.85 reported an 
increased activity of COX in skeletal muscle of patients with COPD.  
Patients with chronic heart failure demonstrate similar skeletal 
muscle metabolic abnormalities, including reduced activities of 
enzymes involved in oxidative carbohydrate and fatty acid energy 
metabolism and a relative increase in anaerobic capacity74,75,78,80,86. 
In only a few studies, muscle biopsies were taken from patients with 
chronic renal failure in order to investigate muscular metabolism. 
Clyne et al.76 found no alterations in oxidative enzymes activities in 
patients with CRF. Pastoris et al.68 reported a hypermetabolic 
tricarboxylic acid cycle, measured by the activities of citrate synthase 
and succinate dehydrogenase, but impaired oxidative 
phosphorylation. Activity of anaerobic enzyme hexokinase was 
increased in this study, while the activities of phosphofructokinase 
and lactate dehydrogenase, both enzymes involved in glycolytic 
metabolism, were unchanged in patients with CRF compared with 
normal subjects. Finally, Conjard et al.87 observed reduced activities 
of both oxidative and anaerobic metabolism in rectus abdominis 
muscle. 
At rest, no major alterations are present in muscle energy status and 
pH measured with 31P MRS in patients with COPD (Table 2.3)88-92. 
During muscle exercise the level of intramuscular phosphocreatine is 
decreased in patients with COPD and the rate of depletion of 
phosphocreatine is increased compared to normal subjects88-93. Also 
pH is lower and this acidification of skeletal muscle occurs faster in 
patients than in controls. In the recovery phase, patients with COPD 
show a prolonged half-time for phosphocreatine and pH 
recovery88-90,92,93, indicating that oxidative metabolism is impaired. 
31P NMR spectra of skeletal muscle at rest in patients with CHF seem 
to be in the normal range92,94-97. During local muscle exercise 
however, the results of the different studies convincingly show a 
greater degree and rate of energy status depletion and acidification 
in patients with CHF, compared to normal subjects74,94-99. Of special 
interest are the results of a study performed by Chati et al.98, who 
compared the 31P NMR spectra of patients with CHF during calf 
muscle exercise with both sedentary and trained controls. Spectra 
from patients were clearly different from those obtained in trained 
controls. No differences however were found in variables of energy 
status between patients and sedentary controls. They concluded that 
metabolic abnormalities in patients with CHF are most likely a 
consequence of deconditioning. Energy spectra during the recovery 
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phase are in line with results during exercise and show a delayed 
recovery92,95,97,99. 
There are only a few studies available investigating muscular 
metabolism with 31P MRS in patients with CRF and the results are 
contradicting. Although one study100 found normal 31P NMR spectra at 
rest in six patients with CRF in comparison to sex and age matched 
healthy controls, other studies101,102 showed impaired muscular 
metabolism at rest. Also an increased energy status at rest has been 
reported in patients with CRF103. During muscular exercise, 
abnormalities in phosphorus spectra and pH are more clear. 
Depletion of phosphocreatine seems to be more enhanced in patients 
with CRF and pH is decreased compared to normal subjects102-104. 
Finally, in the recovery phase the prolonged recovery half times for 
phosphocreatine and pH seem to indicate an impaired oxidative 
metabolism in this disease100,102, although others could not confirm 
this104. 
Discussion 
The results of this review show that peripheral skeletal muscles are 
commonly involved in the process of chronic disabling diseases like 
COPD, CHF and CRF. Although the primary impairments clearly differ 
between these conditions, the alterations in skeletal muscles show 
much resemblance. 
Firstly, changes in body composition, characterized by a loss of 
muscle mass, and a decrease in muscle strength occur in these three 
diseases. Several studies in patients with COPD, CHF and CRF have 
shown that a depletion of lean body mass is associated with a 
reduction in muscle force7,66,70,105. In COPD and CHF muscle mass 
seems to be the main determinant of muscle strength, as indicated 
by the normal ratio of strength to local muscle mass7,64,65,105. Future 
studies need to provide more information about the relationship 
between the quantity of muscle and muscle function in patients with 
CRF.  
Various studies have evaluated muscular endurance in COPD and 
CHF and numerous protocols have been used to measure both 
isometric as well as isokinetic fatigability of muscle groups of the 
upper and lower extremities. The results seem to indicate that 
fatigability of the lower limbs is decreased in patients compared to 
controls. More standardized studies however are necessary to 
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elucidate changes in upper limb endurance in these diseases and to 
evaluate muscle fatigue in CRF. 
In the peripheral skeletal muscles of patients with COPD and CHF a 
relative shift in fibre type distribution occurs. The percentage of type 
I oxidative muscle fibres is decreased and the proportion of type II 
(mainly type IIX) glycolytic muscle fibres is increased. Also, muscle 
fibres seem to be smaller in patients compared to healthy persons. 
Preferential type II muscle fibre atrophy was also found in patients 
with CRF. Until now, no convincing evidence for alterations in muscle 
fibre composition in CRF has been found. 
Studies on muscle energy metabolism in COPD, CHF and CRF show 
that abnormalities in metabolic functioning are common. In patients 
with COPD and CHF both the alterations in activities of metabolic 
enzymes, as well as the variables of 31P magnetic resonance 
spectroscopy indicate that oxidative metabolism is impaired, and 
glycolytic metabolism is enhanced in these diseases. Although the 
results of studies on enzyme activities in CRF are not convincing, 
studies with 31P MRS during and after exercise show the same 
results.  
Contribution of semistarvation 
Many patients with COPD, CHF and CRF suffer from weight loss and a 
depletion of lean body mass106-109. This condition has been related to 
increased morbidity and mortality110. Nutritional depletion in these 
diseases results from a disturbed energy balance, which mainly 
affects body fat mass, and an impaired protein balance, resulting in 
predominant loss of lean tissue. In anorexia nervosa (AN), energy 
intake is dramatically reduced and changes occur in body 
composition and skeletal muscle function and structure. Unlike in 
COPD and CHF, but similar to CRF, a muscle fibre type redistribution 
does not seem to occur in AN. Muscle fibre atrophy of mainly type II 
fibres in AN is in accordance with results from CRF and probably from 
COPD and CHF. Similar to COPD, CHF and CRF, oxidative metabolism 
seems to be impaired in AN, although in AN also glycolytic pathways 
are disturbed. It can be concluded that the state of a negative 
energy balance in chronic diseases might contribute to the observed 
changes in peripheral skeletal muscle.  
Contribution of deconditioning 
As a result of reduced activity or prolonged bed rest patients with 
chronic diseases like COPD, CHF and CRF are subject to varying 
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degrees of deconditioning. Skeletal muscle alterations in patients 
show resemblance to those occurring during disuse. Both in chronic 
disease as well as in disuse, strength and endurance are affected. 
Atrophy occurs, although in disuse mainly type I fibres are affected, 
whereas in patients with chronic disease type II fibres seem to be 
preferentially affected. The potential alterations in fibre type 
distribution as a result of reduced activity are similar to those 
observed in COPD and CHF. Also, results from biopsy studies show 
that a decline in oxidative enzyme activities as described in chronic 
disease may very well be a result of deconditioning. Thus, 
deconditioning of peripheral muscles is very likely to be an important 
contributor to the alterations in peripheral skeletal muscles that 
occur in patients with COPD, CHF and CRF. 
Contribution of aging 
During aging, changes occur in human skeletal muscles, including a 
loss of muscle mass and function, loss and atrophy of mainly type II 
muscle fibres and a decline of metabolic capacity. The proportional 
increase in type I muscle fibres in elderly indicates that aging does 
not contribute to the observed fibre type redistribution in COPD, CHF 
or CRF. Moreover, most studies investigating alterations in skeletal 
muscle in chronic diseases made use of healthy age-matched control 
groups, so age-related changes would have been present in both 
groups, unless patients would respond different to aging. To our 
knowledge no studies have yet investigated age-related changes in 
patients with chronic disease.  
Although more research is recommended, available studies indicate 
that both in aging as well as in the studied chronic diseases muscle 
energy metabolism is altered. Since studies in patients used healthy 
age-matched control groups, this suggests that besides aging, other 
factors negatively influence muscle metabolism in these diseases. 
 
Changes in muscle capillarity may contribute to reduced oxygen 
delivery in skeletal muscle of patients with chronic organ disease and 
can be related to reduced oxidative metabolism. In this review, the 
results of studies on muscle capillarization have been described. The 
controversy in the results is remarkable, making it difficult to draw a 
simple conclusion about the changes that occur in peripheral skeletal 
muscle. The inability to compare the results is probably inherent to 
the fact that various methods were used to describe the capillary 
bed, as pointed out earlier in this review.  
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Most studies on peripheral skeletal muscle in patients with chronic 
organ disease have focused on the lower limbs. It is known however 
that in COPD, patients experience dyspnoea particularly during 
activities which involve movements of the arms and shoulder girdle. 
In COPD, this has been attributed to the occurence of 
dyssynchronous thoracoabdominal breathing during unsupported arm 
exercise111. Also, Baarends et al.112 demonstrated that arm elevation 
in COPD tended to result in an increased metabolic and ventilatory 
response than in healthy subjects. Little is known however about the 
possible contribution of reduced strength and endurance of the upper 
limbs to impairment of arm activities and the occurrence of 
alterations in muscle fibres and energy metabolism in the arms, 
relative to the lower limbs. The available studies seem to indicate 
that muscle function of the upper limbs and shoulder girdle in 
patients with COPD is better preserved than that of the lower 
limbs7,56. This might also be true for patients with CHF65. No studies 
are available comparing upper and lower limb muscle function in 
patients with chronic renal failure. Although more studies in patients 
are certainly indicated, a possible cause for the relatively preserved 
function of the upper limbs could be the greater reduction of physical 
activity of the lower limbs, compared to the upper limbs as a result 
of the disease process. A relative maintenance of arm muscle 
function is also observed in sarcopenia. Again, differences in the 
decline of use between arms and legs with aging might explain these 
results. 
Conclusion 
In this review we have shown that alterations in peripheral skeletal 
muscle performance are remarkably similar in COPD, CHF and CRF. 
Also, changes in muscle morphology and energy metabolism occur in 
these chronic organ diseases. Results of studies on semistarvation 
and disuse indicate that these two factors may substantially 
contribute to the observed alterations. Potential differences in age-
related changes between patients with chronic organ disease and 
healthy subjects need to be further explored. Future investigations 
also need to unravel the role of changes in muscle capillarization in 
the described muscle abnormalities. Finally, from a therapeutic 
perspective muscle endurance and the exact relationship between 
alterations in skeletal muscle of the upper and lower limbs have to 
be systematically studied.  
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Abstract 
Introduction 
Previous studies indicate that energy expenditure related to physical activity is 
enhanced and that mechanical efficiency of leg exercise is reduced in patients with 
chronic obstructive pulmonary disease (COPD). However, it is yet unclear if an 
inefficient energy expenditure is also present during other activities in COPD. This 
study was carried out to examine arm efficiency and peak arm exercise performance 
relative to leg exercise in 33 (23 males) patients with COPD ((mean ± SEM) age: 
61±2 yr; FEV1: 40±2% of predicted) and 20 sex- and age-matched healthy controls.  
 
Methods  
Body composition, pulmonary function, resting energy expenditure (REE) and peak leg 
and arm exercise performance were determined. To calculate mechanical efficiency, 
subjects performed submaximal leg and arm ergometry at 50% of achieved peak 
loads. During exercise testing, metabolic and ventilatory parameters were measured.  
 
Results 
In contrast to a reduced leg mechanical efficiency in patients compared to controls 
(15.6±0.6% and 22.5±0.6% respectively, p<0.001), arm mechanical efficiency was 
comparable in both groups (COPD: 18.3±0.9%, controls: 21.0±1.2%, NS). Arm 
efficiency was not related to leg efficiency, pulmonary function, work of breathing, or 
REE. Also, arm exercise capacity was relatively preserved in patients with COPD (ratio 
arm peak work rate/leg peak work rate in patients: 89% versus 53% in controls, 
p<0.001).  
 
Conclusions 
Mechanical efficiency and exercise capacity of the upper and lower limbs are not 
homogeneously affected in COPD, with a relative preservation of the upper limbs. This 
may have implications for screening of exercise tolerance and prescription of training 
interventions in patients with COPD. Future studies need to elucidate the mechanism 
behind this observation. 
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Introduction 
Weight loss and depletion of fat-free mass (FFM) are common 
problems in patients with chronic obstructive pulmonary disease 
(COPD) and have been related to muscular weakness1 and exercise 
intolerance2 in these patients. Moreover, nutritional depletion is 
associated with a decreased health status and increased mortality in 
COPD3. In general, weight loss occurs when total daily energy 
expenditure (TDE) exceeds dietary intake, whereas loss of muscle 
mass is mainly a consequence of a disturbed protein balance. TDE 
consists of resting energy expenditure (REE), diet induced 
thermogenesis and energy spent during daily activities. Although 
several studies reported an increase in REE in clinically stable 
patients with COPD4,5, the contribution of an elevated REE to 
nutritional depletion seems limited4. Also, previous studies suggest 
that diet induced thermogenesis is normal in patients with COPD5 
and that its contribution to total daily energy expenditure is small5. 
In another study, using the deuterium and oxygen labelled water 
technique, it was demonstrated that TDE is increased in clinically 
stable patients with COPD compared to healthy subjects6 under free-
living conditions. This elevation was primarily attributed to the non-
resting component of TDE, i.e. an increase in energy expenditure 
related to physical activities. The hypothesis of an increase in activity 
related energy expenditure in some patients with COPD compared to 
controls is supported by the demonstration of a decreased 
mechanical efficiency (ME) of submaximal leg exercise in these 
patients7. Moreover, an increased oxygen cost of breathing in 
patients with COPD during exercise8 might contribute to the elevated 
energy expenditure during activities.  
 
Although most studies on exercise in patients with COPD have 
focused on lower-extremity exercise, many patients report disabling 
dyspnoea for unsupported daily activities involving the upper 
extremities at work levels much lower than for lower-extremities 
exercise9. This might be explained by the fact that during arm 
exercise, patients with COPD have to use their shoulder-girdle 
muscles not only for exercise, but also for breathing. This is 
associated with the development of a dyssynchronous breathing 
pattern during arm exercise in patients with severe airway 
obstruction10.  
Based on earlier observations of a decreased mechanical efficiency of 
leg exercise and the impairment of unsupported arm activities in 
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patients with COPD, it can be hypothesized that an inefficient energy 
expenditure is also present during arm exercise in COPD. As a result 
of the dual activity of shoulder-girdle muscles during arm exercise, 
arm inefficiency may be even more pronounced than leg inefficiency. 
Therefore the primary aim of this study was to compare the 
mechanical efficiency of arm exercise to the mechanical efficiency of 
leg exercise in patients with COPD. Since there is no method to 
validly and reliably measure the amount of external work performed 
and thus mechanical efficiency during unsupported arm exercise, 
supported arm exercise in the form of arm ergometry was used. In 
addition, peak arm exercise capacity relative to peak leg exercise 
capacity was compared in patients with COPD and in controls. 
Methods 
Study population 
A group of 33 clinically stable patients with COPD consecutively 
admitted to a pulmonary rehabilitation centre was studied. All 
patients fulfilled the criteria for COPD according to American Thoracic 
Society guidelines11 and suffered from moderate to severe airflow 
obstruction (forced expiratory volume in one second; FEV1: 40±2% 
of predicted). Patients exhibiting an increase in FEV1>10% of 
baseline after inhalation of a β2-agonist or those requiring oxygen 
supplementation (PaO2 at rest <7.3 kPa) were excluded. None of the 
patients suffered from malignancies, clinically apparent heart failure, 
active gastro-intestinal abnormalities, locomotor diseases or severe 
endocrine disorders. Patients were using one or more of the following 
respiratory medications: inhaled/oral short- and long-term β2–
sympathicomimetics, inhaled glucocorticosteroids, inhaled ipra-
tropium bromide, oral theophyllines or low dose oral glucocortico-
steroids as a maintenance therapy. From an advertisement in a local 
newspaper, 20 healthy age- and sex-matched control subjects were 
recruited. Controls did not participate in any exercise training 
programme. Written informed consent was obtained from all subjects 
and the study was approved by the medical ethics committee of the 
University Hospital Maastricht. The results with respect to the leg 
mechanical efficiency of the patients have been published earlier7. 
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Body composition 
Body height was determined to the nearest 0.5 cm (Lameris, WM 
715, Breukelen, The Netherlands) with subjects standing barefoot. 
Body weight was measured with a beam scale (SECA, FRG, 
Germany) without shoes and in light clothing to the nearest 0.1 kg. 
Body mass index (BMI) was calculated as the ratio of weight in 
kilograms to height in squared meters. Fat-free mass (FFM) was 
measured by bioelectrical impedance analysis at a frequency of 50 
kHz (Xitron 4000b, Xitron technologies, San Diego, California, USA) 
and expressed in kilograms. Resistance was measured in supine 
position at the right side as described by Lukaski et al.12. A patient 
specific regression equation, described by Schols et al.13 was used to 
calculate FFM in the patients with COPD. Fat-free mass index (FFMI) 
was calculated as the ratio of FFM to height in squared meters and 
was expressed in kg·m-2. 
Resting energy expenditure 
Energy expenditure at rest (REE) was measured by indirect 
calorimetry using a ventilated hood system (Oxyconbeta, Jaeger, 
Würzburg, Germany). Reproducibility and validity of this method in 
COPD patients was shown by Schols et al.14. The system was 
calibrated daily at the start of the experiment. The accuracy of the 
system was regularly assessed using a methanol combustion test. 
Measurements were performed in the early morning after an 
overnight fast, while the subject was comfortably lying on a bed in 
supine position. Energy expenditure was calculated from oxygen 
consumption and carbon dioxide production using the abbreviated 
Weir formula15. Measured REE was expressed as a percentage of 
predicted REE, which was calculated using the linear regression 
equation of REE on FFM, as described by Creutzberg et al.4.  
Pulmonary function 
Lung function testing included FEV1 and forced vital capacity (FVC), 
which were calculated from the flow-volume curve using a 
spirometer (Masterlab, Jaeger, Würzburg, Germany). The highest 
value of at least three measurements was used. Diffusing capacity 
for carbon monoxide (DLCO) was measured by the single-breath 
method (Masterlab, Jaeger, Würzburg, Germany)16. Instruments 
were calibrated twice a day. Lung function values were expressed as 
a percentage of reference values17. Inspiratory muscle strength 
Thesis Frits Franssen_08.pdf   65 21-11-2008   10:21:53
66⏐Chapter 3 
(Pi-max) was assessed by maximal inspiratory mouth pressure 
according to the method described by Black and Hyatt18 and was 
expressed in positive values. In patients a blood sample was taken 
from the radial artery at rest while breathing room air. Arterial 
oxygen tension (PaO2) and carbon dioxide tension (PaCO2) were 
determined on a blood gas analyzer (Radiometer ABL 330, 
Copenhagen, Denmark). 
Exercise tests 
During exercise tests blood pressure (Bosotron 2, Bosch & Sohn, 
Jungingen, Germany), heart rate and transcutaneous oxygen 
saturation (Autocorr, SIMS BCI, Waukesha, USA) were monitored. 
Oxygen consumption (V& O2), carbon dioxide production (V& CO2), 
minute ventilation (VE), breathing frequency and tidal volume were 
investigated breath by breath through a breathing mask 
(Oxyconbeta, Jaeger, Würzburg, Germany). Maximal voluntary 
ventilation (MVV) was indirectly estimated from FEV1 19. Heart rates 
were expressed as a percentage of predicted20. Equipment was 
calibrated before the tests. Exercise tests were performed on three 
separate occasions in one week. 
Incremental cycle ergometry test 
Patients and control subjects performed an incremental exercise test 
on an electrically braked cycle ergometer (Corival 400, Lode, 
Groningen, The Netherlands). The test was supervised by a physician 
and an electrocardiogram was recorded. Before the start of the test, 
while seated on the cycle ergometer, ventilation characteristics at 
rest were analysed during two minutes. After one minute of unloaded 
cycling, power was increased by 10 watts every minute in patients. 
For the control subjects, the load was increased with 15-25 watts 
every minute, so that the length of the exercise test was comparable 
for patients and controls. None of the subjects knew the exercise 
load and all were encouraged to cycle at 60 revolutions·min-1 until 
exhaustion.  
Incremental arm ergometry test 
Under supervision of a physician, an incremental arm exercise test 
was performed on an electromagnetically braked arm ergometer 
(Combitronic 33, Dynafit, Kaiserslautern, Germany). Subjects were 
seated upright on a chair in front of the ergometer, which was 
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attached to the wall and was adjustable in height. The axis of 
rotation of the arm cycle was placed at midsternal level. The pedals 
of the ergometer were held by the subjects. The trunk was 
unsupported during testing. After a two minutes rest measurement, 
the test was started at 10 watts and the load was increased with 10 
watts every minute in patients. In control subjects, the load was 
increased with 10-20 watts every minute, in order to achieve 
comparable duration of the test in patients and controls. The patients 
were encouraged to sustain the test at 60-70 revolutions·min-1 until 
exhaustion.  
Submaximal leg and arm exercise tests 
In a random order and on separate days, all subjects performed 
7-minute submaximal leg and arm exercise tests at 50% of 
individually measured peak loads of the incremental leg and arm 
ergometry tests. The mean values of metabolic and ventilatory 
variables during the last three minutes of exercise were used for 
analyses. Mechanical efficiency was calculated with the following 
equation: 
 
Mechanical efficiency21 = (load of exercise (watts)·0.01433 
(kcal·min-1) / (energy expenditure during exercise–REE) (kcal·min-
1))·100% 
 
Energy expenditure during exercise was calculated from the steady 
state values of V& O2 and V& CO2 and the abbreviated Weir formula15. A 
good reproducibility of this method was described in a previous study 
in COPD patients7.  
Statistics 
Results are given as mean ± standard error of the mean (SEM). 
Differences between patients and controls were statistically analysed 
using an unpaired Student’s t-test. The paired t-test was used to test 
for differences between upper and lower extremities in both groups. 
Power analysis (1-ß=0.90) was performed in order to calculate 
minimal group sizes for determination of a statistically significant 
difference in mechanical efficiency between patients and controls. 
Effect size was estimated at 5% and standard deviation at 4%, based 
on data of leg efficiency in healthy subjects22 and COPD patients7. 
Correlation coefficient analysis was performed in order to test the 
linear relationship between variables. A p-value <0.05 was 
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considered statistically significant. Data were analysed with the 
computer program “Statistical Package for the Social Sciences” 
(SPSS), version 10.0. 
Results 
General characteristics of the two study groups are presented in 
Table 3.1. There were no differences in age, sex distribution and 
body mass index between the COPD and healthy volunteer groups. 
COPD patients had significantly lower values for FFM, FFMI, FEV1, 
FVC, diffusing capacity for carbon monoxide and Pi-max than 
controls. Resting energy expenditure expressed as a percentage of 
predicted REE was significantly increased in patients with COPD 
compared with the control group.  
 
Table 3.1 Characteristics of study groups (mean ± SEM).  
 Controls COPD 
Sex ♂/♀ 14/6   23/10 
Age, yr  61 ± 1  61 ± 2 
Body mass index, kg·m-2  25.9 ± 0.6  24.0 ± 0.9 
Fat-free mass index, kg·m-2  20.0 ± 0.5  17.0 ± 0.4** 
Resting energy expenditure, %pred  91.8 ± 2.4  105.3 ± 2.9* 
FEV1, %pred  108 ± 3  40 ± 2** 
FVC, %pred  115 ± 3  86 ± 2** 
Diffusing capacity for CO, %pred  112 ± 5  55 ± 3** 
Pi-max, %pred  95 ± 5  77 ± 3* 
PaO2, kPa   -  9.5 ± 0.2 
PaCO2, kPa   -  5.6 ± 0.1 
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; Pi-max: 
peak inspiratory mouth pressure; PaO2: arterial oxygen pressure; PaCO2: arterial 
carbon dioxide pressure; *: p<0.05, **: p<0.001 COPD versus controls. 
 
The results of incremental exercise testing of the lower and upper 
limbs are presented in Table 3.2. Peak load, peak V& O2, peak V& CO2, 
respiratory exchange ratio (RER) and end-of-exercise ventilation 
were significantly lower in patients with COPD, compared to healthy 
controls, for maximal leg as well as maximal arm exercises. The 
lower ventilation in patients was achieved by a combination of a 
smaller tidal volume and a lower breathing frequency. For both 
exercises, peak ventilation expressed as percentage of predicted 
maximal voluntary ventilation was significantly increased in COPD, 
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compared to controls. Peak heart rate of incremental leg exercise, 
expressed as proportion of predicted maximal heart rate, was 
significantly lower in patients than in controls. These results indicate 
that in patients ventilatory limitation is the dominant contributor to 
exercise impairment, whereas mainly cardiovascular factors 
determine exercise capacity in controls. The ratio of peak V& O2 to 
work load during leg exercise was increased in COPD compared with 
controls. 
 
Table 3.2 Results of maximal exercise testing of patients and controls (mean ± SEM). 
 Controls COPD 
Leg exercise    
  Peak load, watts  205 ± 13  61 ± 4** 
  Peak V& O2, ml·min-1  2079 ± 117  1006 ± 63** 
  Peak V& CO2, ml·min-1  2568 ± 149  1026 ± 75** 
  RER  1.23 ± 0.02  1.01 ± 0.02** 
  Peak V ,  l·min-1   89.0 ± 6.2  40.6 ± 2.2** 
  Peak V /MVV, %  69 ± 3  94 ± 5** 
  Peak TV, l  2.18 ± 0.10  1.25 ± 0.06 ** 
  Peak BF, ·min-1  40 ± 2  33 ± 1** 
  Peak HR, %pred  100 ± 2  82 ± 2** 
  Peak V& O2/peak load, ml·min-1·watt-1  10.4 ± 0.3  17.3 ± 0.7** 
Arm exercise   
  Peak load, watts  108 ± 7##  50 ± 3**## 
  Peak V& O2, ml·min-1  1637 ± 124#  851 ± 43**## 
  Peak V& CO2, ml·min-1  1984 ± 147##  875 ± 51**## 
  RER  1.22 ± 0.02  1.02 ± 0.02** 
  Peak V ,  l·min-1   75.5 ± 6.5#  36.2 ± 1.8**## 
  Peak V /MVV, %  60 ± 4#  85 ± 4**## 
  Peak TV, l  1.97 ± 0.13#  1.16 ± 0.06**# 
  Peak BF, ·min-1  39 ± 3  33 ± 1* 
  Peak HR, %pred -  80 ± 2 
  Peak V& O2/Peak load, ml·min-1·watt-1  15.5 ± 0.7##  17.3 ± 0.6 
V& O2: oxygen consumption; V& CO2: carbon dioxide production; RER: respiratory 
exchange ratio; VE: ventilation; MVV: maximal voluntary ventilation; TV: tidal volume; 
BF: breathing frequency; HR: heart rate; *: p<0.05, **: p<0.001 COPD versus 
controls; #: p<0.05, ##: p<0.001 arm versus leg exercise. 
 
In patients as well as in controls, peak load, peak V& O2, peak V& CO2, 
peak VE and peak VE/MVV all were significantly higher during lower 
extremity exercise than during upper extremity exercise, whereas 
RER and peak HR (in patients) did not differ between leg and arm 
exercise. The difference in ventilation can be explained by lower tidal 
volumes during arm exercise in both groups. The ratios of peak load 
achieved during maximal upper limb exercise to peak load during 
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maximal lower limb exercise were 89% in patients with COPD and 
53% in healthy volunteers (p<0.001). Maximal V& O2 of arm exercise 
was 87% of maximal V& O2 during leg exercise in patients and 82% in 
controls (p=0.352).  
 
Table 3.3 Steady state values of exercise testing of lower and upper extremities at 
50% of achieved peak load during 7 minutes (mean ± SEM). 
 Controls COPD 
Leg exercise    
  Load, watts  102 ± 6  31 ± 2** 
  V& O2, ml·min-1  1528 ± 82  813 ± 42** 
  V& CO2, ml·min-1  1426 ± 77  759 ± 40** 
  RER  0.93 ± 0.01  0.94 ± 0.01 
  V ,  l·min-1   42.3 ± 2.4  33.3 ± 1.2** 
  VE/MVV, %  33 ± 1  79 ± 4** 
  V& O2/VE, ml·l-1  36.4 ± 0.7  24.5 ± 0.9** 
  TV, l  1.73 ± 0.07  1.22 ± 0.06** 
  BF, min-1  24 ± 1  29 ± 1* 
  HR, %pred -  71 ± 2 
Arm exercise   
  Load, watts  54 ± 4##  25 ± 1**## 
  V& O2, ml·min-1  1017 ± 69##  641 ± 27**## 
  V& CO2, ml·min-1  1003 ± 76##  606 ± 27**## 
  RER  0.98 ± 0.01#  0.95 ± 0.01 
  V , l·min-1  33.4 ± 2.7#  30.1 ± 1.1# 
  V /MVV , %   26 ± 2##  71 ± 3**# 
  V& O2/ VE, ml·l-1  31.2 ± 0.9##  21.5 ± 0.7**## 
  TV, l  1.43 ± 0.10#  1.10 ± 0.05*# 
  BF, min-1  24 ± 1  28 ± 1* 
  HR, %pred -  68 ± 3 
V& O2: steady state oxygen consumption; V& CO2: steady state carbon dioxide 
production; RER: steady state respiratory exchange ratio; VE: steady state ventilation; 
MVV: maximal voluntary ventilation; TV: tidal volume; BF: breathing frequency; HR: 
heart rate; *: p<0.05,  **: p<0.001 COPD versus controls; #: p<0.05, ##: p<0.001 
arm versus leg exercise. 
 
Table 3.3 shows the steady state results of submaximal leg and arm 
exercise testing in COPD patients and controls. During submaximal 
lower extremity as well as during submaximal upper extremity 
exercise, load, V& O2 and V& CO2 were significantly lower in patients 
compared to controls. There were no differences in RER between 
groups. Steady state ventilation during leg exercise, but not during 
arm exercise, was consistently lower in patients compared to 
controls. During both forms of submaximal exercise, tidal volume 
was decreased and breathing frequency was increased in COPD 
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compared to controls. For both exercises, VE/MVV was increased in 
COPD compared to controls. In patients, steady-state heart rates 
were clearly below predicted peak heart rates. 
In patients as well as in controls, submaximal load, V& O2, V& CO2, VE, 
VE/MVV and V& O2/VE all were significantly higher during leg exercise 
than during arm exercise. Ventilation during submaximal leg exercise 
was increased in comparison to submaximal arm exercise as a result 
of a higher tidal volume during this exercise. In patients, steady 
state RER and heart rate did not differ between leg and arm exercise.  
 
Mechanical efficiency of leg exercise was significantly lower in 
patients than in controls (15.6±0.6% and 22.5±0.6% respectively, 
p<0.001) (Figure 3.1). In contrast, mechanical efficiency of 
supported arm exercise was comparable in patients and controls 
(COPD: 18.3±0.9%, controls: 21.0±1.2%, NS). In patients with 
COPD, mechanical efficiency of submaximal leg exercise was 
significantly lower than mechanical efficiency of submaximal arm 
exercise (p=0.008), whereas mechanical efficiency of the lower limb 
was comparable to that of the upper limb in control subjects 
(p=0.235). 
 
Figure 3.1 Bar diagram of leg and arm mechanical efficiencies in patients (grey bars) 
and controls (white bars). Mean values ± SEM are shown. Significance of 
differences was indicated as **: p<0.001 for COPD patients versus controls 
and #: p<0.05 arm versus leg efficiency. 
 
 
 
 
 
 
 
No significant relationship was found between ME of leg exercise and 
ME of arm exercise in patients (r=0.286, p=0.107) or in controls 
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(r=0.053, p=0.828). In both groups, arm and leg ME were not 
related to variables of body composition or pulmonary function and 
respiratory muscle strength, or to REE or arterial blood gases. Both 
in COPD patients as well as in controls arm mechanical efficiency was 
significantly inversely related to age (r=-0.410, p=0.018 and 
r=-0.512, p=0.025, respectively). In the COPD group, only leg ME 
was correlated to measurements related to the oxygen cost of 
breathing, such as V& O2/VE ratio during maximal and submaximal leg 
exercise (r=-0.439, p=0.011 and r=-0.409, p=0.018 respectively). 
Finally, there was an inverse relationship between the ratio peak 
V& O2/peak load during incremental leg exercise testing and leg ME 
calculated from results of submaximal exercise testing (r=-0.794. 
p<0.001) in the COPD group (Figure 3.2). Arm mechanical efficiency 
was not significantly related to any of the variables of maximal or 
submaximal exercise testing in COPD patients. 
 
Figure 3.2 Leg mechanical efficiency related to ratio peak V& O2/work load in COPD 
patients (r=-0.794, p<0.001). 
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Discussion 
The present study shows a preserved mechanical efficiency of 
submaximal arm exercise in combination with a decreased leg 
efficiency in clinically stable patients with COPD compared with 
control subjects. Moreover, exercise tolerance of the upper limbs 
appears to be relatively high in comparison to that of the lower limbs 
in patients with COPD. 
It is known in healthy persons that leg mechanical efficiency 
generally amounts to 23-25%22, which is higher than arm mechanical 
efficiency that is usually 16-19%23. The lower mechanical efficiency 
of the upper limbs in healthy subjects has been attributed to a 
greater amount of energy expended for unmeasured work, such as 
torso stabilization, during arm exercise compared to leg exercise. 
However, this study shows that leg mechanical efficiency is 
significantly lower than arm mechanical efficiency in clinically stable 
patients with COPD. In patients, leg mechanical efficiency was 
reduced compared to control subjects, whereas there was no 
significant difference in arm mechanical efficiency between both 
groups. As expected, leg mechanical efficiency tended to be higher 
than arm mechanical efficiency in healthy controls. 
It is yet unclear why arm mechanical efficiency is higher than leg 
mechanical efficiency in patients with COPD, but there are several 
possible explanations. In a previous study, the decreased mechanical 
efficiency of the lower limbs seemed to be associated with an 
increased work of breathing in COPD7. However, in the present 
study, arm efficiency did not correlate with parameters related to 
oxygen cost of breathing, such as ratio V& O2/VE during exercise. This 
suggests that arm efficiency is not affected by decreased pulmonary 
function per se. 
Several studies have investigated the influence of different work 
loads on muscular efficiency in healthy subjects21,23,24, and report 
that mechanical efficiency is lower at lower absolute work loads21,23. 
The lower load during submaximal leg exercise could contribute to 
the decreased leg efficiency in patients compared to controls. 
However, this can not explain the comparable arm efficiency in 
patients and controls, despite lower work loads in patients.  
Another possible explanation for the high arm mechanical efficiency 
compared to leg mechanical efficiency might be a greater reliance on 
anaerobic metabolism during upper limb exercise than during lower 
limb exercise. A non-steady state or anaerobic energy deliverance 
during submaximal exercise testing would result in an overestimation 
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of the true mechanical efficiency. Indeed, in this study, the metabolic 
responses during submaximal leg as well as arm exercise relative to 
the peak metabolic responses were increased in patients with COPD 
compared with controls. However, in the COPD patients, there was 
no difference in the metabolic responses as percentage of peak 
response between submaximal leg and arm exercises. Both during 
leg as well as during arm submaximal exercise the metabolic 
response was approximately 80% of peak V& O2, 93% of peak RER 
and 85% of peak VE. Submaximal heart rates in patients expressed 
as percentage of measured peak heart rates were also comparable 
during both tests. These similar responses during leg and arm 
exercise indicate that a contribution of enhanced anaerobic 
metabolism during arm exercise to the observed difference in leg and 
arm efficiency in COPD patients is unlikely. 
As a result of a more sedentary lifestyle, decreased physical activity 
of mainly the lower limbs is likely to occur in patients with COPD. 
This can result in differences in training status between the lower 
and the upper limbs in these patients. In this way, deconditioning 
could contribute to the predominant loss of leg efficiency in COPD 
and the preservation of arm efficiency. Unfortunately, no information 
about the level of daily physical activity in our study groups is 
available. Only a few reports have investigated the relationship 
between training and muscular efficiency. Nickleberry et al.24 
observed no difference in gross and delta efficiencies during 
submaximal leg ergometry between competitive and recreational 
cyclists, despite increased submaximal power output and endurance 
capacity in the group of competitive cyclists. Also, no evidence is yet 
available proving that mechanical efficiency is enhanced as a result 
of exercise training programmes in patients with COPD. Thus, it is 
unlikely that differences in training status between lower and upper 
extremities contribute to the observed difference in mechanical 
efficiencies between leg and arm in COPD. 
Furthermore, differences in muscle fibre type composition between 
lower and upper extremities in patients with COPD should be 
considered as a possible explanation for the observed higher arm 
efficiency. Coyle et al.25 found a positive correlation between the 
percentage of type I fibres in vastus lateralis muscle and cycling 
efficiency during submaximal exercise in healthy subjects. In the 
vastus lateralis of COPD patients, a shift towards smaller fibre sizes 
and an increased percentage of type II fibres has been shown26. In 
contrast to the findings in quadriceps muscles, Gea et al.27 recently 
reported similar muscle fibre sizes and percentages in deltoid muscle 
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biopsies in patients with COPD and controls. These observations 
suggest that the intrinsic skeletal muscle changes in COPD are not 
homogeneously distributed and that the percentage type I muscle 
fibres in the upper arm is preserved, in contrast to the lower limb. 
Future investigations need to elucidate the relationship between 
changes in muscle fibre types and the observed leg and arm 
mechanical efficiencies in patients with COPD.  
A strong correlation between the ratio peak oxygen uptake to peak 
work rate and leg mechanical efficiency was observed in patients 
with COPD. In normal subjects, the slope of the relationship between 
peak V& O2 and work load is 10 ml·min-1·watt-1 20. This value was also 
found in our controls. In the patient group however, the ratio was 
increased. Because decreased mechanical leg efficiency, in particular 
in active patients may contribute to elevated daily energy 
requirements in COPD as reported by Baarends et al.7, a maximal 
exercise test, commonly used in a clinical setting to detect the 
pathophysiology of dyspnoea and exercise limitation in COPD, may 
also be utilized as a diagnostic tool to detect decreased mechanical 
efficiency.  
Furthermore, an inverse relationship between mechanical efficiency 
of the upper limb and age was observed in patients and in controls. 
The influence of aging on cycle efficiency has not been studied 
extensively. In a cross-sectional study that investigated ergocycle 
efficiency in a group of men of various age groups28, no age-related 
differences in gross efficiency were reported. The males in this study 
were younger than our subjects (mean age: 39±1.2 yr). No further 
longitudinal studies are available about the influence of aging on 
mechanical arm efficiency. However, other alterations in skeletal 
muscle are normal features of the aging process and include loss of 
muscle mass and function29 and changes in metabolism and muscle 
fibres. The alterations in muscle fibres consist of atrophy of mainly 
type II fibres and a proportional increase in type I muscle fibres29. 
Based on these changes in muscle fibres during aging and the 
observed correlation between the percentage of type I fibres and 
efficiency, one would expect an increase in mechanical efficiency with 
aging. However, the contrary was observed in this study. 
The results of maximal exercise testing in this study further indicate 
that patients with COPD perform relatively better during supported 
upper-extremity exercise than during lower-extremity exercise. 
Although the achieved load during both tests was less in the patient 
group than in the control group, the ratio of peak load achieved 
during maximal upper limb exercise to peak load during maximal 
Thesis Frits Franssen_08.pdf   75 21-11-2008   10:21:54
76⏐Chapter 3 
lower limb exercise was increased in patients with COPD compared 
with controls. Furthermore, peak oxygen consumption during arm 
exercise in our patients was relatively high compared to leg exercise. 
In a review by Franklin et al.30, it was described that maximal V& O2 of 
arm exercise varies between 64 and 80% of maximal V& O2 of leg 
exercise in healthy (younger) persons. Although this ratio seems to 
be increased in the COPD group, the average of the control group 
was also slightly higher than the reference values. At the same time, 
the ventilatory burden of maximal arm ergometry, as indicated by 
the ratio peak VE/MVV, was less than during leg ergometry in both 
patients as well as controls. Furthermore, ventilatory limitation is an 
important determinant of exercise capacity in COPD patients, 
whereas mainly cardiovascular factors seem to determine exercise 
tolerance in controls. 
The finding that arm exercise tolerance is less impaired than leg 
exercise tolerance in COPD, seems to be in contrast to earlier 
publications that reported enhanced dyspnoea, dyssynchroneous 
breathing10, changes in respiratory muscle recruitment31, dynamic 
hyperinflation32 and an inefficient metabolic and ventilatory response 
to arm elevation33. However it should be noted that in most of these 
studies unsupported arm exercise was investigated, whereas the 
present study measured supported arm exercise. It was 
demonstrated that the ventilatory response to unsupported arm 
elevation is enhanced in comparison to supported arm elevation in 
patients with COPD33. Moreover, only one study10 actually compared 
leg exercise and (unsupported) arm exercise in COPD. 
The findings of preserved mechanical efficiency and exercise capacity 
of the upper extremities in COPD patients, may have significant 
clinical implications. Since a decreased mechanical efficiency might 
contribute to increased energy expenditure during exercise, a 
pulmonary rehabilitation programme specifically focused on training 
inefficient muscle groups might promote catabolism. This might 
negatively influence the response to nutritional therapy, which is 
another important component of pulmonary rehabilitation in depleted 
patients. In that case, endurance training interventions should in 
stead be preferentially aimed at more efficient muscle groups, such 
as the arms. As stated above, no training strategies are yet available 
that enhance mechanical efficiency in patients with COPD. 
Furthermore, the results of this study indicate that the systemic 
alterations related to exercise capacity and the muscular 
compartment must not be generalized for the lower and upper limbs, 
when screening patients with COPD in clinical practice. 
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In summary, this study shows that arm mechanical efficiency, in 
contrast to leg mechanical efficiency, is normal in patients with 
clinically stable COPD. In addition, supported arm ergometry appears 
to be less impaired than leg ergometry in COPD. These observations 
may be important to consider in the screening and the choice of 
specific training interventions in patients with COPD. 
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Abstract 
Introduction 
Lower limb muscle weakness has often been reported in chronic obstructive 
pulmonary disease (COPD) and contributes to exercise intolerance. Controversial 
information is available regarding upper limb muscle adaptations and the influence of 
muscle wasting on muscle weakness. We investigated leg and arm muscle function in 
59 stable COPD patients (GOLD stage III) with preserved fat-free mass (FFM) and in 
28 patients with reduced FFM relative to age- and sex-matched healthy control 
subjects and studied the effects of 8 weeks of whole-body exercise training.  
 
Methods 
FFM was measured with bioelectrical impedance analysis. Isokinetic quadriceps (F-leg) 
and biceps strength (F-arm), as well as quadriceps (E-leg) and biceps endurance 
(E-arm) were determined with a Biodex dynamometer. Exercise training consisted of 
cycle ergometry, treadmill walking, weight training and gymnastics during five 
days·week-1.  
 
Results 
F-leg (76.2±3.6 N·m versus 118.2±6.3 N·m, p<0.001) and F-arm (25.6±1.3 N·m 
versus 38.1±2.1 N·m, p<0.001) were significantly and similarly reduced in the COPD 
patient group compared with controls. Also, E-leg (-2.13±0.12 versus –1.61±0.11, 
p<0.01), but not E-arm (-2.72±0.11 and –2.47±0.13, NS) was decreased in patients. 
F-leg (62.4±4.3 N·m versus 82.8±4.7 N·m, p<0.01), but not F-arm or muscle 
endurance was reduced in FFM depleted compared with non FFM depleted patients. 
Whereas after training, F-leg and E-leg significantly increased by 20% in the whole 
COPD group, biceps muscle function remained unchanged. 
 
Conclusions 
Lower and upper limb muscle dysfunction was observed in COPD patients, irrespective 
of the presence of FFM depletion. Generalized muscle weakness suggests systemic 
muscular involvement, although the preserved arm endurance and the poor response 
of arm performance to exercise training is indicative for intrinsic differences in 
muscular adaptations between leg and arm muscles. 
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Introduction 
Skeletal muscle weakness of the lower extremities is frequently 
observed in patients with chronic obstructive pulmonary disease 
(COPD) and contributes to exercise limitation1,2, impaired health 
status3 and increased utilisation of health care services4. Peripheral 
muscle dysfunction in COPD has been related to muscle wasting of 
the extremities5, while the contribution of abnormalities in 
quadriceps muscle morphology6 and energy metabolism7 has not yet 
been elucidated. Recently, it was suggested that peripheral muscle 
dysfunction is absent in COPD patients with normal muscle mass, 
assessed by fat-free mass (FFM)8, thus emphasizing the role of 
nutritional depletion in the etiology of muscle dysfunction. Muscle 
weakness can be approached as loss of muscle strength, muscle 
endurance or a combination of these. Muscle strength is defined as 
the capacity of the muscle to develop maximal force, while 
endurance is the capacity of the muscle to sustain mechanical output 
during (a series of) loaded contraction(s).  
Although several studies reported lower limb muscle impairment in 
COPD, few and conflicting information is available on the function of 
other peripheral muscle groups, especially of the upper limbs. In 
addition, the relative distribution of muscle weakness between 
different muscle groups remains unclear. Insight in the pattern of 
muscular dysfunction in COPD would contribute to a better 
understanding of underlying local or systemic pathophysiology, such 
as inactivity and deconditioning, malnutrition, systemic inflammation, 
hypoxemia and use of systemic corticosteroids. Some studies 
reported a relative preservation of strength of upper limb muscles2,9, 
while others found a similar degree of muscle weakness for lower 
and upper limbs, however, with differences between proximal and 
distal arm muscle groups10.  
Although muscle endurance was less frequently studied in COPD, 
both normal11 as well as decreased values for lower12-14 and upper 
extremities15 were described. In one study a relative preservation of 
muscle endurance of the upper limb was reported in comparison to 
the lower limb13, while in another study a combination of impaired 
arm muscle endurance and normal leg muscle endurance was 
described15. Differences in the muscle function testing equipment, 
protocols and measured muscle groups together with heterogeneity 
in studied COPD groups probably contribute to divergent results. 
Therefore, the first purpose of the present study was to carefully 
study and compare muscle strength and endurance of the proximal 
Thesis Frits Franssen_08.pdf   83 21-11-2008   10:21:54
84⏐Chapter 4 
lower and upper limbs in severe COPD patients relative to healthy 
subjects. Strength and endurance were measured in a single testing 
protocol, which was identical for lower and upper limb muscle 
function assessment, and the same dynamometer was used for leg 
and arm. To gain more insight in the mechanism and clinical 
implications of muscle dysfunction in COPD, this study additionally 
explored functional differences between muscle groups of lower and 
upper extremities in COPD patients with a preserved muscle mass 
and patients with a reduced muscle mass. Finally, this study 
investigated the effects of eight weeks of exercise training, consisting 
of a combination of whole-body endurance training and strength 
training of lower and upper extremities, on leg and arm muscle 
function in the COPD group. 
Methods 
Subjects 
Eighty-seven patients with moderate to severe COPD16 and 35 age-
matched healthy volunteers were studied at baseline. All patients 
were in clinically stable condition and were consecutively recruited on 
admission to the pulmonary rehabilitation centre Hornerheide, where 
they participated in an intensive inpatient pulmonary rehabilitation 
programme. Patients exhibiting an increase in FEV1>10% of baseline 
after inhalation of a β2-agonist were excluded. Other exclusion 
criteria were recent surgery and chronic diseases, such as malignant 
disorders, clinically apparent heart failure, gastrointestinal 
abnormalities and insulin dependent diabetes mellitus. Within the 
COPD population, 28 subjects fulfilled the criteria for depletion of 
FFM17, while the FFM of the other 59 patients was in the normal 
range. The control group was recruited from an advertisement in a 
local newspaper for baseline comparison of body composition and 
muscle function. Controls did not participate in the exercise training 
programme. Written informed consent was obtained from all subjects 
and the ethical review board of the University Hospital Maastricht 
approved the study. 
Pulmonary function 
Lung function testing included forced spirometry and assessment of 
lung volumes by whole-body plethysmography (Masterlab, Jaeger, 
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Würzburg, Germany). FEV1 and forced vital capacity (FVC) were 
calculated from the flow-volume curves. The highest values of at 
least three measurements were used. Diffusing capacity for carbon 
monoxide (DLCO) was measured by the single breath method 
(Masterlab, Jaeger, Würzburg, Germany). Instruments were 
calibrated twice a day. All values obtained were expressed as a 
percentage of reference values18. Arterial blood gas analysis was 
performed in all patients at rest (ABL 330, Radiometer, Copenhagen, 
Denmark). 
Anthropometric measurements 
Besides body weight and height, FFM was measured by bioelectrical 
impedance analysis at a frequency of 50 kHz (Xitron 4000b, Xitron 
technologies, San Diego, California, USA). Resistance was measured 
in supine position at the right side as described by Lukaski19. A 
patient specific regression equation, described by Schols et al.20 was 
used to calculate FFM in COPD subjects. FFM index was calculated as 
the ratio of FFM to height in meters squared. 
Peripheral muscle function 
Isokinetic muscle strength and endurance of the dominant knee 
extensor (quadriceps) and elbow flexor (biceps) muscles were 
measured using a dynamometer (Biodex System II, Biodex 
Corporation, Shirley, New York, USA). During leg muscle function 
testing, subjects were seated upright on the chair of the 
dynamometer with support of the back. At the level of the chest, 
pelvis and thigh, subjects were secured with straps. The hip joint 
was at an angle between 90 and 100º of flexion during testing. The 
lever arm was attached to the distal part of the tibia and its axis of 
rotation was visually aligned with the anatomical axis of flexion of 
the knee joint. Subjects were instructed to keep their hands on their 
thighs during testing. To assess arm muscle function, equipment was 
reinstalled and subjects sat upright on a chair in front of the 
dynamometer with their backs towards it. The shoulder of the 
dominant arm was placed in 90º abduction. The upper arm was 
supported and fixed with a belt in the horizontal plane on an 
adjustable stand. The ventral side of the forearm was placed in the 
frontal plane. The handgrip of the lever arm was held by the 
subjects. The lateral epicondyle of the humerus was used as the axis 
of elbow rotation and was visually aligned with axis of rotation of the 
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dynamometer. Subjects were instructed to keep their contralateral 
hand on their thigh.  
The isokinetic testing protocol consisted of fifteen sequential 
volitional maximal contractions at an angular velocity of 90º·s-1. 
Maximal isokinetic strength was defined as the highest peak torque 
(in Newton-meters; N·m) in this series of fifteen (Figure 4.1). To 
determine isokinetic muscle endurance, the peak torques of the 
successive contractions were expressed as a percentage of the 
highest value. The first contraction was excluded from analysis. A 
linear curve was fitted through the calculated points. The slope of 
this curve, indicating the proportional decline in peak torque per 
contraction, was used as a measure for muscle endurance (Figure 
4.1). A more negative slope indicated lower muscle endurance or 
increased muscle fatigue. Series in which the slope was ascending or 
in which the curve had a R2<0.209 were excluded. The R2 value of 
0.209 is based on the critical value of the Pearson’s correlation 
coefficient at a one-tailed p-value of 0.10 and 13 degrees of 
freedom. For comparison of lower and upper limb muscle function, 
strength and endurance were also expressed as a percentage of the 
mean values obtained in the control group.  
 
Figure 4.1 Methodology of muscle function testing. Maximal isokinetic strength 
was defined as the highest peak torque in a series of fifteen maximal 
isokinetic contractions. The slope of the linear curve through the 
successive relative peak torques (r) was used as measure for muscle 
endurance. See methods section for details. 
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In addition to the isokinetic muscle function assessment and for 
comparison with other studies on muscle function in COPD, isometric 
handgrip force was measured with a hydraulic hand dynamometer 
(Jamar, Sammons Preston Rolyan, Jackson, Illinois, USA). The 
average value of maximal force of left and right hand during a series 
of three manoeuvres was used for analysis.  
Exercise capacity 
For characterization of the COPD patient group in terms of whole-
body exercise tolerance, exercise capacity was assessed by 
progressive incremental exercise testing on an electrically braked 
cycle ergometer (Corival 400, Lode, Groningen, The Netherlands). 
During the entire exercise test, expired gases were investigated 
using breath by breath analysis through a breathing mask (Oxycon 
Beta, Jaeger, Würzburg, Germany). After two minutes of rest and 
one minute of unloaded cycling, power was increased by 10 W every 
minute in patients. In control subjects, the load was increased with 
15-25 W every minute, depending on relative fitness of the subject, 
so as to lead to fatigue in 10-12 minutes. None of the subjects knew 
the exercise load and all were encouraged to cycle at 60 
revolutions·min-1 until exhaustion.  
Study design 
Inclusion, medical examination and baseline measurements of 
pulmonary function, body composition, peripheral muscle function 
and exercise performance in COPD patients were performed within 
the first two weeks after admission to the pulmonary rehabilitation 
centre. This period also allowed for familiarization with the various 
procedures in order to avoid learning effects. After two weeks, all 
patients participated in a comprehensive inpatient eight-week 
respiratory rehabilitation programme consisting of exercise training 
during five days per week, education and (when appropriate) 
psychosocial and behavioural intervention. During their stay in the 
rehabilitation centre, a standardized weight maintaining diet was 
offered to weight stable patients that were not eligible for nutritional 
supplementation17. All subjects in the FFM depleted group and eleven 
patients with preserved FFM but low body weight or weight loss 
received standardized nutritional support during rehabilitation 
(Respifor, Royal Numico NV, Amsterdam, The Netherlands; three 
times per day, 564 kcal; 20 energy% protein, 60 energy% 
carbohydrate, 20 energy% fat). The physical exercise training 
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programme consisted of a combination of endurance and strength 
exercise training. Submaximal cycle ergometry was performed twice 
a day for 20 minutes. Initial load was set at 50-60% of baseline peak 
work rate. Thereafter, training intensity was adapted to maintain the 
same relative training load during the intervention period under 
supervision of an exercise therapist. In addition, patients exercised 
on a treadmill for 20 minutes per day just below their symptom-
limited rate. All patients participated in daily 30 minutes of 
gymnastics, focused at either strength and endurance or mobilisation 
and flexibility. Furthermore, patients attended daily arm exercise 
training sessions, consisting of 10 times one minute of unsupported 
arm exercise, followed by one minute of rest. Dynamic strength 
training exercises of the upper and lower extremities were 
incorporated in the programme. Muscle groups, load and number of 
repetitions were determined for each individual and were based on 
the experienced functional impairments in daily living and evaluation 
of the patients’ muscular performance by a team of experienced 
physiotherapists.  
Control subjects visited the pulmonary rehabilitation centre on two 
successive days. On the first day, a medical examination was 
performed and body composition and respiratory function were 
assessed. Furthermore, the controls practiced on the Biodex 
dynamometer with an exercise therapist to become familiar with the 
apparatus and minimize learning effects. On the second day, the 
actual muscle function measurement and maximal bicycle ergometry 
were performed. 
Statistical analysis 
Results are expressed as mean ± standard error of the mean (SEM). 
Statistical analysis on baseline differences between patients and 
controls was performed using an unpaired Student’s t-test. One-way 
analysis of variance (ANOVA) was used to determine differences 
between FFM-depleted, non-FFM-depleted patients and controls. LSD 
multiple comparison test was used as post hoc test. The Student’s 
paired t-test for dependent samples was used to test for differences 
in relative muscle strength and endurance between the lower and 
upper limbs in COPD patients. Pearson’s correlation analysis was 
performed in the patient group in order to investigate linear 
relationship between variables of body composition and muscle 
function. Changes in muscle function between baseline and week 
eight were tested with Student’s paired t-test in the whole group of 
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COPD patients. Because of the limited number of paired observations 
in especially the FFM depleted group, due to strict methodological 
criteria (as described in the section about peripheral muscle function 
measurement), the latter analysis was not performed for both COPD 
subgroups separately. All p values <0.05 were considered 
statistically significant. 
Results 
Baseline characteristics 
At baseline, sex distribution, age and height were comparable in 
non-FFM-depleted COPD patients, FFM-depleted patients and controls 
(Table 4.1). Body weight was significantly lower in patients 
compared with controls, and in depleted compared with nondepleted 
patients, resulting in a reduced BMI in the patient group compared 
with controls (22.4±0.4 kg·m-2 versus 26.3±0.4 kg·m-2, p<0.001) and 
in FFM-depleted versus non-FFM-depleted COPD. The reduced body 
weight was mainly the result of a decreased FFM in both patients 
groups, but a decreased fat mass also contributed to the lower body 
weight in the depleted patient group. Patients were characterized by 
severe airflow obstruction with hyperinflation and a reduced diffusing 
capacity for carbon monoxide (GOLD stage III). Despite comparable 
spirometry and blood gases, diffusing capacity for carbon monoxide 
was lower in FFM-depleted patients compared with nondepleted 
patients. Exercise capacity, measured with cycle ergometry, was 
markedly impaired in patients compared with controls (V& O2max: 
961±37 ml·min-1 versus 2134±124 ml·min-1, p<0.001). Although 
exercise performance was lower in FFM-depleted patients compared 
with nondepleted patients, statistical significance was not reached.  
Muscle strength 
Isokinetic strength of the dominant quadriceps (76.2±3.6 N·m versus 
118.2±6.3 N·m, p<0.001) and biceps (25.6±1.3 N·m versus 38.1±2.1 
N·m, p<0.001) muscles was significantly reduced in COPD patients 
compared with controls. Mean quadriceps and biceps strength of 
patients were 65±3% and 67±3% (NS) of the mean control value, 
indicating that lower and upper proximal limb muscle strength were 
equally affected. 
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As shown in Figure 4.2, quadriceps and biceps strength was 
significantly reduced in both non-FFM-depleted as well as FFM-
depleted patients. Furthermore, quadriceps strength was significantly 
lower in FFM-depleted compared with nondepleted patients, whereas 
biceps strength was comparable in both patient groups. Also after 
correcting for FFM, quadriceps (1.57±0.06 N·m·kg-1 versus 2.00±0.07 
N·m·kg-1) and biceps muscle strength (0.53±0.02 N·m·kg-1 versus 
0.64±0.02 N·m·kg-1) were significantly reduced in COPD patients 
compared with controls. However, the difference in quadriceps 
strength between depleted and non-depleted patients disappeared 
after correction for FFM (1.54±0.09 N·m·kg-1 and 1.58±0.07 N·m·kg-
1, respectively, NS).  
 
Table 4.1 Baseline characteristics of the study groups (mean ± SEM).  
 Controls 
 
(n = 35) 
Non-FFM-depleted
COPD 
(n = 59) 
FFM-depleted 
COPD 
(n = 28) 
  Male/Female, No.   24/11          41/18          18/10 
  Age, yrs  62 ± 1  63 ± 1  62 ± 2 
Body composition    
  Height, cm  172.2 ± 1.6  169.9 ± 1.0  168.3 ± 1.5 
  Weight, kg  78.3 ± 2.0  69.6 ± 1.4 #  53.6 ± 1.6 # ** 
  BMI, kg·m-2  26.3 ± 0.4  24.1 ± 0.4 #  18.9 ± 0.4 # ** 
  FFM, kg  59.0 ± 1.9  51.1 ± 1.0 #  40.7 ± 1.0 # ** 
  FFMI, kg·m-2  19.8 ± 0.4  17.7 ± 0.2 #  14.3 ± 0.2 # ** 
  FM, kg  19.4 ± 1.2  18.5 ± 0.9  12.9 ± 0.9 # ** 
  FMI, kg·m-2  6.6 ± 0.4  6.4 ± 0.3  4.6 ± 0.3 # ** 
Lung function    
  FEV1, %predicted  111 ± 3  37 ± 2 #  31 ± 3 # 
  FVC, %predicted  116 ± 3  76 ± 3 #  70 ± 3 # 
  DLCO, %predicted  112 ± 3  53 ± 3 #  39 ± 3 # * 
  PaO2, kPa   -  9.3 ± 0.2  9.3 ± 0.3 
  PaCO2, kPa   -  5.4 ± 0.1  5.7 ± 0.2 
Functional capacity    
  Peak work rate/FFM, W·kg-1  3.4 ± 0.1  1.2 ± 0.1 #  1.3 ± 0.1 # 
 V& O2max/FFM, ml·min-1·kg-1  36.4 ± 1.2  19.2 ± 0.8 #  21.9 ± 1.3 # 
  Handgrip force, kg  40.7 ± 2.4  33.9 ± 1.3 #  31.8 ± 1.5 # 
BMI: body mass index; FFM: fat-free mass, assessed by bioelectrical impedance 
analysis; FFMI: fat-free mass index; FM: fat mass; FMI: fat mass index; FEV1: forced 
expiratory volume in one second; FVC: forced vital capacity; DLCO: diffusing capacity 
for carbon monoxide; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide 
tension; V& O2max: maximal oxygen consumption. Significance of differences between 
patients and controls is indicated as: #: p<0.001. Significant differences between FFM-
depleted and non-FFM-depleted patients are shown as: ** p<0.001 and * p<0.05. 
 
As shown in Figure 4.2, quadriceps and biceps strength was 
significantly reduced in both non-FFM-depleted as well as FFM-
depleted patients. Furthermore, quadriceps strength was significantly 
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lower in FFM-depleted compared with nondepleted patients, whereas 
biceps strength was comparable in both patient groups. Also after 
correcting for FFM, quadriceps (1.57±0.06 N·m·kg-1 versus 2.00±0.07 
N·m·kg-1) and biceps muscle strength (0.53±0.02 N·m·kg-1 versus 
0.64±0.02 N·m·kg-1) were significantly reduced in COPD patients 
compared with controls. However, the difference in quadriceps 
strength between depleted and non-depleted patients disappeared 
after correction for FFM (1.54±0.09 N·m·kg-1 and 1.58±0.07 N·m·kg-
1, respectively, NS).  
 
Figure 4.2 Baseline muscle strength (expressed as peak torque) and fatigue 
(expressed as proportional decline in peak torque per contraction) of the 
lower and upper extremities in controls (white bars), non-FFM-depleted 
COPD patients (light grey bars) and FFM-depleted COPD patients (dark 
grey bars) (mean ± SEM). Quadriceps and biceps muscle strength were 
significantly reduced in both patient groups compared with controls. 
Quadriceps muscle strength was significantly lower in FFM-depleted than 
in non-FFM-depleted patients. Quadriceps fatigue, but not biceps fatigue 
was significantly higher in both patient groups than in controls, while 
fatigue was comparable in subgroups of COPD. ### p<0.001; ## 
p<0.01; # p<0.05 versus controls; * p<0.05 versus non-FFM-depleted 
COPD.  
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Handgrip strength was significantly lower in COPD patients than in 
controls (33.2±0.9 kg versus 40.7±2.4 kg, p<0.01). As shown in 
Table 4.1, both FFM-depleted as well as nondepleted patients had 
decreased handgrip strength, with no difference between these two 
groups. 
Muscle endurance 
Quadriceps muscle endurance was significantly reduced in COPD 
patients and both subgroups compared with controls (proportional 
decline in peak torque per contraction: -2.13±0.12 versus 
-1.61±0.11, p<0.01) and was 80±7 % of the mean control value. 
Lower limb endurance was comparable in FFM-depleted and non-
FFM-depleted patients, as indicated in Figure 4.2. Biceps muscle 
endurance was 10±4% lower in patients than in controls (-2.72±0.11 
and –2.47±0.13, respectively), but the difference was not statistically 
significant. Also, there was no statistically significant difference in 
upper limb muscle endurance between non-FFM-depleted and FFM-
depleted patients. 
Correlation analysis 
On bivariate correlation analysis in the COPD group, quadriceps 
strength (r=0.43, p<0.001), biceps strength (r=0.47, p<0.001) and 
handgrip force (r=0.40, p<0.001) correlated strongly with FFMI, 
while quadriceps and biceps muscle endurance were not related to 
FFMI. Lower (r=0.534, p<0.001) and upper extremity strength 
(r=0.612, p<0.001) correlated strongly with V& O2max. Skeletal muscle 
function was not related to parameters of pulmonary function.  
Effects of exercise training 
After the exercise training programme, both strength as well as 
endurance of the quadriceps muscle increased with 20% in the COPD 
patient group (p<0.01), while biceps muscle function did not 
significantly change (Figure 4.3). Body weight (+1.8±0.3 kg, 
p<0.001) and FFM (+1.5±0.3 kg, p<0.001) significantly increased 
after the pulmonary rehabilitation programme, while FM remained 
unchanged (+0.34±0.2 kg). Peak cycling work rate (+15±2 W, 
p<0.001) and V& O2max (+137±26 ml·min-1, p<0.001) also improved 
significantly, indicating an enhanced exercise capacity in patients. 
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Figure 4.3 Muscle strength (expressed as peak torque) and fatigue (expressed as 
proportional decline in peak torque per contraction) of the lower and 
upper extremities in COPD before (light grey bars) and after (dark grey 
bars) eight weeks of whole-body exercise training in comparison to the 
baseline control group (white bars) (mean ± SEM). The increase in 
strength and reduction in fatigue of the quadriceps muscle during training 
was statistically significant. Biceps muscle function did not change during 
eight weeks of exercise training. ### p<0.001; ## p<0.01 versus 
controls; ** p<0.01 versus baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
The results of the present study can be summarized as follows. First, 
a reduced skeletal muscle function of the lower and upper limbs was 
observed in COPD patients. Quadriceps and biceps muscle strength 
were comparably affected, whereas the loss of muscle endurance 
was restricted to the lower extremities. Also, quadriceps strength 
was more impaired in FFM-depleted patients compared with non-
FFM-depleted patients, whereas biceps strength and peripheral 
muscle endurance were comparable in these groups. Finally, 
enhanced quadriceps muscle function was observed after eight 
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weeks of intensive whole-body exercise training, whereas biceps 
muscle function was unchanged. 
Reduced muscle strength of the lower and upper extremities was 
previously reported in COPD2,9,10,21 and was confirmed here. 
However, the relative involvement of the different muscle groups 
remains controversial. In this study, isokinetic muscle strength of 
quadriceps and biceps muscles was equally affected, indicating 
generalized muscle weakness. This result is not consistent with 
reports of a relatively preserved arm function in COPD2,9,21. Bernard 
et al.9 reported a proportionally greater reduction in isokinetic 
quadriceps strength than that of pectoralis major and latissimus dorsi 
muscles in 34 normal-weight COPD patients compared with controls. 
In addition, Gosselink et al.2 observed lower relative values for 
isometric quadriceps strength compared with handgrip force in 41 
COPD patients, related to reference values. However in another 
study, the same authors10 described a similar extent of weakness for 
quadriceps and arm muscles. In that study, isometric strength of 
proximal arm muscles was more affected than that of distal arm 
muscles. In a recent study of non-volitional muscle strength by Man 
et al.21, quadriceps strength was substantially reduced in COPD, 
whereas strength of adductor pollicis muscle and diaphragm were 
normal. For several reasons, it is difficult to compare the results of 
the various studies. First, quadriceps muscle strength was used as a 
measure for lower limb muscle function in all studies, but numerous 
muscle groups of the upper limbs were investigated. Differences in 
the intensity of recruitment of shoulder girdle muscles, proximal arm 
muscle groups and distal and hand muscle groups during activities of 
daily living may account for various degrees of conditioning of these 
muscle groups and thus for relative differences in the observed 
degree of muscle weakness. Furthermore, the muscles of the 
shoulder girdle are additionally stimulated in COPD patients, because 
they act as accessory inspiratory muscles when ventilatory demands 
increase22. Also, methods and equipment for muscle function testing 
differed, not only between studies, but also between lower and upper 
extremity in the same study2. Furthermore, both isokinetic protocols, 
in which the velocity of muscle contraction is constant, as well as 
isometric protocols, in which muscle fibre length and joint angle are 
constant, were used. Finally, heterogeneity regarding age, sex, 
severity of disease and body composition of the studied COPD 
patients might have contributed to the conflicting results. The 
present study in severe COPD patients, using the same isokinetic 
protocol and equipment for quadriceps and biceps muscle function 
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testing, showed that lower and upper extremity strength were 
equally affected, which is indicative for the presence of generalized 
proximal muscle weakness in COPD.  
This is the first study that explored differences in muscle weakness 
between subgroups of COPD patients with preserved and reduced 
FFM, independent of body weight. Lower extremity muscle strength 
was more impaired in FFM-depleted patients than in patients with a 
preserved muscle mass. After correcting for the difference in FFM 
between the groups, quadriceps strength was comparable, 
suggesting that muscle mass is the main cause of the variation in the 
degree of muscle weakness observed within the COPD group. It is 
however important to notice that significant muscle dysfunction of 
lower and upper extremities was present not only in COPD patients 
with a reduced FFM, but also in patients with a preserved FFM. This 
observation is in contradiction to the results of a recent study by 
Heijdra et al.8, who reported normal values for expiratory and 
handgrip muscle strength in COPD GOLD stage III outpatients with a 
normal FFM index and concluded that a clinically significant systemic 
myopathy is absent in this subset of patients. Quadriceps and biceps 
muscle function was not assessed. The present results, however, 
indicate that although muscle mass is an important determinant of 
muscle strength, the occurrence of muscle dysfunction is not limited 
to a subset of FFM-depleted COPD patients, but is already present in 
patients with preserved muscle mass. Others also observed muscle 
dysfunction in normal-weight COPD patients with a milder degree of 
airflow obstruction13. Since muscle dysfunction contributes to 
exercise intolerance1,2 and reduced quality of life3, specific therapies 
aimed at enhancing muscular performance, such as exercise training 
and  nutritional and anabolic interventions, should not be limited 
beforehand to the subset of cachectic COPD patients. Unlike 
quadriceps strength, biceps muscle strength was not different 
between cachectic patients and those with normal FFM. Since loss of 
muscle mass is strongly related to muscle weakness, a comparable 
biceps strength in the two subgroups suggests that the additional 
muscular atrophy in cachectic patients is mainly restricted to the 
lower limb muscles. Among other factors, chronic underuse of 
locomotor muscles of the lower extremities is probably important in 
the development of this additional atrophy. Although this study 
included detailed measurements of body composition, the regional 
distribution of muscle mass was not assessed. 
The ratio of muscle strength to whole-body FFM was reduced in 
COPD patients compared with controls. Also, differences in muscle 
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strength between patients with preserved and reduced FFM 
disappeared after correcting for FFM. This observation is in 
agreement with a study by Engelen et al.5, who reported lower 
values for muscle function per kilogram of whole-body FFM in COPD 
compared with controls. In contrast, muscle function per kilogram of 
extremity FFM was comparable in patients and controls in that study. 
In addition, a normal ratio of quadriceps strength to quadriceps 
muscle cross-sectional area was reported in COPD9. These combined 
results indicate a relative redistribution of FFM in COPD with 
preservation of trunk FFM and predominant loss of extremity muscle 
mass.  
In accordance with previous publications12-14, impaired quadriceps 
muscle endurance was perceived in this study. The observation of a 
comparable muscular endurance in COPD patients with normal and 
reduced FFM is new. In agreement with this observation, muscle 
mass, assessed by FFM, was not related to muscle endurance in the 
COPD group or in controls. This suggests that intrinsic muscular 
abnormalities are involved in increased skeletal muscle fatigue in 
COPD. These abnormalities include alterations in muscle substrate 
and energy metabolism and altered muscle fibre type distribution23. 
Although a causal relationship between morphological or metabolic 
alterations in skeletal muscle and muscle function has not been 
shown in COPD, a role for increased exercise-induced muscle 
oxidative stress in the development of decreased quadriceps 
endurance was recently suggested14. Contrary to lower extremity 
endurance, upper limb muscle endurance was comparable in COPD 
patients and controls, suggesting that this component of upper 
extremity muscle function is preserved. This finding is supported by 
the study of Clark et al.13. Despite a reduced quadriceps endurance 
and impaired strength for lower and upper limbs, sustained isokinetic 
arm function was normal in a group of normal-weight mild COPD 
patients. In addition to the normal upper limb muscle endurance in 
the present study, preserved values for arm mechanical efficiency 
and peak arm exercise capacity were recently reported in a 
comparable group of COPD patients24. These combined observations 
might very well be related to an uneven distribution of intrinsic 
alternations, such as changes in percentage type I muscle fibres and 
oxidative capacity, in peripheral skeletal muscles between leg and 
arm of COPD patients25.    
The efficacy of exercise training as part of a respiratory rehabilitation 
programme in improving functional exercise capacity in COPD is well 
established26,27. In the present group of patients with baseline 
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muscle weakness, eight weeks of whole-body exercise training 
resulted in improvements in quadriceps strength and endurance by 
20% and an increase of 16% in maximal oxygen uptake. These 
improvements very likely resulted from the combination of highly 
intensive aerobic cycling and treadmill training, which formed the 
major components of the physical training programme, and lower 
limb strengthening exercises. Significant crossover training effects 
between strength and endurance training were previously described 
and the combination of these training modalities seems an optimal 
strategy for COPD patients28,29. Considerable increases in quadriceps 
strength after aerobic training28,30,31 and improvements in endurance 
performance after resistance training29 were reported. The results of 
the present study confirm that muscle dysfunction in COPD is 
remediable with aimed therapy and that the applied methodology for 
measuring strength and endurance can be used to evaluate the 
outcome of rehabilitation. In contrast to lower extremity 
performance, biceps muscle weakness, which was determined with 
identical methodology at baseline, was not repelled during the 
rehabilitation period. The lack of a training effect is probably related 
to intensity and specificity of the exercise training. Although subjects 
participated in daily unsupported arm exercises, gymnastics 
involving arm activities and individualized upper limb resistance 
training, the training stimulus to the muscle groups of the upper 
limbs may have been insufficient. Furthermore, specificity of training 
effects for trained muscle groups in COPD was earlier demonstrated 
by Lake et al.32. Upper limb exercises resulted in improved arm 
performance, while lower limb training increased walking distance. 
No crossover training benefits were seen between arms and legs. As 
mentioned before, lower extremity endurance training was the main 
component of the exercise programme. Baseline preservation of 
upper extremity muscular structure, metabolism and endurance 
capacity may also have contributed to the lack of response of arm 
function to the offered comprehensive training programme.   
Clinical implications 
This study showed that muscular dysfunction of lower and upper 
extremities occurs in both cachectic COPD patients as well as 
patients with a relatively normal body composition. Loss of muscle 
mass is a main contributor to muscle weakness, but the loss of 
muscle endurance and the reduced strength per kilogram muscle 
mass suggest that other factors are also important. Limiting specific 
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therapies aimed at enhancing muscle function or exercise tolerance 
to patients with a reduced FFM, would result in an undertreatment of 
the group of patients with functional impairments despite a normal 
body composition. Therefore, screening of COPD patients for such 
therapies should include not only assessments of body mass index 
and FFM, but also measurements of muscle function. Furthermore, 
the results of muscle function testing in this study indicate that 
strength and endurance are distinct and independent components of 
muscle function, which should ideally both be determined when 
assessing muscle performance in clinical and scientific setting in 
COPD. Whereas the equal distribution of strength loss between lower 
and upper extremities is indicative for a systemic muscle 
involvement, the normal endurance component of muscle function of 
the upper limb suggests structural and metabolic differences 
between leg and arm in COPD. 
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Abstract 
Introduction 
Skeletal muscle wasting is related to muscle dysfunction, exercise intolerance and 
increased mortality risk in patients with chronic obstructive pulmonary disease 
(COPD). The aims of this study were to investigate the effects of whole-body exercise 
training on body composition in normal-weight COPD patients and to study the 
relationship between changes in body composition and functional capacity.  
 
Methods 
Fifty COPD patients (FEV1: 39% of predicted [SD, 16]) admitted to pulmonary 
rehabilitation centre Hornerheide, and 36 healthy age-matched controls (for baseline 
comparison) were included. Patients participated in a standardized inpatient exercise 
training programme consisting of daily submaximal cycle ergometry, treadmill 
walking, weight training and gymnastics during eight weeks. Fat-free mass (FFM) was 
measured by bioelectrical impedance analysis. None of the patients met the criteria for 
nutritional supplementation (BMI ≤21 kg·m-2 or FFM Index ≤15 kg·m-2 in females and 
≤16 kg·m-2 in males). Exercise capacity was measured using incremental cycle 
ergometry. Isokinetic quadriceps strength was measured with a Biodex dynamometer 
(Biodex Medical Corporation; Shirley, New York, USA). 
 
Results 
At baseline, patients were characterized by a significantly lower FFM than the control 
subjects. Age and FFM were independent predictors of skeletal muscle function and 
exercise capacity in patients. After rehabilitation, weight (72.4±9.8 kg to 73.0±9.4 kg, 
p<0.05) significantly increased, as a result of increased FFM (52.4±7.3 kg to 53.4±7.7 
kg, p<0.05), while fat mass (20.0±6.1 kg to 19.6±5.7 kg) tended to decrease. Peak 
work rate (63±29 W to 84±42 W, p<0.001), maximal oxygen consumption (1028 ± 
307 ml·min-1 to 1229±421 ml·min-1, p<0.001) and isokinetic quadriceps strength 
(82.5±36.4 N·m to 90.3±34.9 N·m, p<0.05) all improved. Changes in FFM were 
proportionally smaller than functional improvements, and were related to changes in 
maximal oxygen consumption (r=0.361, p<0.05), but not to other changes in 
functional capacity. 
 
Conclusions 
Intensive exercise training per se is able to induce an anabolic response in normal-
weight COPD patients classified into GOLD stages III-IV. Improvements in exercise 
performance and muscle function are proportionally larger than increases in FFM. 
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Introduction 
Muscle wasting is a common systemic manifestation in patients with 
advanced chronic obstructive pulmonary disease (COPD). Reductions 
in fat-free mass (FFM), as an indirect measure of muscle mass, may 
be a result of weight loss, but may also occur disproportionate to 
weight loss and in a substantial proportion of patients with a normal 
body weight1,2. Loss of muscle mass has been related to skeletal 
muscle dysfunction3 and exercise intolerance4 in these patients. 
Moreover, weight loss and skeletal muscle mass are strong 
predictors of mortality risk in COPD5,6, independent of the degree of 
airflow limitation.  
Weight loss and muscle wasting have long been considered 
irreversible terminal events in the progression of COPD. However, in 
the last decades several investigators have challenged this concept 
and showed positive effects of anabolic interventions such as caloric 
supplementation as integrated part of a pulmonary rehabilitation 
programme and anabolic agents. One study furthermore showed that 
weight gain is associated with increased survival in these patients5. 
Until now, most studies investigated body weight and body 
composition changes only in malnourished patients. Recently 
however, the prognostic importance of weight change was also 
shown in normal-weight patients7 and in another study muscle mass 
was even more closely related to survival than body weight in 
normal-weight COPD patients6. However instead of caloric 
intervention, exercise is the first option in normal-weight stable 
patients to increase muscle mass. Therefore, the first aim of the 
present study was to investigate if whole-body exercise per se is able 
to induce anabolism in these patients.  
Based on the relationship between muscle wasting and functional 
capacity, it can be hypothesized that improvements in exercise 
capacity and muscle function after exercise training programmes in 
COPD are related to changes in body composition. This relationship 
however is yet unclear in COPD, due to a lack of studies on the 
effects of exercise training in COPD that included detailed 
measurements of changes in body composition. Therefore, the 
second aim of this study was to investigate the relationship between 
changes in exercise performance, muscle function and muscle mass. 
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Methods 
Participants 
The study group consisted of 50 patients with moderate to severe 
COPD8 consecutively admitted to Asthma Centre Hornerheide for an 
intensive inpatient pulmonary rehabilitation programme. Baseline 
characteristics are presented in Table 5.1. For inclusion, FEV1 had to 
be less than 70% of the reference value and the increase in FEV1 
after inhalation of a β2-agonist had to be less than 10% of the 
reference value. None of the patients met the criteria for nutritional 
supplementation, which were defined as body mass index (BMI)≤21 
kg/m2 and/or FFM Index ≤15 kg·m-2 in females and ≤16 kg·m-2 in 
males. Patients in clinically unstable condition were excluded from 
participation in the study. Other exclusion criteria were malignancies, 
clinically apparent heart failure, renal, hepatic or gastro-intestinal 
abnormalities, insulin dependent diabetes mellitus, inflammatory 
disease and recent surgery. Patients were receiving the following 
pulmonary maintenance medication: inhaled short- and long-acting 
β2-adrenoceptor agonists, 76%; anticholinergics by inhalation, 78%; 
combined inhalers of short-acting β2-adrenoceptor agonists and 
short-acting anticholinergics, 18%; inhalation corticosteroids, 60%; 
combined inhalers of β2-sympathicomimetics and corticosteroids, 
22%; and oral N-acetylcysteine, 66%. At the time of admission to 
the pulmonary rehabilitation centre, 16% of patients were current 
smokers, 78% were ex-smokers and 6% were non-smokers. 
Smoking was not allowed during the entire rehabilitation period. 
Smoking history of the current smokers (52±18 packyears) was 
significantly increased compared to that of ex-smokers (35±20 
packyears, p<0.05), while there were no significant differences in 
age, body composition, lung function or functional capacity between 
these two groups. Also, the responses to exercise training were 
comparable in both groups. 
Thirty-six age-matched healthy volunteers were recruited from an 
advertisement in a local newspaper for baseline comparison of body 
composition and functional capacity. Controls did not participate in 
any exercise training programme. Written informed consent was 
obtained from all subjects and the ethical review board of the 
University Hospital Maastricht approved the study. 
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Study design 
Patients were included within the first two weeks after admission to 
the pulmonary rehabilitation centre. During this period, subjects 
underwent medical examination by a chest physician and the 
baseline measurements of pulmonary function, body composition, 
exercise performance and muscle function were performed. 
Furthermore, this two-week period allowed for familiarization with 
the various procedures in order to avoid learning effects.  
After two weeks, patients participated in a comprehensive inpatient 
respiratory rehabilitation programme consisting of exercise training 
during five days per week, education and (when appropriate) 
psychosocial and behavioural intervention. During their stay in the 
rehabilitation centre, a standardized weight maintaining diet was 
offered to all patients. The aimed daily dietary protein intake was 60 
to 80 g. No additional nutritional supplements or anabolic agents 
were used. The physical exercise-training programme consisted of a 
combination of endurance and strength exercise training. 
Submaximal cycle ergometry was performed twice a day for 20 
minutes. Initial load was set at 50-60% of baseline peak work rate. 
Thereafter, training intensity was adapted to maintain the same 
relative training load during the intervention period under 
supervision of an exercise therapist. In addition, patients exercised 
on a treadmill for 20 minutes per day just below their symptom-
limited rate. All patients participated in daily 30 minutes of 
gymnastics, focused at either strength and endurance or mobilisation 
and flexibility. Furthermore, patients attended daily unsupported arm 
exercise training sessions, consisting of 10 times one minute of 
exercise, followed by one minute of rest. Dynamic strength training 
exercises of the upper and lower extremities were incorporated in the 
programme. Muscle groups, load and number of repetitions were 
determined for each individual and were based on the experienced 
functional impairments in daily living and evaluation of the patients’ 
muscular performance by a team of experienced physiotherapists. 
Assessments 
Pulmonary function 
Lung function testing included forced spirometry and assessment of 
lung volumes by whole-body plethysmography (Masterlab, Jaeger, 
Würzburg, Germany). FEV1 and forced vital capacity (FVC) were 
calculated from the flow-volume curves. The highest values of at 
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least three measurements were used. Maximal voluntary ventilation 
was indirectly estimated from FEV1 9. Diffusing capacity for carbon 
monoxide (DLCO) was measured by the single breath method 
(Masterlab, Jaeger, Würzburg, Germany). Instruments were 
calibrated twice a day. All values obtained were expressed as a 
percentage of reference values10. Arterial blood gas analysis was 
performed in all patients at rest (Radiometer ABL 330, Copenhagen, 
Denmark). 
Anthropometric measurements 
In COPD patients, anthropometric measurements were performed on 
admission and after 2, 4, 6 and 8 weeks of exercise training. Body 
height was determined to the nearest 0.5 cm (WM 715, Lameris, 
Breukelen, The Netherlands) with subjects standing barefoot. Body 
weight was measured with a beam scale (SECA, Hamburg, Germany) 
without shoes and in light clothing to the nearest 0.1 kg. BMI was 
calculated as the ratio of weight to height in meters squared. FFM 
was measured by bioelectrical impedance analysis at a frequency of 
50 kHz (Xitron 4000b, Xitron technologies, San Diego, California, 
USA). Resistance was measured in supine position at the right side 
as described by Lukaski et al.11. A patient specific regression 
equation, described by Schols et al.12 was used to calculate FFM in 
COPD subjects. FFM index was calculated as the ratio of FFM to 
height in meters squared. 
Exercise capacity 
At baseline and after eight weeks, all patients performed an 
incremental exercise test on an electrically braked cycle ergometer 
(Corival 400, Lode, Groningen, The Netherlands) under supervision 
of a chest physician. Before the start of the test, while seated on the 
cycle ergometer, ventilation characteristics at rest were analysed 
during two minutes. During the entire exercise test, expired gases 
were investigated using breath-by-breath analysis through a 
breathing mask (Oxycon Beta, Jaeger, Würzburg, Germany). Heart 
rate, blood pressure and percutaneous oxygen saturation were 
monitored. After one minute of unloaded cycling, power was 
increased in patients by 10 W every minute. In control subjects, the 
load was increased with 15 to 25 W every minute, so that the 
duration of the test was equal in patients and controls. None of the 
subjects knew the exercise load and all were encouraged to cycle at 
60 revolutions·min-1 until exhaustion.  
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Skeletal muscle strength 
Isokinetic quadriceps strength of the dominant leg was measured 
using a Biodex dynamometer (Biodex Medical Corporation, Shirley, 
New York, USA) before and after the training programme. The 
testing protocol consisted of fifteen sequential maximal voluntary 
contractions at an angular velocity of 90º·s-1. Quadriceps strength 
was defined as the highest peak torque in this series of fifteen. 
During the test, subjects were seated upright on the chair of the 
dynamometer with support of the back. At the level of the chest, 
pelvis and thigh, subjects were restrained with straps. The hip joint 
was at an angle between 90 and 100º of flexion during testing. The 
lever arm was attached to the distal part of the tibia and its axis of 
rotation was visually aligned with the anatomical axis of flexion of 
the knee joint. Subjects were instructed to keep their hands on their 
thighs during testing. In order to avoid learning effects, all subjects 
practiced on the dynamometer under supervision of a physiotherapist 
the day before the actual test. 
Statistical analysis 
Results are expressed as mean±standard deviation, unless indicated 
otherwise. Statistical analysis on baseline differences between 
patients and controls was performed using an unpaired Student’s 
t-test. Changes within the COPD group between baseline and week 
eight were tested with Student’s paired t-test for dependent 
samples. Pearson’s correlation analysis was performed in the patient 
group in order to investigate linear relationship between variables of 
(changes in) body composition and (changes in) exercise capacity 
and muscle function. Multiple stepwise regression analysis was used 
to identify independent predictors of exercise performance and 
quadriceps strength. All p values <0.05 were considered statistically 
significant. 
Results 
Baseline characteristics of the study groups are presented in Table 
5.1. Fifty patients (37 men and 13 women) met the selection criteria 
and were enrolled in the study. Mean age of the COPD patients was 
64 years. BMI averaged 25.0 kg·m-2 and mean FFM Index was 18.1 
kg·m-2, which indicates that the patients had a normal body weight 
and FFM and were not eligible for nutritional supplementation. 
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However, BMI of the patients was significantly reduced in comparison 
to the 36 age-matched control subjects, as a result of a 6.3 kg 
difference in FFM (p<0.01), despite a comparable fat mass. On 
average, patients suffered from moderate to severe airflow 
obstruction with hyperinflation and reduced diffusing capacity for 
carbon monoxide. Group values for PaO2 and PaCO2 were within the 
normal limits. Six patients received long-term oxygen therapy. At 
baseline, exercise capacity and quadriceps strength of patients were 
significantly reduced compared to controls. These differences in 
functional exercise capacity also existed after correction for FFM.   
 
Table 5.1 Baseline characteristics of the study groups (mean ± SD).  
 Control 
subjects 
COPD 
patients 
  Subjects (♂/♀), No 36 (24/12) 50 (37 / 13) 
  Age, yr  61 ± 6  64 ± 9 
Body composition   
  Height, cm  171.9 ± 9.3  169.9 ± 7.0 
  Weight, kg  78.4 ± 11.6  72.4 ± 9.7 # 
  BMI, kg·m-2  26.4 ± 2.5  25.0 ± 2.8 # 
  FFM, kg  58.7 ± 10.8  52.4 ± 7.1 ## 
  FFMI, kg·m-2  19.7 ± 2.1  18.1 ± 1.8 ### 
  FM, kg  19.8 ± 7.4  20.0 ± 6.0 
Pulmonary function   
  FEV1, %predicted  111 ± 17  39 ± 16 ### 
  FVC, %predicted  116 ± 15  77 ± 20 ### 
  TLC, %predicted  107 ± 10  113 ± 17 
  DLCO, %predicted  112 ± 17  56 ± 21 ### 
  PaO2, kPa   -  9.3 ± 1.1 
  PaCO2, kPa   -  5.4 ± 0.9 
Functional capacity   
  Peak work rate, W  198 ± 66  63 ± 29 ### 
 V& O2max, ml·min-1  2129 ± 658  1028 ± 307 ### 
 V& O2max/FFM, ml·kg-1·min-1  36.5 ± 6.5  19.3 ± 4.7 ### 
  QF, N·m  118 ± 37  83 ± 36 ### 
  QF/FFM, N·m·kg-1  2.00 ± 0.42  1.55 ± 0.57 ### 
BMI: body mass index; FFM: fat-free mass, assessed by bioelectrical impedance 
analysis; FFMI: fat-free mass index; FM: fat mass; FEV1: forced expiratory volume in 
one second; FVC: forced vital capacity; TLC: total lung capacity; DLCO: diffusing 
capacity for carbon monoxide. PaO2: arterial oxygen tension; PaCO2: arterial carbon 
dioxide tension; V& O2max: maximal oxygen consumption ; QF : isokinetic quadriceps 
strength. Significance of differences between patients and controls is indicated as: #: 
p<0.05; ##: p<0.01; ###: p<0.001. 
 
In bivariate correlation analysis in the COPD group, age, FFM, FEV1, 
DLCO and PaO2 all significantly correlated with maximal oxygen 
consumption (V& O2max) and peak work load (Wmax) (data not shown). 
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These parameters were entered in a stepwise regression model with 
V& O2max as dependent variable (Table 5.2). FFM alone accounted for 
38% of the variation in V& O2max and in combination with age and DLCO 
explained 56% of variation in V& O2max. FEV1 and PaO2 were excluded. 
When entering Wmax as dependent variable, FFM, age, FEV1 and DLCO 
all individually contributed and explained 49% of variation. 
Furthermore, FFM and age of patients, but none of the variables of 
pulmonary function, were independently related to isokinetic 
quadriceps strength with a total adjusted r2 of 0.50. FFM and age 
were not mutually correlated (r=-0.024, p=0.868). Also, isokinetic 
quadriceps strength was related to V& O2max and Wmax (r=0.54 and 
r=0.40 respectively, p<0.01) at baseline. 
 
Table 5.2 Results of stepwise regression analysis for baseline exercise capacity and 
quadriceps strength in COPD patients.  
 V& O2max, ml·min-1 Wmax, W QF, N·m 
Age, yr -0.37 **  -0.43 *** -0.33 *** 
FFM, kg   0.55 *** 0.22 * 0.63 ** 
FEV1, l  NS  0.37 **  NS 
DLCO, %predicted 0.33 ** 0.25 *  NS 
PaO2, kPa  NS  NS  NS 
V& O2max: maximal oxygen consumption; Wmax: peak work rate; QF: isokinetic 
quadriceps stength; FFM: fat-free mass; FEV1: forced expiratory volume in one 
second; DLCO: diffusing capacity for carbon monoxide. PaO2: arterial oxygen tension. 
Partial r values are shown. Significance of relationships is indicated as: *: p<0.05; **: 
p<0.01; ***: p<0.001. NS: not statistically significant. 
 
Changes in body composition after eight weeks of exercise training 
are shown in Figure 5.1. After training, body weight significantly 
increased from 72.4±9.8 kg to 73.0±9.4 kg (p<0.05), as a result of 
an increase in FFM from 52.4±7.3 kg to 53.4±7.7 kg (p<0.05). 
There was a slight decrease in fat mass by 0.4 kg (NS). Forty-six 
percent and 58% of the gain in body weight and FFM, respectively, 
were achieved in the last two weeks of the intervention period. 
Exercise performance was significantly enhanced during the training 
period, as indicated by the 35% increase in peak work rate 
(p<0.001) and 17% increase in V& O2max (p<0.001) (Figure 5.2, 
panels A and B). The relative increase in peak work rate was greater 
than the improvement in V& O2max (p<0.01). COPD patients 
demonstrated a 30% improvement in quadriceps strength (p<0.05), 
as shown in panel C of Figure 5.2.  
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Figure 5.1 Changes in anthropometric measurements in nondepleted COPD patients 
during eight weeks of whole-body physical exercise training embedded in 
an inpatient respiratory rehabilitation programme (mean ± SEM). A) 
Change in body weight. Weight after eight weeks of intervention was 
significantly increased, compared to baseline. B) Change in FFM. A 
consistent and significant increase in FFM was observed during exercise 
training. C) Change in fat mass. Fat mass tended to decrease during the 
training programme. Significant within-group differences were detectable 
at eight weeks. *: p<0.05 versus baseline. 
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Figure 5.2 Individual and mean responses of functional exercise capacity and 
muscle strength during eight weeks of whole-body exercise training. A) 
Change in V& O2max. B) Response of Wmax. C) Change in isokinetic 
quadriceps strength. All variables improved significantly. Closed circles 
and lines are individual values at baseline and after eight weeks. Open 
circles represent mean values and SEM. *: p<0.05 ;  ***: p<0.001 versus 
baseline. 
 
 
 
 
 
 
 
 
 
 
Changes in FFM correlated significantly with changes in V& O2max, but 
not with changes of Wmax or quadriceps strength (Figure 5.3). 
Changes in V& O2max and Wmax were mutually related (r=0.644, 
p<0.001). Changes in V& O2max, Wmax or quadriceps strength were not 
related to age of the COPD patients, i.e. older patients showed a 
comparable anabolic response than younger patients (data not 
shown). 
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Figure 5.3 Bivariate correlations between changes in FFM and changes in functional 
exercise capacity and muscle function. A) Change in VO2max is related to 
change in FFM (r=0.361, p<0.05, n=36). B) Change in Wmax is not 
related to change in FFM (r=-0.080, NS, n=43). C) Change in quadriceps 
strength is not related to change in FFM (r=-0.009, NS, n=39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
The results of the present study indicated that intensive exercise 
training per se is able to induce an anabolic response in normal-
weight COPD patients. After eight weeks of whole-body exercise 
training, body weight increased as a result of increased FFM, while 
body fat tended to decrease. Although exercise performance and 
muscle strength were strongly related to skeletal muscle mass at 
baseline, changes in functional capacity after the training programme 
were only partially related to changes in body composition. Finally, it 
was shown that age is a predictor of baseline functional capacity in 
COPD patients, independent of FFM and pulmonary function, but not 
of the response to rehabilitation. 
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Exercise as anabolic stimulus 
Improvements in exercise performance, peripheral muscle function 
and quality of life after exercise training in patients with COPD are 
well documented13,14. However, the influence of exercise training per 
se on body composition has rarely been studied in COPD. In the 
present study, body weight and FFM increased in normal-weight 
patients after a balanced exercise training programme of both 
endurance as well as strength training. This suggests that exercise 
training can act as an anabolic stimulus in these patients. These 
results are in accordance with a study by Bernard et al.13, who 
reported enhanced bilateral midthigh muscle cross-sectional area, a 
measure of skeletal muscle mass, assessed by computed 
tomography after 12 weeks of aerobic training combined with 
strength training in normal-weight COPD patients. However, BMI did 
not change in their group. The changes in body composition reported 
in this study are similar to those reported after exercise conditioning 
in healthy elderly subjects. Besides improved muscle function, 
Frontera et al.15 described a 0.5 and 1.0 kg increase in body weight 
and FFM, respectively, after 12 weeks of strength training in 
untrained healthy older men. In general, the ability of exercise to 
induce changes in body weight, FFM and fat mass is affected by 
various factors, including the type, intensity, frequency and duration 
of exercise16. Traditionally, whole-body endurance training played a 
central role in pulmonary rehabilitation. In order to reverse muscle 
weakness and increase muscle mass, however, resistance training 
might be more effective and various combined training regimens are 
currently being implemented in respiratory rehabilitation in patients 
with COPD. The results of this study confirm that a combination of 
whole-body endurance training and strength training results in 
improved physiological function, but may also increase FFM. 
Clinical implications of muscle wasting in normal-weight 
COPD patients 
The results of this study in normal-weight patients are different from 
findings in depleted patients with COPD. Schols et al.17 studied the 
effects of nutrition intervention versus placebo treatment embedded 
in the same pulmonary rehabilitation programme in both depleted as 
well as nondepleted patients with COPD. Depleted patients who did 
not receive nutritional support showed no significant changes in body 
weight, FFM or respiratory muscle function after eight weeks of 
whole-body exercise training. In this group FFM even tended to 
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decrease by 0.6 kg. A subsequent study by Creutzberg et al.18 
showed that nutritional supplementation therapy implemented in a 
pulmonary rehabilitation programme resulted in improved body 
composition, exercise performance, muscle function and quality of 
life in depleted or weight-losing patients with COPD. The discrepancy 
in response to exercise training between depleted and nondepleted 
patients might be related to enhanced protein catabolism in depleted 
patients with COPD19. In order to induce an anabolic response in 
depleted patients, extensive nutritional support, including caloric 
supplements and anabolic agents is probably indicated, whereas this 
study shows that less intervening physiologic interventions are 
sufficient in normal-weight patients.  
Although the patients with COPD in this study had a normal body 
weight and were not eligible for nutritional support, their body mass 
index was significantly lower than that of the age-matched control 
subjects. This difference in body weight resulted from a significantly 
lower FFM in patients, despite a comparable fat mass. These baseline 
results once again indicate that loss of FFM may occur in normal-
weight patients and that nutritional assessment in patients with 
COPD should include measurements of both body weight and FFM.  
Relationship between functional improvements and 
changes in body composition 
In the present study, changes in functional capacity were only in part 
related to changes in FFM, although at baseline FFM was a strong 
predictor of cycling performance and quadriceps strength. Also, the 
increase in FFM (2%, p<0.05) was insufficient to account for the 
increases in V& O2max, Wmax and strength. Despite the lack of 
correlation, the vast majority of patients showed enhanced functional 
capacity, FFM, or both (Figure 5.3). Several possible explanations 
may account for the absence of a direct relationship between 
improvements in muscle mass and functional capacity. In the present 
study whole-body FFM was used as an indirect measure of muscle 
mass. Local increase in quadriceps muscle bulk as a result of 
exercise training was not assessed and may have been 
underestimated by the use of bio-electrical impedance analysis. It 
was previously reported that quadriceps muscle quantity and 
strength are directly related to cycling capacity and walking 
distance20,21. In the previously mentioned study of Bernard et al.13 
quadriceps muscle mass was assessed before and after exercise 
training. Correlations between changes in quadriceps muscle cross-
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sectional area and functional improvements however were not 
mentioned. Low sensitivity of bioelectrical impedance analysis to 
detect local changes and redistributions in muscle mass probably 
plays a minor role in the nonexistence of a relationship between 
changes in muscle structure and functional capacity. In accordance 
with the present results, several investigations in healthy subjects 
showed that gains in muscle strength after resistance training were 
not related to local muscle hypertrophy15,22 and that increments in 
strength were proportionally greater than increases in muscle bulk.  
In addition to an increase in FFM, exercise training induces intrinsic 
alterations in skeletal muscle, such as increments in mitochondria or 
oxidative enzymes, which contribute to the improved physiologic 
function and may explain the lack of correlation between increased 
FFM and functional capacity. Furthermore, as a result of exercise 
training, patients with COPD might have developed the ability to 
increase motor-unit recruitment during exercise and thereby 
performance might have increased more than muscle mass22. Others 
also suggested a contribution of neurological factors to functional 
improvements after training in elderly15. Finally, decreased exertional 
dyspnea and anxiety to engage in exercise and increased motivation 
after pulmonary rehabilitation may also have contributed to the 
disproportionate gain in functional capacity, compared with FFM. In 
order to further investigate the possible mechanisms whereby 
functional capacity might be increased more than muscle mass future 
studies are necessary. A prospective study consisting of a 
combination of local assessments of muscle mass, muscle biopsies 
and non-volitional strength measurements before and after an 
exercise training programme would be able to discriminate between 
the mentioned factors. 
Changes in FFM were positively related to changes in V& O2max, but not 
with changes in Wmax, although improvements in functional 
parameters were strongly correlated. The reason for this discrepancy 
is not readily apparent. The facts that muscle mass is the 
metabolically active tissue and that the effort to exercise influences 
peak work rate more than oxygen consumption probably contribute 
to this observation. 
Determinants of functional capacity 
FFM was strongly related to exercise capacity and muscle strength, 
which is in accordance with earlier studies1,3,4. In keeping with the 
conclusions of Hamilton et al.20, quadriceps strength was related to 
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maximal work capacity. Loss of muscle mass and redistribution of fat 
mass with age have been demonstrated and are referred to as 
sarcopenia. Also, the normal aging process is accompanied by a 
decline in functional capacity23. Frontera et al.24 observed reduced 
muscle strength in 65- to 78-year-old men and women compared to 
younger subjects. When adjusted for FFM, estimated from 
hydrostatic weighing, age-related differences disappeared, indicating 
that loss of muscle mass is the most important determinant of age-
related differences in skeletal muscle strength. Reduced muscle mass 
and strength also contribute to the decrease in maximal aerobic 
exercise capacity that occurs during aging25. In the present cross-
sectional study in 43- to 78-year-old patients with COPD, advanced 
age was negatively related to muscle function and exercise capacity. 
Moreover, stepwise regression analysis showed that the relationship 
between age and functional capacity was independent of the 
influence of FFM. Also, no mutual correlation was observed between 
FFM and age. These results suggest that age-related factors, other 
than loss of FFM, contribute to disability in patients with advanced 
COPD and that the course of the aging process may be different in 
COPD compared with healthy subjects. Potential factors contributing 
to age-related functional impairment in COPD include changes in 
muscle morphology and energy metabolism and reduced activity of 
motor neurons. Larsson et al.26 observed a selective atrophy of type 
II muscle fibres and a decreased proportion of type II fibres in 
biopsies of the vastus lateralis muscle with increasing age in 51 
healthy male subjects of different ages. In the same study, it was 
found that age, FFM and type II fibre area were independent 
predictors of the age-related decline in strength. In accordance with 
these findings, a preferential muscle fibre type IIX atrophy was 
recently reported in vastus lateralis biopsies of COPD patients27. 
Thus, muscular type II fibre atrophy may partially explain muscular 
weakness with increasing age, independent of the loss of lean body 
mass in COPD. Reduced oxidative capacity of vastus lateralis muscle 
has been reported in COPD28 and is related to peak exercise capacity. 
However, no major alterations in the activities of oxidative or 
glycolytic enzymes in skeletal muscles were described in relation to 
age in healthy subjects29. Thus, it is unlikely that changes in muscle 
energy metabolism in COPD result from accelerated aging. Studies 
have shown that both the number and size of active motor units are 
affected during aging30, but the prevalence and role of these and 
other neuropathic changes in age-related functional impairment in 
patients with COPD is unknown. Although advancing age was 
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independently related with reduced functional capacity in COPD, the 
exact mechanism behind this observation remains unclear. The 
effects of the exercise training programme on weight, FFM and 
exercise performance were not related to age of the participants, 
indicating that the ability to adapt to an anabolic stimulus is 
maintained in older COPD patients.  
In conclusion, normal-weight COPD patients classified into GOLD 
stages III-IV show an anabolic response to physical exercise training, 
which together with other training-induced adaptations contributes to 
functional improvements. The influence of changes in FFM on 
prognosis in normal-weight patients needs to be studied. 
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Introduction  
In the last decades it has become clear that COPD is more than a 
chronic disease affecting the lungs. Peripheral skeletal muscle 
dysfunction and loss of fat-free mass have been identified as extra-
pulmonary manifestations of the disease with significant clinical 
implications. The recognition of the role of abnormal muscle function 
and body composition in symptomatology and prognosis of COPD 
patients has offered new treatment opportunities, including 
pulmonary rehabilitation. It is important to understand the 
pathophysiology of skeletal muscle dysfunction, in order to design 
strategies for intervention. A systematic review of the literature 
(chapter 2) revealed a shift from type I to type II skeletal muscle 
fibres and an impaired skeletal muscle oxidative capacity of the lower 
extremities in COPD and other chronic organ diseases. The etiology 
of skeletal muscle dysfunction is complex and only partially 
understood. Instead of one leading mechanism, a combination of 
several disease-related factors and comorbid conditions probably 
accounts for the alterations described in chapter 2. These COPD-
related factors include chronic hypoxia1-3, oxidative stress4, acute 
and chronic hypercapnia5-7 and persistent low-grade systemic 
inflammation8-10. In addition, semi-starvation and deconditioning are 
two conditions that may very well contribute to skeletal muscle 
dysfunction in COPD, as was extensively reviewed in chapter 2. The 
following section will focus on implications of sarcopenia in COPD.  
COPD and sarcopenia: common traits 
Body composition and functional implications 
Sarcopenia, which literally means “poverty of the flesh” in Greek, is 
used to describe age-related loss in skeletal muscle mass and 
functioning11. Multiple factors are considered to contribute to 
sarcopenia, including loss of α-motoneuron activity, alterations in 
endocrine function, a sedentary lifestyle and changes in protein 
metabolism12. Although basal rate of muscle protein synthesis was 
not reduced in elderly men with muscle loss and net muscle protein 
balance was similar compared with younger men13, the response of 
skeletal muscle to endocrine and nutritional stimuli seems impaired 
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at advanced age. Insulin is a potent anabolic stimulus for skeletal 
muscle, primarily by promoting protein synthesis14. In the elderly 
however, muscle protein synthesis is resistant to the anabolic action 
of insulin, independent of glucose tolerance15. Also, responsiveness 
of muscle protein synthesis to essential amino acid ingestion is 
diminished in advanced age, independent of insulin signaling16. 
Similar to the age-related adaptations, a substantial proportion of 
COPD patients suffers from reduced fat-free mass, despite a normal 
body weight17. This subgroup of patients is often referred to as the 
sarcopenic phenotype of COPD and is characterized by impaired 
muscle strength18, exercise intolerance17, poor health status19 and 
increased mortality risk20 in comparison to patients with relatively 
preserved fat-free mass. Since most cross-sectional studies in COPD 
included age-matched controls, it was hypothesized that an 
increased rate of aging contributes to the quantitative change in 
muscle mass in patients with chronic airflow limitation21. However, 
no longitudinal studies have investigated potential differences in rate 
of development of sarcopenic changes in skeletal muscle between 
COPD patients and healthy subjects. Considering the possible 
etiology of accelerated muscle wasting in weight stable COPD 
patients, a potential role for reduced insulin action on protein 
metabolism is intriguing. Although hardly studied, available data 
suggest increased circulating insulin levels in normal-weight COPD 
patients22,23 and decreased insulin sensitivity of glucose metabolism 
was reported in some of these patients23,24. Also, significant 
disturbances in protein metabolism were observed in patients with 
COPD. In normal-weight patients, increased whole-body protein 
breakdown and synthesis were observed25, while enhanced 
myofibrillar protein breakdown was shown in cachectic COPD 
patients26 (chapter 9). The relationship between insulin and protein 
turnover however has not yet been studied in patients with COPD. 
Skeletal muscle morphology and energy metabolism 
As reviewed in chapter 2, pathophysiologic alterations in skeletal 
muscle in sarcopenia include a decline in the total number of muscle 
fibres and specific atrophy of type II fibres. Within the group of type 
II muscle fibres, especially type IIX fibres  are subject to age-related 
atrophy27,28. In addition, alterations in the proportion of type I and II 
muscle fibres have been reported in healthy elderly. However, the 
exact direction of this shift in fibre type distribution in sarcopenia 
remains uncertain29,30. Furthermore, there is growing evidence for 
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reduced oxidative enzyme activity and decline in the rate of 
mitochondrial protein synthesis with aging31-34. Decreased age-
related muscle mitochondrial respiratory capacity35 is correlated with 
a greater increase in the ratio of inorganic phosphate to 
phosphocreatinine during exercise in elderly compared to younger 
persons31. Also, an age-related shift in fuel use during exercise has 
also been reported35,36. It seems that fat oxidation during moderate 
intensity exercise is reduced in healthy elderly, while carbohydrate 
oxidation rate is increased36,37.  
While substrate metabolism during exercise in patients with COPD 
will be subject of the second part of this thesis, alterations in skeletal 
muscle morphology and oxidative capacity that occur in patients with 
COPD thus show much resemblance to the changes that occur in 
healthy elderly. These alterations include atrophy of type IIX muscle 
fibres38, a type I-to-II fibre type shift39 and reduced oxidative 
capacity40 (chapter 2).  
Definition of sarcopenia in COPD 
In patients with COPD, the sarcopenic phenotype is usually defined 
by reduced fat-free mass in combination with normal or increased 
body weight, resulting in a relative or absolute increase in body fat 
mass. The prevalence of fat-free mass depletion in COPD depends on 
the choice of cut-off values for fat-free mass index (FFMI), defined as 
fat-free mass standardized for height. Until now, no official guidance 
for the use of cut-offs for FFMI in COPD patients is available. The 
traditional Dutch criteria by Schols et al.17 suggested a cut point of 
15 kg·m-2 for women and 16 kg·m-2 for men with COPD. In a more 
recent study, the lowest 10th percentile of the general COPD 
population of the Copenhagen City Heart Study was defined as 
depleted, resulting in a cut-off value of 14.62 kg·m-2 for women and 
17.05 kg·m-2 for men with COPD20. These values compare with the 
lower limits of normal in the healthy adult Caucasian population, 
where lower limits of normal of 14.6 kg·m-2 for women and 16.7 
kg·m-2 for men were identified in subjects with normal body mass 
index41. Compared to the Dutch criteria, the use of the Danish cut-off 
values results in a decreased prevalence of fat-free mass depletion in 
female patients and a substantially increased prevalence of low fat-
free mass in male patients20. In this thesis, the Dutch criteria were 
used to discriminate between COPD patients with normal and 
reduced fat-free mass. That may explain some discrepancies in 
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description of the COPD phenotypes ranging from cachexia to hidden 
loss of fat-free mass and sarcopenia. 
In addition to a sarcopenic body composition, characterized by low 
fat-free mass combined with preserved body weight, pulmonary 
cachexia is commonly observed in patients with COPD and is defined 
as low fat-free mass in combination with low body weight. Since 
longitudinal studies on changes in body composition are lacking in 
COPD, it is currently unknown if sarcopenia and cachexia are truly 
two different phenotypes of this disease. Also, it is unclear if the 
mechanisms underlying the loss of fat-free mass are the same in 
both conditions. Alternatively to the existence of two distinct 
phenotypes, sarcopenia and cachexia might be different stages in the 
natural progression of changes in body composition in COPD. Thus, 
loss of fat-free mass may represent the early stage of pulmonary 
cachexia, with weight loss as a terminal event. 
Accelerated aging in COPD?  
It was earlier hypothesized that accelerated aging contributes to 
skeletal muscle dysfunction and loss of fat-free mass in COPD21,42, 
but only a few studies directly investigated the relationship between 
aging and COPD until now. Accelerated senescence of alveolar 
epithelial and endothelial cells was observed in emphysema patients 
in comparison to asymptomatic smokers and nonsmokers43. Length 
of telomeres, which are DNA-protein structures located at the end of 
chromosomes, is considered a marker of cell aging and senescence44. 
Although cigarette smoking causes enhanced shortening of telomere 
length, no differential effect of smoking on telomere length in 
circulating lymphocytes was observed in COPD patients and healthy 
smokers45. In addition, decreased levels of human sirtuin (SIRT1) 
were observed in macrophages and lungs of COPD patients and 
healthy smokers46. Sirtuins are NAD+-dependent deacetylases and 
mono-ADP-ribosyl transferases that regulate a wide array of proteins 
involved in energy metabolism, cell survival and DNA repair47,48. 
There is growing evidence for a role of sirtuins in regulation of 
human aging49. Finally, impaired skeletal muscle mitochondrial 
respiratory function50 and reduced mitochondrial number and 
fractional area in vastus lateralis muscle were reported in COPD 
patients in comparison to age-matched controls51. Decreased 
activities of the mitochondrial electron transport chain complexes 
and an increased release of reactive oxygen species from 
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mitochondria are well documented with age52. Consequently, 
mitochondrial dysfunction is considered one of the possible 
mechanisms underlying biological aging53. The observation of 
disturbed mitochondrial function in patients with COPD enforces the 
hypothesis of accelerated aging in this disease. However, until now 
no studies investigated biomarkers of aging in skeletal muscle 
samples of patients with COPD. In addition, no longitudinal studies 
comparing changes in skeletal muscle mass or function between 
healthy elderly and patients with COPD have been performed. In the 
absence of these studies, the contribution of premature aging to 
skeletal muscle dysfunction and disturbed energy metabolism in 
COPD remains hypothetical but intruiging.  
Upper versus lower extremity functional capacity 
in COPD 
The distribution of skeletal muscle dysfunction and exercise 
intolerance between lower and upper limbs in COPD is yet unknown, 
since most studies focused on the lower extremities. This is 
surprising, since many patients experience disabling dyspnoea when 
performing arm activities. This was partly attributed to 
dyssynchronous breathing during upper extremity exercise54. 
Differentiation between the various features of upper and lower 
extremity performance and investigation of the role of body 
composition may contribute to the understanding of skeletal muscle 
dysfunction and to the development of muscle group specific 
interventions in COPD. In chapter 4 upper and lower limb muscle 
strength and endurance and the relationship with fat-free mass were 
carefully studied, using a volitional isokinetic testing protocol. Both 
quadriceps and biceps muscle strength were reduced in COPD 
patients compared to controls and were equally affected. Fat-free 
mass was an important predictor of muscle strength, although loss of 
muscle strength was not limited to cachectic patients. Determinants 
of functional capacity in COPD were further explored in chapter 5. 
Independent of fat-free mass, advanced age was negatively related 
to quadriceps strength and exercise performance. These are 
important observations, since it was previously suggested that 
muscle dysfunction is absent in COPD patients with normal fat-free 
mass55. The observation of muscle weakness in COPD patients with 
normal fat-free mass indicates that screening for skeletal muscle 
dysfunction should not be restricted to cachectic patients. Since 
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muscle dysfunction is associated with poor exercise capacity56 and 
impaired health status57, therapies aimed at increasing muscle 
function should be available not only for patients with low fat-free 
mass. In particular, sarcopenic COPD patients are at increased risk 
for undertreatment, since the shift towards reduced fat-free mass 
and increased fat mass is not easily recognized with traditional 
anthropometric measurements, consisting of height and weight. 
Furthermore, the association between age and functional capacity, 
independent of body composition (chapter 5) suggests a role for 
aging in the etiology of skeletal muscle dysfunction in COPD.  
A preservation of mechanical efficiency and exercise capacity of the 
upper limbs in patients with COPD was observed in chapter 3. In 
line with these observations, normal upper limb muscle endurance in 
COPD was found in chapter 4, while lower limb muscle endurance 
was impaired. In contrast to muscle strength, endurance and 
mechanical efficiency of leg and arm muscles were not related to fat-
free mass. This suggests that other factors determine muscle 
endurance and mechanical efficiency in COPD. Indeed, quadriceps 
endurance correlated with muscle citrate synthase activity and 
proportion of type I muscle fibres in patients with COPD, indicating 
that muscular endurance is related to muscle oxidative capacity58. 
Also, cycling efficiency was positively related to the percentage of 
type I muscle fibres in healthy subjects59,60. In COPD patients, a link 
between decreased mechanical efficiency during maximal single leg 
knee-extensor and bicycle exercise and increased proportion of type 
II muscle fibres was also suggested61. The potential role of skeletal 
muscle mitochondrial dysfunction50 in metabolic inefficiency in 
patients with COPD has not been studied. 
The uneven distribution of skeletal muscle dysfunction between 
upper and lower limbs suggests a role for local or muscle specific 
etiologic factors. A preservation of oxidative capacity and proportion 
of type I muscle fibres in the upper limbs of patients with COPD62 
might be the explanation for the maintained muscle endurance and 
mechanical efficiency in these patients. With regard to this 
observation, a different training status of lower and upper limb, 
resulting from a more sedentary lifestyle is probably an important 
factor and thus exercise training might be beneficial. Indeed, eight 
weeks of strength training focused on the quadriceps muscle resulted 
in a significant improvement in mechanical efficiency during 
submaximal cycle ergometry in patients with severe COPD63. It is yet 
unknown if this increase in mechanical efficiency is the result of a 
training-induced shift in muscle fibre type distribution towards the 
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more fatigue resistant type64. Also, Also, the clinical implications of 
improving mechanical efficiency in COPD have yet to be established.   
The results of chapter 3 and 4 clearly indicate a preservation of 
upper limb functional capacity in patients with COPD. This suggests 
that in addition to systemic causes of skeletal muscle dysfunction in 
COPD, such as gas exchange abnormalities and low-grade 
inflammation, muscle specific adaptations in energy metabolism are 
important.    
Management of sarcopenia in COPD 
Loss of fat-free mass is the result of an imbalance between muscle 
protein synthesis and breakdown. Several studies suggested a link 
between increased muscular protein breakdown and reduced fat-free 
mass in patients with COPD65. Increased urinary excretion of 
pseudouridine, a measure for cellular protein breakdown, was 
observed in COPD patients with a sarcopenic phenotype in 
comparison to controls and was related to fat-free mass65. In 
addition, increased expression of atrogin-1 and MuRF1 mRNA in 
quadriceps muscle of COPD patients with muscle atrophy suggests 
activation of the ubiquitin–proteasome pathway in these subjects66. 
In the absence of anticatabolic therapies, sarcopenic COPD patients 
may benefit from anabolic interventions aimed at restoration of fat-
free mass and functional capacity. Pulmonary rehabilitation is an 
evidence-based non-pharmacological treatment for patients with 
COPD67, aimed at reducing symptoms, improving quality of life and 
increasing physical and emotional participation in activities of daily 
life. Physical exercise training, education, nutritional intervention, 
psychosocial support and patient assessments are essential 
components of pulmonary rehabilitation68.  
Traditionally, pulmonary rehabilitation was reserved for COPD 
patients with severe disease, suffering from disabling dyspnoea, poor 
exercise tolerance and pulmonary cachexia. However, the results of 
chapter 4 and 5 of this thesis indicate that pulmonary rehabilitation 
should be integrated in the clinical management of all COPD patients 
with moderate and more severe disease. Significant increases in fat-
free mass and body weight were demonstrated after eight weeks of 
intensive exercise training in normal-weight COPD patients, 
indicating that whole-body aerobic and muscle exercise induces an 
anabolic response in these patients (chapter 5). Since fat-free mass 
is an important determinant of muscle strength (chapter 4) and 
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muscle weakness is not restricted to cachectic COPD patients 
(chapter 4), increasing fat-free mass is expected to be beneficial for 
all patients. Furthermore, weight gain was previously associated with 
reduced mortality in low to normal-weight severe COPD patients69. 
The long-term effects of the increase in fat-free mass and body 
weight observed in chapter 5 on functional capacity and prognosis 
are currently unknown. In addition, the impact on clinically important 
co-morbid conditions of COPD, including alterations in insulin 
sensitivity (chapter 7) and cardiovascular risk70, remains to be 
studied.   
In contrast to “normal” sarcopenia, the contribution of decreased 
muscle protein synthesis to loss of fat-free mass in normal-weight 
COPD patients has not been demonstrated. Also, the effects of amino 
acid suppletion alone or in combination with insulin therapy on 
skeletal muscle protein turnover are yet unexplored. This kind of 
intervention may be an interesting supplement to exercise training 
as an anabolic stimulus in sarcopenic COPD patients.   
In chapter 3 and 4 of this thesis, it was shown that skeletal muscles 
of the upper limb are less affected by dysfunction and inefficiency 
than lower limb muscles in COPD. This is an important finding in the 
wake of pulmonary rehabilitation. Possibly, upper extremities are 
less deconditioned in COPD patients as a result of competitive 
recruitment of upper limb and shoulder girdle muscle groups for 
extremity movement and ventilation. However, the observation of 
reduced biceps muscle strength in COPD in chapter 4 indicates that 
these patients may benefit from tailored upper extremity training or 
occupational therapy embedded in pulmonary rehabilitation. The 
need for upper extremity conditioning is further emphasized by the 
impairment of unsupported arm activities in COPD patients71 and the 
importance of arm muscles for many activities of daily living 
including lifting, washing and combing hair72.  
Exercise training in combination with dynamic strength training 
resulted in significant improvements in lower extremity muscle 
strength and endurance (chapter 4) and peak exercise capacity 
(chapter 5). However, the impairment in upper extremity muscle 
strength was not reversed by the comprehensive exercise training 
programme. This lack of effect on biceps muscle function indicates 
the specificity of training effects for the muscle groups trained. It 
was previously shown that lower limb exercise training increased 
walking distance, while upper limb exercises improved the maximum 
work load achieved on arm ergometry in patients with COPD72.  
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In the first part of this thesis, physiological implications of sarcopenia 
in COPD were demonstrated. In the next part, relationship between 
substrate metabolism and body composition will be presented. 
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Abstract 
Introduction 
Muscle biopsy and 31P-nuclear magnetic resonance studies have consistently shown 
decreased oxidative capacity in patients with moderate to severe chronic obstructive 
pulmonary disease (COPD). Limited information is available regarding potential 
adaptations or abnormalities in anaerobic metabolism and intermediary glucose 
metabolism.  
 
Methods 
Using stable isotope tracer methodology, glucose metabolism was assessed at rest 
and during exercise in COPD patients with moderate disease severity (FEV1: 52±3%), 
prestratified into normal (n=7, BMI: 27.5±0.9 kg·m-2) and underweight subjects (n=6, 
BMI: 20.6±0.7 kg·m-2) and in 8 healthy controls matched for age and BMI with the 
normal-weight COPD group. Glucose tolerance was normal in all subjects. Rate of 
appearance (Ra) of glucose at rest and during submaximal cycling exercise was 
measured by infusion of [6,6-2H2]glucose in postabsorptive state and expressed per kg 
fat-free mass. 
 
Results 
Resting glucose Ra was significantly enhanced in COPD compared to controls 
(16.4±0.4 μmol·kgFFM-1·min-1 versus 15.1±0.4 μmol·kgFFM-1·min-1, p<0.05) and was 
inversely related to fat-free mass (r=-0.75, p<0.01) Also, the exercise-induced 
increase in glucose Ra was enhanced in COPD (81.9±3.4% versus 72.1±2.0%, 
p=0.05), resulting in elevated end-of-exercise glucose output. Differences were most 
pronounced in the underweight COPD group, which was characterized by enhanced 
plasma catecholamine levels and decreased insulin concentrations (all: p<0.05). In 
normal-weight patients, there was evidence for decreased insulin sensitivity assessed 
by homeostatic modelling technique. 
 
Conclusions 
Whole-body glucose production is increased in clinically stable COPD patients with 
normal glucose tolerance. It is hypothesized that epiphenomena of COPD such as 
reduced skeletal muscle oxidative capacity, relative hypoxemia and sympathetic 
activation contribute to this observation. 
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Introduction 
31P-Nuclear magnetic resonance1 as well as muscle biopsy studies2 
have shown a reduced skeletal muscle fat oxidative capacity and 
abnormal mitochondrial function in patients with chronic obstructive 
pulmonary disease (COPD) but implications for glucose metabolism 
are yet unknown. These may be relevant since the risk for 
cardiovascular mortality is significantly increased in COPD3, which 
could be related to insulin resistance in these patients, as was 
recently suggested4. Hypoxemia5, loss of lean body mass6, 
neurohumoral activation7, a pro-inflammatory state8 and medi-
cations, such as glucocorticosteroids, are known to influence glucose 
metabolism. We therefore hypothesized that COPD patients, even 
with normal glucose tolerance, are at increased risk for disturbances 
in intermediary glucose metabolism.  
In the present study, glucose metabolism, measured by whole-body 
glucose production and concentration and plasma levels of hormones 
involved in glucose homeostasis, was assessed in COPD patients and 
controls. Since disturbances in intermediary metabolism might 
contribute to changes in body composition in COPD (i.e. ratio of fat 
versus fat-free mass) and body composition itself is a determinant of 
glucose output, potential alterations in glucose metabolism were 
studied in both normal-weight as well as underweight COPD patients. 
Submaximal bicycle exercise was used as a stimulus to endogenous 
glucose production in order to augment potential small disturbances 
at rest.  
Methods 
Study population 
Patients were recruited at the outpatient department for respiratory 
disease of the University Hospital Maastricht, while the control group 
was recruited from an advertisement in a local newspaper. All 
subjects were men. Patients fulfilled the criteria for COPD according 
to American Thoracic Society guidelines9 and suffered from chronic 
irreversible airflow obstruction, defined as forced expiratory volume 
in one second (FEV1) less than 70% of predicted and less than 10% 
improvement in FEV1 compared to baseline after inhalation of a β2-
agonist. An oral glucose tolerance test was performed in 16 COPD 
patients and nine controls. Three patients and one control subject 
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dropped out of the study because of abnormal values, as defined 
below. For subgroup analysis, the COPD group was divided into a 
group of seven patients with a body mass index (BMI) comparable to 
the control group and a comparable group of patients with a 
significantly lower BMI. None of the patients exhibited chronic 
respiratory insufficiency, defined as PaO2<7,3 kPa, or received 
supplemental oxygen therapy. To ensure a homogeneous group of 
COPD patients without comorbidity in order to study altered glucose 
metabolism as primary defect, subjects with a history of diabetes 
mellitus type I or II, thyroid or other endocrine disorders, recent 
weight loss, malignancies, clinically apparent heart failure, renal, 
hepatic or other gastro-intestinal disease or recent surgery were 
excluded. Furthermore, none of the subjects used oral 
glucocorticosteroids as maintenance treatment or suffered from 
respiratory tract infection or exacerbation within a 4-week period 
prior to the study. Patients were using the following pulmonary 
maintenance medications: inhaled short- and long-acting 
ß2-adrenoceptor agonists, 54%; anticholinergics by inhalation, 54%; 
combined inhalers of short-acting ß2-adrenoceptor agonists and 
short-acting anticholinergics, 8%; inhalation corticosteroids, 8%; 
combined inhalers of sympathicomimetics and corticosteroids, 46%; 
xanthines, 31%; and oral N-acetylcysteine, 23%. There was no 
significant difference in the use of pulmonary medications between 
COPD subgroups. Written informed consent was obtained from all 
subjects and the study was approved by the medical ethical 
committee of the University Hospital Maastricht.  
Study design 
The study was performed at the outpatient metabolic ward on two 
separate mornings in all subjects. On the first visit, an oral glucose 
tolerance test was carried out, followed by a medical history and 
examination, measurement of body composition, lung function 
testing and determination of exercise capacity. The second part of 
the study consisted of the glucose stable isotope tracer protocol, as 
described below. On this second morning of the study, pulmonary 
maintenance medications were suspended in order to avoid potential 
acute medication effects on glucose metabolism. 
Oral glucose tolerance test 
After an overnight fast, an oral glucose tolerance test (OGTT) was 
performed in 16 COPD patients and nine controls. On the three days 
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prior to testing, subjects were allowed unrestricted diet with a 
minimal carbohydrate intake of 150 g·day-1, in order to obtain the 
best reproducibility of the test and to minimize falsely abnormal 
results. Dietary history of the previous days was obtained on the 
morning of the test. A cannula was placed in an anticubital vein of 
the arm for blood sampling in the fasting state and 120 minutes after 
ingestion of a standardized dose of 83.5 gram of dextrose 
monohydrate diluted to 250 ml with water. The solution was 
consumed within a 5 minute period. During the OGTT no physical 
activity was allowed and subjects rested on a chair. According to 
WHO criteria for diagnosis of diabetes mellitus and glucose 
intolerance10, a fasting blood glucose level >7,8 mmol·l-1 or a two 
hours postload glucose concentration >11,1 mmol·l-1 were 
considered as an indication for the presence of diabetes mellitus. 
Glucose intolerance was defined as a two hours post load glucose 
concentration in the range 7,8-11,1 mmol·l-1. Only subjects with 
normal glucose tolerance were allowed to participate in the second 
part of the study (Table 7.1).  
Body composition 
Body height was determined to the nearest 0.5 cm with subjects 
standing barefoot. Body weight (BW) was measured with a beam 
scale (SECA, Hamburg, Germany) without shoes and in light clothing 
to the nearest 0.1 kg. Body mass index was calculated as the ratio of 
weight to height in meters squared. Fat-free mass (FFM) was 
measured by bioelectrical impedance analysis at a spectrum of 48 
frequencies ranging from 5 to 500 kHz (Xitron 4000b, Xitron 
technologies, San Diego, California, USA). Resistance was measured 
in supine position at the right side as described by Lukaski11. In 
subjects with COPD, FFM was estimated from impedance 
measurements using the sex-specific regression equation described 
by Steiner12, while the equation of Dey13 was used for the healthy 
elderly controls. Fat-free mass index (FFMI) was calculated as the 
ratio of FFM to height in meters squared. 
Pulmonary function 
Lung function testing included spirometry before and after inhalation 
of a ß2-agonist for determination of FEV1 and forced vital capacity 
(FVC). The highest value of at least three measurements was used. 
Diffusing capacity for carbon monoxide (DLCO) was measured by the 
single-breath method (MasterLab Transfer, Jaeger, Würzburg, 
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Germany). Total lung capacity (TLC) and residual volume (RV) were 
measured by whole-body plethysmography (MasterLab Body, Jaeger, 
Würzburg, Germany). All values were expressed as a percentage of 
predicted14. In patients blood was drawn from the radial artery at 
rest on the morning of the tracer study. Arterial oxygen tension 
(PaO2) and carbon dioxide tension (PaCO2) were determined on a 
blood gas analyzer (ABL 700, Radiometer, Copenhagen, Denmark). 
 
Table 7.1. Baseline characteristics of the study groups (mean ± SEM).  
 Controls 
 
(n=8) 
COPD 
All 
(n=13) 
COPD 
normal BMI 
(n=7) 
COPD 
reduced BMI 
(n=6) 
  Age, yr  65 ± 2  67 ± 3  64 ± 4  70 ± 4 
Body composition     
  Height, cm  175.1 ± 2.3  170.7 ± 1.4  172.9 ± 1.9  168.1 ± 1.5a 
  Weight, kg  83.9 ± 5.1  71.3 ± 4.0  82.5 ± 3.5  58.2 ± 2.1c,e 
  BMI, kg·m-2  27.3 ± 1.4  24.3 ± 1.1  27.5 ± 0.9  20.6 ± 0.7c,f 
  FFM, kg  61.8 ± 2.5  51.1 ± 2.1b  56.1 ± 2.4  45.3 ± 1.5c,e 
  FFMI, kg·m-2  20.1 ± 0.7  17.5 ± 0.6a  18.8 ± 0.8  16.0 ± 0.4c,d 
  FM, kg  22.1 ± 3.0  20.2 ± 2.5  26.4 ± 2.9  12.9 ± 0.8a,e 
  FMI, kg·m-2  7.1 ± 0.9  6.8 ± 0.8  8.8 ± 0.9  4.6 ± 0.3a,e 
Lung function     
  FEV1, %predicted  103 ± 4  52 ± 3c  53 ± 5c  51 ± 5c 
  DLCO, %predicted  113 ± 6  62 ± 4c  62 ± 7c  62 ± 4c 
  RV, %predicted  111 ± 8  150 ± 11a  124 ± 10  180 ± 12c,e 
  PaO2, kPa -  8.5 ± 7.4  8.5 ± 7.4  8.5 ± 7.8 
  PaCO2, kPa -  5.1 ± 0.2  5.1 ± 0.2  5.1 ± 0.1 
Functional capacity     
  Peak work rate, W  220 ± 23  74 ± 7c  83 ± 11c  65 ± 6c 
  V& O2max, ml·min-1  2522 ± 167  1266 ± 86c  1409 ± 133c  1099 ± 55c 
OGTT     
  Glucose T0, mmol·l-1  5.8 ± 0.2  5.7 ± 0.3  5.9 ± 0.5  5.4 ± 0.3 
  Glucose T2, mmol·l-1  4.8 ± 0.6  6.4 ± 1.0  7.1 ± 1.7  5.6 ± 0.5 
BMI: body mass index; FFM: fat-free mass, assessed by bioelectrical impedance 
analysis; FFMI: fat-free mass index; FM: fat mass; FMI: fat mass index; FEV1: forced 
expiratory volume in one second; DLCO: diffusing capacity for carbon monoxide; RV: 
residual volume; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; 
V& O2max: maximal oxygen consumption. OGTT: oral glucose tolerance test. T0: fasting 
plasma concentration; T2: plasma concentration two hours after oral glucose load. 
Significance of differences between COPD patients and controls is indicated as: a: 
p<0.05, b: p<0.01, c: p<0.001. Significant differences between COPD patients 
matched for BMI and patients with a reduced BMI are shown as: d: p<0.05, e p<0.01 
and f p<0.001. 
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Exercise capacity 
All subjects performed an incremental exercise test on an electrically 
braked cycle ergometer (Corival 400, Lode, Groningen, The 
Netherlands) under supervision of a physician. Before the start of the 
test, while seated on the cycle ergometer, ventilation characteristics 
at rest were analysed during two minutes. During the entire exercise 
test, expired gases were investigated using breath-by-breath 
analysis through a breathing mask (Oxycon Beta, Jaeger, Würzburg, 
Germany). Heart rate, blood pressure and percutaneous oxygen 
saturation were monitored. After one minute of unloaded cycling, 
power was increased by 10 W every minute in patients. For the 
control subjects, the load was increased with 15 to 25 W every 
minute, so that the length of the exercise test was comparable for 
patients and controls. None of the subjects knew the exercise load  
and all were encouraged to cycle at 60 revolutions·min-1 until 
exhaustion. Peak work load (Wmax) and peak oxygen consumption 
(V& O2max) were used in the analysis.  
Basic principles of stable isotope tracer methodology 
Isotopes are atoms with a slightly different weight than the naturally 
abundant atoms of a chemical element, due to a differing number of 
neutrons. For example, the [6,6-2H2]glucose isotope refers to a 
stable molecule of glucose in which the 6 carbon position is labelled 
with two hydrogens that are enriched with atoms of mass two 
(deuterium). Since the different number of neutrons in the atom 
does not affect the chemical properties of the molecule, a stable 
isotope will show identical endogenous kinetics as the naturally 
abundant form of the molecule. The difference in molecule weight 
enables detection by mass spectrometry and determination of 
plasma substrate enrichment, i.e. the ratio between stable isotope 
tracer and tracee (endogenous substrate). Continuous infusion of a 
stable isotope tracer in steady state conditions in vivo enables 
calculation of substrate kinetics, i.e. rate of appearance (endogenous 
production and exogenous infusion) and rate of disappearance 
(irreversible tissue uptake and loss) by analysis of plasma substrate 
enrichment.  
Glucose stable isotope tracer protocol 
After an overnight fast, subjects reported at the laboratory at 07.30 
h and were studied at rest in the supine position. A teflon catheter 
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was inserted into a forearm vein for isotope infusion and a second 
catheter for sampling of arterialized venous blood was placed 
retrograde in a dorsal hand vein of the contralateral arm and 
maintained at 60ºC in a thermoregulated box. At 08.00 h, after 
taking a blood sample for background enrichment of plasma glucose, 
subjects were administered a single intravenous dose of [6,6-
2H2]glucose (17.6 μmol·kgBW-1, >99% enriched; Cambridge Isotopes 
Inc, Andover, Massachusetts, USA) in order to prime the glucose 
pool. Thereafter (t=0), a continuous infusion of [6,6-2H2]glucose 
(0.22 μmol·kgBW-1·min-1) dissolved in 0.9% saline was started via a 
calibrated pump (IVAC 560, San Diego, California, USA). Blood 
samples were taken at t=110 and 120 minutes. The exact infusion 
rate in each experiment was determined by measuring the glucose 
concentration and enrichment in the infusate. At t=120 minutes 
COPD patients started to exercise on a cycle ergometer at a 
workload of 50% Wmax for 20 minutes, while controls exercised at an 
identical absolute work load (30 W=50% of mean Wmax in COPD 
patients) for the same duration. Blood samples were drawn at 
t=125, 130, 135 and 140 minutes. The protocol continued with one 
hour recovery period, during which blood samples were taken at 
t=155, 170, 185 and 200 minutes. Thereafter, controls performed a 
second 20 minute exercise test at 50% of their individual Wmax in 
order to study potential alterations in glucose kinetics at identical 
relative submaximal work load. Blood samples were taken at t=205, 
210, 215 and 220 minutes during exercise and at t=235, 250, 265 
and 280 minutes during a second recovery period of one hour. 
Plasma levels of glucoregulatory hormones were determined at 
t=110, 140, 200, 220 and 280 minutes. To minimize changes in 
substrate isotopic enrichment, infusion rate of glucose tracer was 
doubled (0.44 μmol·kgBW-1·min-1) during submaximal exercise15. 
During the study, subjects were allowed to drink water only. 
Sample collection and analysis 
During the OGTT, venous blood samples were collected in sodium 
fluoride containing tubes and immediately placed on ice. Within 15 
minutes, blood glucose was analysed by the glucose oxidase method 
with a YSI 2300 STAT Plus analyzer (YSI Incorporated, Yellow 
Springs, Ohio, USA). 
Blood samples (5 ml) for [6,6-2H2]glucose enrichment and glucose 
and glycerol concentrations were collected on heparin, immediately 
put on ice, and centrifuged at 4000 rpm at +4ºC for 10 minutes. For 
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determination of insulin and cortisol, 3 ml of arterialized-venous 
blood were put into a coagulation tube, which was centrifuged for ten 
minutes at 3000 rpm at room temperature. Serum was separated 
and centrifuged again for five minutes at 3000 rpm. An iced EDTA 
and trasylol containing tube was used to collect blood for the 
measurements of glucagon. After mixing, plasma was separated 
from cells by centrifugation at 4000 rpm for 10 minutes at +4ºC. 
Samples for catecholamines were collected in iced EDTA tubes, 
centrifuged at 4000 rpm for 10 minutes at +4ºC and stored in a 
glutathione containing tube. All aliquots of plasma and serum were 
frozen immediately in liquid nitrogen, stored –80°C and transported 
on dry ice before assay.  
Plasma insulin concentrations were determined by a 
chemiluminescent immunometric assay and plasma cortisol 
concentrations were measured by a chemiluminescent immunoassay, 
both on an Immulite 2000 system (Diagnostic Products Corporation, 
Los Angeles, California, USA). Glucagon was determined by RIA 
(125-I Glucagon RIA, LINCO Research, St. Charles, Missouri, USA). 
Serum free fatty acids (FFA) were measured by an enzymatic 
colorimetric method (NEFAC; Wako Chemicals GmbH, Neuss, 
Germany).Catecholamines were determined by an in-house reversed 
phase HPLC method with fluorescence detection. 
Gas chromatography-mass spectrometry 
[6,6-2H2]glucose enrichment and glucose and glycerol concentration 
were measured as described earlier16,17. Briefly, plasma samples 
were deproteinized with methanol. The aldonitril penta-acetate 
derivative of glucose was injected into a gas chromatograph/mass 
spectrometer system (model 6890 gas chromatograph coupled to a 
model 5973 mass selective detector, equipped with an electron 
impact ionization mode; Hewlett-Packard, Palo Alto, California, USA). 
Separation was achieved on a J&W DB17 column (30 m x 0.25 mm, 
df 0.25 µm; Agilent Technologies Nederland BV, Amstelveen, The 
Netherlands). Glucose concentrations were determined by gas 
chromatography using xylose as an internal standard. Glucose was 
monitored at mass-to-charge ratio 187, 188, and 189. The 
enrichment of [6,6-2H2]glucose was determined by dividing the peak 
area of mass-to-charge ratio 189 by the peak area of mass-to-
charge ratio 187 and correcting for natural enrichments. 
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Calculations 
The rate of glucose appearance (Ra) at rest was calculated by 
dividing the infusion rate of [6,6-2H2]glucose by the resulting 
enrichment of plasma aldenotril pentaacetate glucose. Glucose Ra is 
composed of endogenous glucose production and exogenous tracer 
infusion. During submaximal exercise glucose Ra was calculated 
using the single-pool non-steady state Steele equation, adapted for 
stable isotope methodology as described elsewhere18: 
 
Ra = (F – Vd[(C2+C1)/2][(E2-E1)/(t2-t1)])/((E2+E1)/2), 
 
where F is the infusion rate (µmol·kgFFM-1·min-1), Vd is the 
distribution volume of glucose, C1 and C2 are glucose concentrations 
at times 1 (t1) and 2 (t2), respectively, and E1 and E2 are the glucose 
enrichments at t1 and t2, respectively. Because of the short duration 
of submaximal exercise, the volume of distribution of glucose was 
assumed to be 100 ml·kgBW-1 (Personal communication with prof. 
dr. Robert R. Wolfe18).  
Insulin sensitivity was assessed using the homeostatic modelling 
technique (HOMA)19, based on fasting plasma glucose and insulin 
levels.   
Statistics 
Results are expressed as mean ± standard error of the mean (SEM). 
Statistical analysis on baseline differences between COPD patients 
and controls was performed using an unpaired Student’s t-test. One 
way analysis of variance (ANOVA) was used to determine differences 
in rate of appearance of glucose, substrate and hormone 
concentrations and functional parameters between patients with a 
reduced BMI, patients with a normal BMI and controls. LSD multiple 
comparison test was used as post hoc test. Pearson’s correlation 
analysis was performed in order to investigate linear relationship 
between variables of glucose metabolism, glucoregulatory hormones, 
body composition, lung function and exercise performance. All p 
values <0.05 were considered statistically significant.  
Results 
Thirteen male COPD patients and eight male healthy volunteers 
participated in the glucose stable isotope tracer protocol (Table 7.1). 
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Fat-free mass was significantly reduced in COPD patients compared 
to controls, while fat mass was comparable. Patients were 
characterized by moderate airflow obstruction, a moderately reduced 
diffusing capacity and normoxaemia at rest. Exercise capacity was 
significantly reduced in COPD versus controls, while peripheral 
oxygen saturation at rest was comparable and no significant 
exercise-induced desaturation occurred in any of the groups (data 
not shown). Underweight COPD patients were characterized by 
reduced fat-free mass and fat mass in comparison to normal-weight 
patients and increased residual volumes but the severity of airflow 
limitation and arterial blood gases were comparable in both COPD 
groups. Also, exercise capacity was equally impaired in both COPD 
groups. 
 
Glucose Ra at rest was significantly increased in COPD patients 
compared to controls (16.4±0.4 μmol·kgFFM-1·min-1 versus 15.1±0.4 
μmol·kgFFM-1·min-1, p<0.05). Only in patients, glucose Ra was 
inversely related to fat-free mass (r=-0.75, p<0.01). Resting glucose 
Ra of underweight COPD patients (16.6±0.4 μmol·kgFFM-1·min-1) was 
significantly enhanced compared to controls (15.0±0.4 μmol·kgFFM-
1·min-1, p<0.05), while glucose Ra at rest of normal-weight patients 
(16.1±0.6 μmol·kgFFM-1·min-1, NS) was not statistically increased 
(Figure 7.1).   
 
There was a physiological increase in glucose Ra during submaximal 
exercise in both COPD patients as well as controls (p values for 
paired samples <0.001), but the proportional increase in glucose Ra 
during submaximal exercise at identical workload was enhanced in 
COPD compared to controls (81.9±3.4% versus 72.1±2.0%, 
p=0.05). The relative increase in glucose production was related to 
norepinephrine concentrations in COPD (r=0.61, p<0.05). Also, the 
proportional increase in glucose Ra was significantly enhanced in 
COPD patients with a reduced BMI (+90.4±5.3%) compared to 
normal BMI  patients (+74.7±2.2%, p<0.01). Consequently, glucose 
Ra was significantly elevated in patients compared to controls during 
submaximal exercise at both identical absolute and relative 
workloads and during the following recovery periods. End-of-exercise 
glucose Ra of underweight patients (31.6±0.8 μmol·kgFFM-1·min-1) 
was significantly enhanced in comparison to controls after 
submaximal exercise at both identical absolute (25.8±0.6 
μmol·kgFFM-1·min-1, p<0.001) as well as identical relative work load 
(24.1±0.7 μmol·kgFFM-1·min-1, p<0.001) (Figure 7.1). Also, normal 
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BMI patients showed significantly elevated glucose Ra (28.0±1.0 
μmol·kgFFM-1·min-1) after submaximal exercise in comparison to 
controls.  
 
Figure 7.1 Rate of appearance (Ra) of glucose at rest, during exercise at 30 W 
(=50% of peak work load of COPD patients), exercise at 50% of 
individual peak work loads and recovery (mean ± SEM). COPD patients 
with a reduced BMI are represented by closed circles. Values of COPD 
patients with a normal BMI are shown as open circles and control values 
are depicted by closed triangles. Glucose Ra was significantly increased 
during the entire protocol in COPD patients with a reduced BMI, in 
comparison to controls. During exercise, glucose Ra of normal BMI 
patients was also significantly enhanced compared to controls.  
 
 
 
 
 
 
 
 
 
 
Fasting plasma levels of glucose, insulin, glucagon, cortisol, FFA and 
glycerol were comparable in COPD patients and controls, while 
concentrations of epinephrine and norepinephrine tended to be 
increased in COPD patients (p=0.05 and p=0.07, respectively) (Table 
7.2). Plasma levels of glucose remained constant during submaximal 
exercise and recovery in comparison to fasting levels and were 
comparable in both groups. As expected, end-of-exercise glucagon 
and catecholamine concentrations were significantly enhanced in 
COPD patients and controls in comparison to baseline values, while 
insulin levels were significantly suppressed (data not shown).  
As shown in Table 7.2, low BMI patients were characterized by 
reduced plasma insulin concentrations and elevated catecholamine 
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levels in comparison to patients with a normal BMI and controls. 
Normal BMI patients showed an increase in insulin levels compared 
to controls. Plasma concentrations of glucose, glucagon, cortisol, FFA 
and glycerol were comparable in all groups. 
 
Table 7.2 Post-absorptive resting and end-of-exercise plasma substrate and 
hormone concentrations (mean ± SEM).  
 Controls 
 
(n=8) 
COPD 
All 
(n=13) 
COPD 
normal BMI 
(n=7) 
COPD 
reduced BMI 
(n=6) 
Resting state     
 Glucose, mmol·l-1  5.79 ± 0.19  5.65 ± 0.29  5.90 ± 0.48 5.37 ±0.26 
 Insulin, pmol·l-1  49 ± 8  51 ± 10  76 ± 12# 22 ±6** 
 HOMA score  13.4 ± 2.5  14.3 ± 3.2  21.5 ± 4.1$ 5.8 ±1.5 ** $$ 
 Glucagon, pmol·l-1  63 ± 6  68 ± 4  71 ± 7 65 ± 5 
 Cortisol, nmol·l-1  292 ± 31  306 ± 28  303 ± 36 310 ±49 
 FFA, mmol·l-1  1.12 ± 0.14  1.04 ± 0.08  1.08 ± 0.13 0.99 ±0.11 
 Glycerol, mmol·l-1  83.3 ± 6.5  90.6 ± 7.1  85.0 ± 9.5 97.1 ±11.1 
 Epinephrine, nmol·l-1  0.42 ± 0.07  0.74 ± 0.14  0.52 ± 0.12 1.01 ±0.24 # * 
 Norepinephrine, nmol·l-1  0.42 ± 0.10  1.02 ± 0.24  0.85 ± 0.21 1.22 ±0.46# 
End-of-exercise     
 Glucose, mmol·l-1  6.19 ± 0.19  6.30 ± 0.21  6.21 ± 0.27 6.41 ±0.36 
 Insulin, pmol·l-1  51 ± 8  55 ± 10  66 ± 13 19 ±3# ** 
 Glucagon, pmol·l-1  62 ± 7  71 ± 6  79 ± 10 64 ± 4 
 Cortisol, nmol·l-1  285 ± 23  394 ± 30  386 ± 37 404 ±52# 
 FFA, mmol·l-1  1.75 ± 0.24  1.44 ± 0.13  1.45 ± 0.15 1.42 ±0.25 
 Glycerol, mmol·l-1 223.1 ± 36.5 217.6 ± 30.4 207.7 ± 40.5 229.1 ± 49.7 
 Epinephrine, nmol·l-1  0.79 ± 0.16  3.28 ± 1.23  3.68 ± 2.40 2.88 ±1.00 
 Norepinephrine, nmol·l-1  1.32 ± 0.18  2.30 ± 0.45  2.41 ± 0.51 2.18 ±0.86 
Significance of differences between patients and controls is indicated as: #: p<0.05; 
$: p=0.06; $$: p=0.09. Significant differences between COPD patients with normal BMI 
and patients with a reduced BMI are shown as: *: p<0.05 and **: p<0.01. 
 
HOMA score was comparable in COPD patients and controls (Table 
7.2), but was significantly reduced in patients with a reduced BMI in 
comparison to normal-weight patients (Figure 7.2). In normal-weight 
patients HOMA score tended to be increased in comparison to 
controls, indicating reduced insulin sensitivity this patient group. 
HOMA score was significantly related to BMI (r=0.57, p<0.05) and 
fat-mass index (r=0.74, p<0.01) (Figure 7.3) in bivariate regression 
analysis. 
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Figure 7.2 Homeostasis model assessment (HOMA) index for insulin sensitivity in 
subgroups of COPD patients with normal and reduced body mass index 
(BMI) and controls. Insulin sensitivity was significantly reduced in COPD 
patients with normal BMI in comparison to patients with reduced BMI (#: 
p<0.01). Also, there was a strong tendency towards decreased insulin 
sensitivity in normal-weight COPD patients in comparison to controls 
matched for BMI ($: p=0.06)  
 
 
 
 
 
 
 
 
 
Figure 7.3 Bivariate correlation between fat-mass index and homeostasis model 
assessment (HOMA) index for insulin sensitivity in COPD patients. COPD 
patients with reduced BMI are depicted by closed circles, while open 
circles represent normal-weight COPD patients. A significant positive 
correlation was observed (r=0.74, p<0.01). 
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Discussion 
The results of this first study on glucose kinetics in COPD can be 
summarized as follows. Post-absorptive whole-body glucose 
production is enhanced in COPD patients with moderate disease 
severity compared to healthy subjects. The increased glucose 
turnover is present in the resting state and is amplified during 
submaximal exercise. COPD subgroup analysis shows that alterations 
in glucose production are predominantly present in underweight 
patients, although submaximal exercise revealed enhanced 
intermediary carbohydrate metabolism in normal-weight COPD 
patients as well. Finally, there is indirect evidence for insulin 
resistance in normal-weight patients. Possible explanations for these 
observations and the clinical implications are discussed here.  
Glucose production in COPD 
Whole-body resting post-absorptive glucose production was 
enhanced in glucose tolerant COPD patients. After an overnight fast 
(as in the present study), the major part of total glucose production 
constitutes of hepatic glycogenolysis, while the contribution of 
gluconeogenesis, in which glucose is formed from especially lactate, 
alanine and glycerol, increases during exercise or prolonged 
starvation.  
There are several possible pathophysiological explanations for the 
increased glucose production in COPD. Acute and chronic hypoxemia, 
which may be chronically present in end-stage COPD or 
intermittently during exercise in less severe COPD, cause an 
increment in glucose production in normal subjects5. Although 
chronic respiratory failure was an exclusion factor in the present 
study and exercise-related oxygen desaturation did not occur, 
resting arterial oxygen tension of the COPD patients was below 
reference values for healthy subjects.  
Furthermore, decreased skeletal muscle oxidative capacity may 
result in enhanced endogenous glucose production in COPD. The 
observation of an increased glucose production in combination with 
normoglycemia implicates an increased glucose tissue uptake. After 
uptake, glucose can be either stored as glycogen, lactate or fat or it 
can be oxidized. No muscle biopsies were performed in the present 
study, since the protocol was already quite invasive. Jakobsson et 
al.5 reported reduced resting glycogen concentrations in quadriceps 
muscle of normal-weight COPD patients with chronic respiratory 
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failure. In another study by Engelen et al.20 muscle glycogen content 
was comparable in COPD patients and controls, but resting lactate 
and pyruvate concentrations were enhanced in quadriceps muscle of 
patients with COPD. In the presence of adequate oxygen delivery, 
muscle pyruvate and lactate increase when the rate of pyruvate 
production by glycolysis exceeds the oxidative capacity of the 
tricarboxylic acid pathway. Indeed, COPD patients are characterized 
by an impaired skeletal muscle oxidative capacity and this is 
associated with disturbed lactic acid kinetics21. Furthermore, an 
increased proportion of type 2 muscle fibres, with a reduced 
oxidative enzyme activity, is observed in COPD22, indicating a shift 
toward a glycolytic energy production in these patients. The finding 
of an increased glucose turnover in the present study might very well 
be an adaptation to an increased dependence on glucose for energy 
provision, as a result of decreased oxidative capacity in COPD. The 
fact that enhanced glucose production was accompanied by a 
reduced fat mass and the finding of non-elevated muscle glycogen 
content in previous studies supports this hypothesis of increased 
muscle glucose use for high energy phoshate production at the cost 
of increased glucose storage. In line with this hypothesis, an 
increased carbohydrate oxidation was previously reported in 
malnourished COPD patients and contributed to a hypermetabolic 
state23.  
Neurohumoral activation, reflected by elevated catecholamines, is 
consistently found in COPD patients and may contribute to the 
systemic manifestations of the disease7. Catecholamines increase 
glucose production by stimulating glycogenolysis and 
gluconeogenesis, and elevated levels of these were indeed observed 
in the present study. However, no linear relationship between 
catecholamine levels and resting glucose production was found in the 
present study, possibly due to the small group size. 
The systemic use of corticosteroids in COPD may lead to 
hyperglycemia by increasing hepatic glucose production and 
inhibiting glucose uptake and utilization by peripheral tissues. Also, 
ß-adrenoceptor agonists are able to induce hyperglycemia in 
humans. Since none of the patients in the study used oral 
glucocorticosteroids and daily inhalations of ß2-adrenoceptor agonists 
were suspended until after the study and equally distributed between 
patient groups, a role for medication in the observed results is 
unlikely. 
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Glucose production and body composition in COPD 
Basal and exercise-induced glucose output of underweight patients 
was slightly increased in comparison to normal-weight patients and 
was evidently elevated compared to healthy subjects. Although 
glucose production was inversely related to fat-free mass, differences 
in body composition between COPD subgroups cannot explain these 
results. Studies in healthy non-diabetic individuals showed that lean 
body mass was a positive predictor of postabsorptive endogenous 
glucose output, irrespective of body weight6,24. Thus, disease specific 
factors related to cachexia, such as more pronounced hypoxemia, 
reduced oxidative capacity or skeletal muscle fibre type redistribution 
may account for the predominant disturbance of glucose output in 
the underweight COPD patients. Moreover, preferential atrophy of 
type IIX glycolytic muscle fibres in COPD might affect the 
relationship between whole-body glucose production and fat-free 
mass25. Also, increased levels of catecholamines in underweight 
patients could contribute, since catecholamines are considered the 
primary drive behind stimulation of exercise-induced glucose 
production in healthy subjects26 and a positive correlation between 
norepinephrine levels and delta glucose production was observed in 
this study. 
Insulin sensitivity 
Fasting plasma levels of glucose and insulin were comparable in 
COPD patients and controls in the present study, resulting in a 
similar index of insulin sensitivity estimated by homeostasis model 
assessment (HOMA). HOMA is a simple and validated alternative to 
the euglycemic hyperinsulinemic clamp technique, which is regarded 
the reference method for assessment of insulin sensitivity in vivo27. 
In COPD patients, only one study used this glucose clamp technique 
to determine insulin sensitivity. In line with the observation in the 
present study, Jakobsson et al.28 reported normal insulin sensitivity 
in advanced normal-weight patients with chronic respiratory failure in 
comparison to controls.  
In contrast to the present results, Bolton et al.4 recently reported 
insulin resistance in a group of normal-weight COPD patients with 
normal oxygen saturation compared to healthy subjects. Circulating 
levels of inflammatory mediators were increased in these patients 
and both BMI as well as interleukin 6 levels were predictive variables 
of insulin resistance in these COPD patients. Although the results by 
Bolton et al. may have been confounded by the fact that some of the 
Thesis Frits Franssen_08.pdf   155 21-11-2008   10:22:00
156⏐Chapter 7 
patients were glucose intolerant, as indicated by slight fasting 
hyperglycemia, the possible association between BMI and insulin 
resistance in COPD is interesting. In the present study, insulin 
sensitivity was significantly decreased in normal-weight COPD 
patients compared to underweight patients and HOMA score was 
related to BMI and fat mass. Furthermore, in comparison to controls, 
insulin sensitivity of normal-weight patients tended to be decreased, 
whereas there was a trend towards increased insulin sensitivity in 
underweight COPD patients. Regarding this observation, several 
points must be emphasized. First of all, in contrast to the study by 
Bolton et al., the present study actively excluded patients with 
glucose intolerance, so results cannot have not been confounded by 
this factor. Secondly, normal-weight COPD patients and controls 
were matched for BMI (see Table 7.1), so a discrepancy in body 
composition did not account for the lower insulin sensitivity in 
normal-weight COPD patients. Finally, the observations in the 
present study are in accordance with recently published data on 
insulin sensitivity in COPD by Koehler et al.29. In their study, insulin 
sensitivity, measured by HOMA score, was significantly reduced in a 
large group of normal-weight patients compared to underweight 
COPD patients. Interestingly, similar to the present results, insulin 
sensitivity tended to be decreased in normal-weight patients in 
comparison to controls with an identical BMI. Regarding the 
possibility of increased insulin sensitivity in underweight versus 
normal-weight COPD patients, it is important to notice that being 
underweight is associated with increased insulin sensitivity in healthy 
subjects30, so this is not a unique feature in COPD. However, as 
stated before, the decrease in insulin resistance in normal-weight 
patients compared to controls cannot be explained by any difference 
in body composition.    
Although assessment of insulin sensitivity in COPD was not the 
primary goal of the present study, the combination of observations in 
this and other recent studies suggest that a certain degree of insulin 
resistance may already occur in normal-weight COPD patients. The 
underlying pathophysiological mechanism(s) are yet unknown, but 
there are several possible explanations. Jakobsson et al.31 observed 
a significant increase in glucose tolerance and insulin sensitivity 
during oxygen supplementation in chronic hypoxemic COPD patients. 
Although the degree of insulin resistance was not compared to 
controls, their study suggests that hypoxemia plays a role in insulin 
resistance in COPD. Fascinatingly, the authors described a positive 
correlation between the change in glucose uptake with and without 
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supplemental oxygen and BMI, suggesting that insulin sensitivity is 
more impaired in more obese COPD patients. Again, this observation 
is in line with the present study.  
Before drawing conclusions on the issue of insulin resistance in 
(subgroups of) COPD patients, a study using the “gold standard” 
method to measure insulin sensitivity, i.e. the hyperinsulinaemic 
euglycaemic glucose clamp procedure, is needed. Preferentially such 
a study will include well-stratified COPD subgroups, such as normal-
weight versus underweight patients and normoxaemic versus 
hypoxemic patients in order to investigate the potentially opposite 
effects of body composition and hypoxemia in COPD on insulin 
sensitivity and glucose uptake. Until then, also the contribution of 
insulin resistance to increased cardiovascular mortality in COPD3 
remains speculative.  
Clinical implications 
In contrast to underweight COPD patients, who showed clear 
disturbances in resting glucose production, endogenous glucose 
production of normal-weight COPD patients was comparable to 
controls at rest. However, short-term submaximal bicycle exercise 
revealed an enhanced glucose turnover in this group. This 
observation is relevant to daily living conditions in these patients. 
Early lactic acidosis is a common finding in COPD32, indicating 
increased metabolic stress during relatively low intensity exercise. 
The metabolic demands of specific physical activities are usually 
quantified in metabolic equivalents (METS), defined as the ratio of 
work to resting metabolic rate. The calculated energy cost of the 
submaximal bicycle exercise in the present study is approximately 
three METS, which is comparable to home activities such as 
sweeping, downstairs and implied walking, walking the dog and 
carrying small children in healthy subjects33. Performance of these or 
more intense activities of daily living by both underweight as well as 
normal-weight COPD patients might thus result in temporary 
enhancements in glucose turnover. The clinical implications of these 
daily bursts of metabolic stress and especially the effects on energy 
balance, body composition and cardiovascular risk are unknown and 
subject of future investigations.  
Limitations of the study 
The individual contribution of gluconeogenesis and glycogenolysis to 
total glucose production was not determined in the present study. In 
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further studies on glucose kinetics in COPD, quantification of 
fractional gluconeogenesis can be achieved by the use of a 
deuterium labeled water tracer in addition to [6,6-2H2]glucose. 
Furthermore, a relationship between increased glucose production 
and reduced oxidative capacity cannot be proven based on the 
present results, since no muscle biopsies were taken.  
Conclusions 
Postabsorptive resting and exercise-induced whole-body glucose 
production is increased in clinically stable patients with COPD GOLD 
stage II-III. Enhanced glucose output is observed in both 
underweight as well as normal-weight patients, but predominantly in 
the first group. It was hypothesized that epiphenomena of COPD 
such as reduced skeletal muscle oxidative capacity, relative 
hypoxemia and sympathetic and inflammatory activation contribute 
to this increased glucose production. Additional research is warranted 
to further clarify the relationships between whole-body substrate 
metabolism, muscle energy supply and pulmonary cachexia and the 
clinical implications of the present findings. Nevertheless, this study 
provides a strong rational to investigate the value of nutritional and 
pharmacological interventions targeting intermediary glucose 
metabolism in moderate COPD.  
 
Thesis Frits Franssen_08.pdf   158 21-11-2008   10:22:00
 Glucose production in COPD⏐159 
References 
1. Kutsuzawa T, Shioya S, Kurita D, Haida M, Ohta Y, Yamabayashi H. 31P NMR 
study of skeletal muscle metabolism in patients with chronic respiratory 
impairment. Am Rev Respir Dis 1992;146:1019-1024. 
2. Maltais F, LeBlanc P, Whittom F, Simard C, Marquis K, Belanger M, Breton MJ, 
Jobin J. Oxidative enzyme activities of the vastus lateralis muscle and the 
functional status in patients with COPD. Thorax 2000;55:848-853. 
3. Sin DD, Wu L, Man SF. The relationship between reduced lung function and 
cardiovascular mortality: A population-based study and a systematic review of 
the literature. Chest 2005;127:1952-1959. 
4. Bolton CE, Evans M, Ionescu AA, Edwards SM, Morris RH, Dunseath G, Luzio SD, 
Owens DR, Shale DJ. Insulin resistance and inflammation - a further systemic 
complication of COPD. COPD 2007;4:121-126. 
5. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in 
patients with advanced chronic obstructive pulmonary disease, with and without 
chronic respiratory failure. Eur Respir J 1990;3:192-196. 
6. Natali A, Toschi E, Camastra S, Gastaldelli A, Groop L, Ferrannini E. Determinants 
of postabsorptive endogenous glucose output in non-diabetic subjects. European 
group for the study of insulin resistance. Diabetologia 2000;43:1266-1272. 
7. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link 
to systemic manifestations of chronic lung disease. Chest 2005;128:3618-3624. 
8. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, 
Hoogeveen R, Folsom AR, Heiss G. Low-grade systemic inflammation and the 
development of type 2 diabetes: The atherosclerosis risk in communities study. 
Diabetes 2003;52:1799-1805. 
9. American Thoracic Society Statement. Standards for the diagnosis and care of 
patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 
1995;152:S77-121. 
10. WHO expert committee on diabetes mellitus: Second report. World Health Organ 
Tech Rep Ser 1980;646:1-80. 
11. Lukaski HC, Johnson PE, Bolonchuk WW, Lykken GI. Assessment of fat-free mass 
using bioelectrical impedance measurements of the human body. Am J Clin Nutr 
1985;41:810-817. 
12. Steiner MC, Barton RL, Singh SJ, Morgan MD. Bedside methods versus dual 
energy x-ray absorptiometry for body composition measurement in COPD. Eur 
Respir J 2002;19:626-631. 
13. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gómez JM, Heitmann 
BL, Kent-Smith L, Melchior JC, Pirlich M, Scharfetter H, Schols AM, Pichard C; 
Composition of the ESPEN Working Group. Bioelectrical impedance analysis-part 
i: Review of principles and methods. Clin Nutr 2004;23:1226-1243. 
14. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung 
volumes and forced ventilatory flows. Report working party standardization of 
lung function tests, European community for steel and coal. Official statement of 
the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40. 
15. Romijn JA, Coyle EF, Sidossis LS, Gastaldelli A, Horowitz JF, Endert E, Wolfe RR. 
Regulation of endogenous fat and carbohydrate metabolism in relation to exercise 
intensity and duration. Am J Physiol 1993;265:E380-391. 
16. Ackermans MT, Pereira Arias AM, Bisschop PH, Endert E, Sauerwein HP, Romijn 
JA. The quantification of gluconeogenesis in healthy men by 2H2O and [2-
13C]glycerol yields different results: Rates of gluconeogenesis in healthy men 
measured with 2H2O are higher than those measured with [2-13C]glycerol. J Clin 
Endocrinol Metab 2001;86:2220-2226. 
Thesis Frits Franssen_08.pdf   159 21-11-2008   10:22:00
160⏐Chapter 7 
17. Ackermans MT, Ruiter AF, Endert E. Determination of glycerol concentrations and 
glycerol isotopic enrichments in human plasma by gas chromatography/mass 
spectrometry. Anal Biochem 1998;258:80-86. 
18. Wolfe RR. Radioactive and stable isotope tracers in biomedicine : Principles and 
practice of kinetic analysis. New York: Wiley-Liss; 1992. 
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: Insulin resistance and beta-cell function from 
fasting plasma glucose and insulin concentrations in man. Diabetologia 
1985;28:412-419. 
20. Engelen MP, Schols AM, Does JD, Gosker HR, Deutz NE, Wouters EF. Exercise-
induced lactate increase in relation to muscle substrates in patients with chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1697-1704. 
21. Maltais F, Simard AA, Simard C, Jobin J, Desgagnes P, LeBlanc P. Oxidative 
capacity of the skeletal muscle and lactic acid kinetics during exercise in normal 
subjects and in patients with COPD. Am J Respir Crit Care Med 1996;153:288-
293. 
22. Gosker HR, van Mameren H, van Dijk PJ, Engelen MP, van der Vusse GJ, Wouters 
EF, Schols AM. Skeletal muscle fibre-type shifting and metabolic profile in 
patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19: 
617-625. 
23. Goldstein SA, Thomashow BM, Kvetan V, Askanazi J, Kinney JM, Elwyn DH. 
Nitrogen and energy relationships in malnourished patients with emphysema. Am 
Rev Respir Dis 1988;138:636-644. 
24. Giusti V, Schneiter P, Thiebaud D, Landry M, Burckhardt P, Jequier E, Tappy L. 
Influences of body weight, body composition, and substrate oxidation rate on 
resting postabsorptive glucose production and gluconeogenesis. Int J Obes Relat 
Metab Disord 1996;20:842-847. 
25. Gosker HR, Engelen MP, van Mameren H, van Dijk PJ, van der Vusse GJ, Wouters 
EF, Schols AM. Muscle fibre type IIx atrophy is involved in the loss of fat-free 
mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002;76:113-119. 
26. Kreisman SH, Ah Mew N, Arsenault M, Nessim SJ, Halter JB, Vranic M, Marliss EB. 
Epinephrine infusion during moderate intensity exercise increases glucose 
production and uptake. Am J Physiol Endocrinol Metab 2000;278:E949-957. 
27. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, 
Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the 
glucose clamp technique in the assessment of insulin sensitivity: Studies in 
subjects with various degrees of glucose tolerance and insulin sensitivity. 
Diabetes Care 2000;23:57-63. 
28. Jakobsson P, Jorfeldt L, von Schenck H. Insulin resistance is not exhibited by 
advanced chronic obstructive pulmonary disease patients. Clin Physiol 1995;15: 
547-555. 
29. Koehler F, Doehner W, Hoernig S, Witt C, Anker SD, John M. Anorexia in chronic 
obstructive pulmonary disease - association to cachexia and hormonal 
derangement. Int J Cardiol 2007;119:83-89. 
30. Tayek JA, Manglik S, Abemayor E. Insulin secretion, glucose production, and 
insulin sensitivity in underweight and normal-weight volunteers, and in 
underweight and normal-weight cancer patients: A clinical research center study. 
Metabolism 1997;46:140-145. 
31. Jakobsson P, Jorfeldt L. Oxygen supplementation increases glucose tolerance 
during euglycaemic hyperinsulinaemic glucose clamp procedure in patients with 
severe COPD and chronic hypoxaemia. Clin Physiol Funct Imaging 2006;26: 
271-274. 
32. Casaburi R, Patessio A, Ioli F, Zanaboni S, Donner CF, Wasserman K. Reductions 
in exercise lactic acidosis and ventilation as a result of exercise training in 
patients with obstructive lung disease. Am Rev Respir Dis 1991;143:9-18. 
Thesis Frits Franssen_08.pdf   160 21-11-2008   10:22:00
 Glucose production in COPD⏐161 
33. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, O'Brien WL, 
Bassett DR Jr, Schmitz KH, Emplaincourt PO, Jacobs DR Jr, Leon AS. 
Compendium of physical activities: An update of activity codes and met 
intensities. Med Sci Sports Exerc 2000;32:S498-504. 
 
 
Thesis Frits Franssen_08.pdf   161 21-11-2008   10:22:00
 Thesis Frits Franssen_08.pdf   162 21-11-2008   10:22:00
   
163 
 
 
 
 
Chapter 8 
Whole-body resting and exercise-
induced lipolysis in sarcopenic 
patients with chronic obstructive 
pulmonary disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frits M.E. Franssen, Hans P. Sauerwein, Erica P.A. Rutten,  
Emiel F.M. Wouters, Annemie M.W.J. Schols 
European Respiratory Journal 2008; 32: 1466-1471 
Thesis Frits Franssen_08.pdf   163 21-11-2008   10:22:00
164⏐Chapter 8 
Abstract 
Introduction 
An impaired β-adrenoceptor-mediated lipolysis was reported in sarcopenic patients 
with chronic obstructive pulmonary disease (COPD). This could play a role in the shift 
in body composition towards decreased fat-free mass (FFM) and relative maintenance 
of fat mass (FM). Lipolysis could be affected by chronic treatment with β2-agonists or 
disease-related factors. Therefore, whole-body resting and exercise-induced lipolysis 
was investigated in sarcopenic COPD patients with moderate disease severity. 
 
Methods 
Seven sarcopenic COPD patients (FEV1: 53±5%, BMI: 27.5±0.9 kg·m-2) and 7 controls 
matched for age, gender and BMI were studied. In addition, 6 underweight COPD 
patients (FEV1: 51±5%, BMI: 20.6±0.7 kg·m-2) matched for disease severity were 
recruited. Lipolysis and plasma levels of catecholamines were assessed during infusion 
of [2H5]glycerol at rest and during submaximal cycling exercise.  
 
Results 
Proportional FM was comparable between sarcopenic patients and controls, while FFM-
index was significantly reduced in patients. At rest, the rate of appearance (Ra) of 
glycerol (4.1±0.6 μmol·kgFFM-1·min-1 and 3.3±0.2 μmol·kgFFM-1·min-1, respectively) 
was not significantly different. In underweight patients, glycerol Ra (4.3±0.5 
μmol·kgFFM-1·min-1) was also comparable. End-of-exercise lipolytic rates were not 
significantly different between groups. Glycerol Ra was not related to fat mass. Resting 
epinephrine levels were significantly increased in underweight COPD patients and were 
related to resting lipolysis (r=0.520, p<0.05). 
 
Conclusions 
Sarcopenia in COPD patients with moderate disease severity is not characterized by 
abnormal lipolytic rate. Altered regulation of muscle protein turnover seems to be the 
trigger in the body compositional shift observed in these patients. 
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Introduction 
Cachexia, defined as weight loss with a disproportional loss of fat-
free mass (FFM), occurs in a substantial number of patients with 
chronic obstructive pulmonary disease (COPD) and is an independent 
predictor of mortality1. Its prevalence depends on the population 
analysed and varies from 11% in moderate to severe COPD out-
patients2 to 26% in severe patients eligible for pulmonary 
rehabilitation3. Furthermore, in a substantial proportion of normal-
weight COPD patients (10–15%)3,4 hidden depletion of fat-free mass 
occurs, also referred to as sarcopenia. The clinical implications of this 
body compositional shift towards decreased FFM and relative or even 
absolute abundance of fat mass were illustrated in a study showing a 
greater degree of physical impairment in normal-weight COPD 
patients with low FFM compared to underweight patients with 
preserved fat-free mass3. We hypothesized that sarcopenia in COPD 
is associated with alterations in intermediary metabolism, towards 
accelerated net muscle protein breakdown and/or impaired fat 
oxidation or decreased lipolysis. There are some indications that 
depletion of FFM is indeed associated with altered regulation of 
protein turnover towards increased protein breakdown5-7. Also, 
reduced skeletal muscle activity of 3-hydroxyacyl CoA 
dehydrogenase (HADH), which regulates the β-oxidation of fatty 
acids, has consistently been shown in normal-weight COPD patients8. 
Finally, an impaired β-adrenoceptor-mediated increase in plasma 
levels of nonesterified fatty acids was reported in sarcopenic COPD 
patients9, which is suggestive for a reduced lipolysis. However, 
whole-body lipolytic rate and differences in lipid kinetics between 
sarcopenic and underweight COPD patients have not been studied 
until now.  
The primary aim of the present study was to investigate resting 
whole-body lipolysis in sarcopenic COPD patients versus healthy 
controls, matched for age and BMI. Secondary, potential differences 
in lipolytic rate between normal and underweight COPD patients 
matched for disease severity were explored, since loss of fat mass 
may be due to increased lipolysis, as previously observed in cancer 
patients10. Since oxidation of free fatty acids accounts for the major 
portion of energy requirements during low intensity exercise, 
submaximal bicycle exercise was used as metabolic stressor for 
whole-body lipolysis.  
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Methods 
Study population 
Seven male and clinically stable COPD out-patients11 with moderate 
airflow obstruction and seven healthy controls, matched for age, sex 
and body mass index (BMI) volunteered for this study. Additionally, 
six COPD patients with low BMI were recruited, matched for FEV1. 
Details on body composition of the groups are shown in Figure 8.1. 
Exclusion criteria for participation were glucose intolerance, diabetes 
mellitus, thyroid or other endocrine disorders, recent involuntary 
weight loss, malignancies, chronic heart failure, renal, hepatic or 
other gastro-intestinal disease or recent surgery. Patients did not 
exhibit chronic respiratory insufficiency or receive supplemental 
oxygen therapy. The following pulmonary maintenance medications 
were used: inhaled short- and long-acting β2-adrenoceptor agonists, 
54%; anticholinergics by inhalation, 54%; combined inhalers of 
short-acting β2-adrenoceptor agonists and short-acting 
anticholinergics, 8%; inhalation corticosteroids, 8%; combined 
inhalers of sympathicomimetics and corticosteroids, 46%; xanthines, 
31%; and oral N-acetylcysteine, 23%. The use of pulmonary 
medications was equally distributed between COPD subgroups. On 
the evening before the test day and on the morning of the study, 
pulmonary maintenance medications were suspended in order to 
avoid potential acute effects of these on lipolysis. Written informed 
consent was obtained from all subjects and the study was approved 
by the medical ethical committee of the University Hospital 
Maastricht.  
Study design 
The study was performed at the out-patient metabolic ward of the 
University Hospital Maastricht on two separate occasions. During the 
first visit, medical history was checked and physical examination was 
performed by a physician. Furthermore, body composition was 
measured and lung function and incremental exercise tests were 
carried out. Eligible subjects subsequently participated in the glycerol 
stable isotope tracer protocol, as described below. 
Lung function tests 
Subjects underwent spirometry for measurement of forced expiratory 
volume in one second (FEV1) and forced vital capacity (FVC). The 
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highest value of at least three technically acceptable maneuvers was 
used. Total lung capacity (TLC) and residual volume (RV) were 
determined by whole-body plethysmography (MasterLab Body, 
Jaeger, Würzburg, Germany). Diffusing capacity for carbon monoxide 
(DLCO) was assessed by the single-breath method (MasterLab 
Transfer, Jaeger, Würzburg, Germany). All values obtained were 
related to a reference value and expressed as a percentage of the 
predicted value. In patients, arterial blood gases were determined on 
a blood gas analyzer (ABL 700, Radiometer, Copenhagen, Denmark). 
Body composition 
Body height was determined to the nearest 0.5 cm with subjects 
standing barefoot. Body weight (BW) was measured with a beam 
scale (SECA, Hamburg, Germany) without shoes and in light clothing 
to the nearest 0.1 kg. Body mass index was calculated as the ratio of 
weight to height in meters squared. FFM was measured by 
bioelectrical impedance analysis at a spectrum of 48 frequencies 
ranging from 5 to 500 kHz (Xitron 4000b, Xitron technologies, San 
Diego, California, USA). Resistance was measured in supine position 
at the right side as described by Lukaski12. In subjects with COPD, 
FFM was estimated from impedance measurements using the sex-
specific regression equation described by Steiner13, while the 
equation of Dey14 was used for the healthy elderly controls. Fat-free 
mass index (FFMI) was calculated as the ratio of FFM to height in 
meters squared. 
Exercise capacity 
In order to determine the submaximal bicycle exercise load for each 
individual, subjects performed a standardized incremental exhaustive 
exercise test on an electrically braked cycle ergometer, as previously 
published15. 
Glycerol stable isotope tracer protocol 
After an overnight fast, subjects reported at the laboratory at 07.30 
h and were studied at rest in the supine position. A catheter was 
placed in an antecubital vein of the arm for stable isotope infusion. A 
second catheter for sampling of arterialized venous blood was placed 
retrograde in a dorsal hand vein of the contralateral arm and 
maintained at 60ºC in a thermoregulated box. At 08.00 h, after 
taking a blood sample for background enrichment of plasma glycerol, 
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subjects were administered a single intravenous dose of [2H5]glycerol 
(1.5 μmol·kgBW-1, >99% enriched; Cambridge Isotopes Inc, 
Andover, Massachusetts, USA) in order to prime the glycerol pool. 
Thereafter (t=0), a continuous infusion of [2H5]glycerol (0.1 
μmol·kgBW-1·min-1) dissolved in 0.9% saline was started via a 
calibrated pump (IVAC 560, San Diego, California, USA). Resting 
blood samples were taken at t=110 and 120 minutes. In each 
experiment, the exact [2H5]glycerol infusion rate was determined 
from the glycerol concentration and enrichment in the infusate. At 
t=120 minutes COPD patients started to exercise on a cycle 
ergometer at a workload of 50% maximal workload (Wmax) for 20 
minutes, while controls exercised at an identical absolute work load 
(30 W = 50% of mean Wmax in COPD patients) for the same duration. 
Blood samples were drawn at t=125, 130, 135 and 140 minutes. The 
protocol continued with one hour recovery period, during which blood 
samples were taken at t=155, 170, 185 and 200 minutes. 
Thereafter, controls performed a second 20 minute exercise test at 
50% of their individual Wmax in order to study potential alterations in 
glycerol kinetics at identical relative submaximal work load. Blood 
samples were taken at t=205, 210, 215 and 220 minutes during 
exercise and at t=235, 250, 265 and 280 minutes during a second 
recovery period of one hour. Plasma levels of regulatory hormones 
were determined at t=110, 140, 200, 220 and 280 minutes. During 
the study, subjects were allowed to drink water only. 
Analytic procedures 
Blood samples (5 ml) for [2H5]glycerol enrichment and glycerol 
concentration were collected on heparin, immediately put on ice, and 
centrifuged at 4000 rpm at +4ºC for 10 minutes. Samples for 
catecholamines were collected in iced EDTA tubes, centrifuged at 
4000 rpm for 10 minutes at +4ºC and stored in a glutathione 
containing tube. For determination of insulin, 3 ml of arterialized-
venous blood were put into a coagulation tube, which was 
centrifuged for 10 minutes at 3000 rpm at room temperature. Serum 
was separated and centrifuged again for 5 minutes at 3000 rpm. All 
aliquots of plasma and serum were frozen immediately in liquid 
nitrogen, stored –80°C and transported on dry ice before assay.  
Isotope enrichment of glycerol in plasma was determined by gas 
chromatography-mass spectrometry, as described by Ackermans et 
al.16. Serum free fatty acids (FFA) were measured by an enzymatic 
colorimetric method (NEFAC; Wako Chemicals GmbH, Neuss, 
Thesis Frits Franssen_08.pdf   168 21-11-2008   10:22:01
 Lipolysis and body composition in COPD⏐169 
Germany). Catecholamines were determined by an in-house reversed 
phase HPLC method with fluorescence detection. Plasma insulin 
concentrations were determined by radioimmunoassay (RIA) 
(Immulite, Diagnostic Products Corporation, Los Angeles, California, 
USA). 
Calculations 
Rate of appearance (Ra) of glycerol at rest was calculated by dividing 
the infusion rate of [2H5]glycerol by the plasma glycerol enrichment. 
During submaximal exercise glycerol Ra was calculated using the 
single-pool non-steady state Steele equation, adapted for stable 
isotope methodology as described elsewhere17: 
 
Ra = (F – Vd[(C2+C1)/2][(E2-E1)/(t2-t1)])/((E2+E1)/2), 
 
where F is the infusion rate (µmol·kgFFM-1·min-1), Vd is the 
distribution volume of glycerol, C1 and C2 are glycerol concentrations 
at times 1 (t1) and 2 (t2), respectively, and E1 and E2 are the glycerol 
enrichments at t1 and t2, respectively. The effective Vd was assumed 
to be 230 ml·kgBW-1 18. 
Statistics 
Results are expressed as mean ± standard error of the mean (SEM). 
One way analysis of variance (ANOVA) was used to determine 
differences in baseline characteristics and substrate and hormone 
concentrations between normal-weight patients, underweight 
patients and controls. LSD multiple comparison test was used as post 
hoc test. Mixed design ANOVA for repeated measures was performed 
in order to analyse potential differences in glycerol Ra between the 
three study groups. Groups were entered as between-group 
variables, while individual glycerol Ra’s at various timepoints of the 
protocol were used as within-group variables. This analysis was 
performed for each of the phases of the protocol (rest, submaximal 
exercise and recovery) and specifically focused on significant 
between-group differences in glycerol Ra during any of these phases. 
Levene’s test showed homogeneity of variance of repeated measures 
of glycerol Ra‘s. In order to assess the variation explained by 
between-group differences and the variation explained by 
unsystematic factors, F-ratios were calculated. Mauchly’s test of 
sphericity was performed to assess equality of variances of the 
differences between groups. Since the condition of sphericity was not 
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met, Greenhouse-Geisser correction was applied in the production of 
F-ratios. 
Results 
General characteristics of all subjects are shown in Table 8.1.  
 
Table 8.1 Baseline characteristics of the study groups (mean ± SEM).  
 Controls 
(n=7) 
Sarcopenic COPD 
(n=7) 
Underweight COPD 
(n=6) 
  Age, yr  64 ± 2  64 ± 4  70 ± 4 
Body composition    
  Height, cm 173.7 ± 2.2  172.9 ± 1.9  168.1 ± 1.5a 
  Weight, kg  85.5 ± 5.6  82.5 ± 3.5  58.2 ± 2.1c,e 
  BMI, kg·m-2  28.2 ± 1.2  27.5 ± 0.9  20.6 ± 0.7c,f 
  FFM, kg  62.6 ± 2.7  56.1 ± 2.4g  45.3 ± 1.5c,e 
  FFMI, kg·m-2  20.7 ± 0.5  18.8 ± 0.8a  16.0 ± 0.4c,d 
  FM, kg  22.9 ± 3.3  26.4 ± 2.9  12.9 ± 0.8a,e 
  FMI, kg·m-2  7.5 ± 0.9  8.8 ± 0.9  4.6 ± 0.3a,e 
Pulmonary function    
  FEV1, %predicted  105 ± 4  53 ± 5c  51 ± 5c 
  FEV1/FVC%  73.0 ± 1.8  43.0 ± 1.9c  34.4 ± 4.6c 
  DLCO, %predicted  117 ± 5  62 ± 7c  62 ± 4c 
  RV/TLC%  36.3 ± 1.6  43.2 ± 3.5  51.0 ± 10.0 
  PaO2, kPa -  8.5 ± 7.4  8.5 ± 7.8 
  PaCO2, kPa -  5.1 ± 0.2  5.1 ± 0.1 
Exercise capacity    
  Peak work rate, %predicted  129 ± 9  48 ± 5c  44 ± 4c 
  V& O2max, %predicted  110 ± 6  62 ± 5c  57 ± 3c 
BMI: body mass index; FFM: fat-free mass, assessed by bioelectrical impedance 
analysis; FFMI: fat-free mass index; FM: fat mass; FMI: fat mass index; FEV1: forced 
expiratory volume in one second; DLCO: diffusing capacity for carbon monoxide; RV: 
residual volume; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; 
V& O2max: maximal oxygen consumption. Significance of differences between COPD 
patients and controls is indicated as: a: p<0.05, b: p<0.01, c: p<0.001. Significant 
differences between sarcopenic and underweight COPD patients are shown as: d: 
p<0.05, e p<0.01, f p<0.001. g p=0.06 versus controls. 
 
As expected, the normal-weight COPD patients could be typified as 
sarcopenic based on a comparable FM but reduced fat-free mass 
index in comparison to controls. In the underweight COPD patients, 
fat mass (index) and fat-free mass (index) were significantly 
decreased in comparison to the other COPD group and controls 
(Figure 8.1). Lung function and arterial blood gases were equally 
impaired in both COPD groups. Functional capacity was impaired in 
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COPD and was more reduced in underweight patients compared to 
sarcopenic patients. This was probably the result of the difference in 
fat-free mass, since V& O2max was related to FFMI (r=0.679, p<0.05).  
 
Figure 8.1 Body composition of the study groups, displayed in stacked bars. The 
contribution of fat mass index (FMI, white area) and fat-free mass index 
(FFMI, grey area) to the body mass index (BMI) is shown. BMI of 
sarcopenic COPD patients was comparable to controls, although FFMI 
was significantly reduced. Underweight COPD patients were characterized 
by reduced BMI, FFMI and FMI. Standard errors of the mean and p-
values are displayed in Table 8.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resting postabsorptive rate of appearance of glycerol was 
comparable in sarcopenic COPD patients (4.1±0.6 μmol·kgFFM-1·min-
1) and controls (3.3±0.2 μmol·kgFFM-1·min-1, p=0.25) (Figure 8.2). 
Glycerol Ra in underweight COPD patients (4.3±0.5 μmol·kgFFM-
1·min-1, NS) was comparable to the other groups. Mixed design 
ANOVA for repeated measures revealed a non-significant effect of 
study group on whole-body glycerol Ra at rest (F(1, 2)=308.47, NS). 
Fasting plasma levels of FFA and glycerol were comparable in the 
three groups (Table 8.2). In underweight COPD patients, 
catecholamine concentrations were significantly increased compared 
to sarcopenic patients and controls. Also, insulin levels were 
significantly increased in sarcopenic patients, while insulin 
concentrations in underweight COPD patients were decreased.  
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Table 8.2 Resting and end-of-exercise plasma free fatty acid (FFA), glycerol and 
hormone concentrations (mean ± SEM).  
 Controls 
(n=7) 
Sarcopenic COPD 
(n=7) 
Underweight COPD 
(n=6) 
Resting state    
  FFA, mmol·l-1  1.04 ± 0.14  1.08 ± 0.13  0.99 ± 0.11 
  Glycerol, mmol·l-1  79.9 ± 6.4  85.0 ± 9.5  97.1 ± 11.1 
  Insulin, pmol·l-1  47 ± 9  76 ± 12a  22 ± 6c 
  Epinephrine, nmol·l-1  0.45 ± 0.07  0.52 ± 0.12  1.01 ± 0.24a,b 
  Norepinephrine, nmol·l-1  0.35 ± 0.09  0.85 ± 0.21  1.22 ± 0.46a 
End-of-exercise1    
  FFA, mmol·l-1  1.79 ± 0.28  1.45 ± 0.15  1.42 ± 0.25 
  Glycerol, mmol·l-1  230.6 ± 41.2  207.7 ± 40.5  229.1 ± 49.7 
  Insulin, pmol·l-1  51 ± 8  66 ± 13  19 ± 3a,c 
  Epinephrine, nmol·l-1  0.85 ± 0.18  3.68 ± 2.40  2.88 ± 1.00 
  Norepinephrine, nmol·l-1  1.34 ± 0.21  2.41 ± 0.51  2.18 ± 0.86 
1: for controls, values after exercise at identical absolute workload are shown. 
Significance of differences between patients and controls is indicated as: a: p<0.05. 
Significant differences between COPD subgroups are shown as: b: p<0.05 and 
c: p<0.01. 
 
Submaximal bicycle exercise resulted in significant increases in 
glycerol Ra in all three groups (Figure 8.2). The proportional increase 
in glycerol Ra during submaximal exercise was slightly less in 
sarcopenic COPD patients (59±18%) in comparison to underweight 
patients (82±22%, NS). In controls, the relative increment in 
glycerol Ra was even greater during submaximal exercise at both 
identical absolute workload (107±22%, NS) as well as identical 
proportional load (177±39%, p<0.05 for both COPD groups). As a 
consequence, the end-of-exercise values for glycerol Ra were lower in 
sarcopenic patients (6.8±1.2 μmol·kgFFM-1·min-1), than in 
underweight patients (7.6±1.0 μmol·kgFFM-1·min-1) and controls (30 
Watt: 7.7±1.3 μmol·kgFFM-1·min-1; 50% Wmax: 7.9±1.1 
μmol·kgFFM-1·min-1), but differences were not significant (Figure 
8.2). After exercise, glycerol Ra recovered to baseline in all groups 
and values were comparable (Figure 8.2). No significant effects of 
study group on whole-body glycerol Ra was observed during 
submaximal exercise at identical absolute work load (F(1, 
2)=201.96, NS) and identical relative work load (F(1,2)=213.76, NS) 
and during recovery periods (F(1,2)=189.71, NS and F(1,2)=212.86, 
NS, respectively). Plasma concentrations of FFA, glycerol and 
catecholamines increased significantly after submaximal exercise in 
all groups, and end-of-exercise values were also identical (Table 
8.2). 
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Figure 8.2  Whole-body lipolysis measured by rate of appearance (Ra) of glycerol at 
rest, during submaximal cycle exercise and during recovery from 
exercise. Healthy controls (n=7), closed triangles; sarcopenic COPD 
patients (n=7), closed circles; underweight COPD patients (n=6), open 
circles. No significant differences were observed between groups at any 
part of the study. For clearity, standard errors of the mean are not 
shown. 
 
 
 
 
 
 
 
 
 
 
 
 
In bivariate correlation analysis in the total study population, resting 
glycerol Ra was related to plasma epinephrine concentration 
(r=0.520, p<0.05) and basal glycerol level (r=0.760, p<0.001), 
while correlations with body mass index, fat-free mass (index) and 
fat mass (index) were absent. End-of-exercise glycerol Ra was 
significantly related to post-exercise glycerol (r=0.762, p<0.01) and 
FFA (r=0.631, p<0.05) plasma levels and to resting norepinephrine 
concentration (r=0.618, p<0.05) in COPD patients. 
Discussion 
This is the first study that investigated lipid kinetics using glycerol 
stable isotope tracer methodology in patients with COPD. Also, the 
contribution of derangements in whole-body lipolysis to body 
composition was not previously studied in COPD. No differences in 
resting and exercise-induced lipolysis were observed between 
sarcopenic patients with COPD and age-matched controls. Thus, in 
normal-weight and clinically stable COPD patients, (relative) 
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maintenance of fat mass with evidence of muscle wasting is not 
related to altered adipocyte lipolysis.  
Total body fat mass is determined by the balance between lipid 
synthesis and degradation. Lipids are stored in the adipocytes as 
triglycerides and constitute the main fuel reserve of the body. 
Following hormonal stimulation, the stored triglycerides are 
hydrolyzed to their components fatty acids and glycerol and this 
process is called lipolysis. The released fatty acids are either used for 
mitochondrial beta-oxidation to produce ATP or reesterified to 
triacylglycerol and restored. FFA are the major source of energy for 
resting muscle. It has been consistently shown that muscle fat 
oxidative capacity is reduced in COPD patients8, partly as an 
adaptation to a more sedentary lifestyle due to disease related 
symptoms. Although the effects of physical inactivity on adipose 
tissue lipolysis in COPD have not been studied, available evidence 
suggests that whole-body lipolytic rate is not related to training 
status19. No difference in exercise-induced lipolysis was observed 
between untrained and endurance-trained healthy subjects, although 
fat oxidation was enhanced in the latter group20.  
Previously, Schiffelers et al.9 reported a reduced increase in plasma 
fatty acid levels and a blunted thermogenic response during β-
adrenergic stimulation in normal-weight COPD patients with high fat 
mass compared to controls. The authors suggested that disturbed 
lipolytic responsiveness contributes to the development or 
maintenance of increased fat mass in the subgroup of sarcopenic 
COPD patients. In contrast to the present study, no patients with a 
reduced fat mass were studied and whole-body lipolysis was not 
assessed. However, the results of the present study are in line with 
these previous observations. Although whole-body lipolytic rate was 
comparable between groups, homeostatic control of lipolysis was 
altered in sarcopenic COPD patients, as indicated by 
hyperinsulinaemia. Thus, the inhibitory effect of insulin on lipolytic 
rate seemed impaired in sarcopenic COPD patients. Also, the lipolytic 
response to exercise tended to be decreased in this subgroup.   
In contrast to the present results, Jakobsson et al.21 reported 
increased turnover rate and plasma levels of free fatty acids in 
normal-weight COPD patients (BMI: 23.6 kg·m-2), suggestive for 
increased state of lipolysis. The fact that included patients were 
chronically hypoxaemic may account for the distinct results 
compared to the normoxaemic patients in the present study. In 
healthy subjects, elevated levels of FFA were observed during 
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chronic hypobaric hypoxia, probably related to enhanced 
epinephrine-induced lipolysis22.  
Lipolytic rate was not enhanced in underweight COPD patients in 
comparison to normal-weight patients or controls, despite 
significantly elevated catecholamine levels. Since catecholamines are 
the primary stimulators of lipolysis via β-adrenoceptors, alterations 
in sympathetic tone may result in changes in fat mass and body 
weight in COPD patients. Indeed, Hofford et al.23 reported nearly 
doubled plasma norepinephrine levels in underweight patients with 
severe COPD in comparison to healthy normal-weight control 
subjects. However, results of the present study suggests a reduced 
sensitivity to circulating catecholamines and confirm the observations 
by Schiffelers et al.9. Due to chronic overstimulation of the sympathic 
nervous system in COPD24 and the long-term usage of β2-agonists for 
bronchodilatation, β-adrenoceptors may become desensitized and 
subsequently the lipolytic response following hormonal stimulation 
might be reduced25. 
Since the contribution of impaired lipolysis to the sarcopenic 
phenotype of COPD patients is unlikely, selective wasting of fat-free 
mass rather than preservation of fat mass seems to be the 
predominant pathophysiological mechanism. Indeed, increased 
whole-body myofibrillar protein breakdown, assessed by a 
methylhistidine stable isotope tracer protocol, has been reported in 
underweight COPD patients with reduced fat-free mass and fat mass, 
in comparison to normal-weight patients and controls with preserved 
fat-free mass5. In addition, increased cellular6 and muscular protein 
catabolism7 was observed in COPD patients with evidence for muscle 
atrophy. This suggests that increased muscle protein breakdown is 
the trigger in the body compositional shift in COPD, towards reduced 
fat-free mass. 
This study assessed potential differences in lipolytic rate in clinically 
stable sarcopenic COPD patients without recent weight loss. 
However, the present body composition of these COPD patients may 
result from foregoing episodes of shifts in body fat and fat-free 
tissues. During acute exacerbations of the disease a combination of 
enhanced hypoxemia, increased sympathetic tone, more frequent 
use β2-agonists as reliever therapy, administration of systemic 
corticosteroids and a reduced dietary intake may induce short-term 
bursts of increased lipolysis resulting in degradation of body fat mass 
and weight loss. Thus, it might be interesting to study potential 
periods with deranged lipid metabolism during acute exacerbation in 
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relation to longitudinal changes in body composition in COPD in the 
future.  
In summary, resting and exercise-induced whole-body lipolytic rate 
was comparable in sarcopenic COPD patients, underweight patients 
and matched control subjects, despite significant alterations in 
endocrinological control of lipolysis. Disturbances in lipolytic rate do 
not contribute to alterations in body composition in COPD.  
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Abstract 
Introduction 
Experimental studies indicate that greater skeletal muscle protein breakdown is a 
trigger for the cachexia that often is prevalent in chronic obstructive pulmonary 
disease (COPD).  
 
Methods 
We compared myofibrillar protein breakdown (MPB) with to whole-body (WB) protein 
breakdown (PB) in nine cachectic COPD patients (FEV1: 48±4% of predicted), seven 
noncachectic COPD patients (FEV1: 53±5% of predicted), and seven age-matched 
healthy control subjects, who were matched by body mass index  with the 
noncachectic patients. 
After the subjects fasted overnight (10 hours) and discontinued the maintenance 
medication, a primed constant and continuous infusion protocol was used to infuse L-
[ring-2H5]-phenylalanine and L-[ring-2H2]-tyrosine to measure WB protein turnover 
and L-[2H3]-3-methylhistidine to measure WB MPB. Three arterialized venous blood 
samples were taken between 80 and 90 minutes of infusion to measure amino acid 
concentrations and tracer enrichments.  
 
Results 
Body composition, WB protein turnover and WB MPB did not differ significantly 
between the noncachectic COPD and control subjects. Cachectic COPD had lower fat 
mass and fat-free mass values (both: p<0.01) than did the noncachectic COPD 
patients. WB MPB was significantly (p<0.05) higher in the cachectic COPD group (18±3 
nmol·kg-1·min-1) than in the combined control and noncachectic COPD groups (10±1 
nmol·kg-1·min-1), but WB protein turnover did not differ significantly between the 
groups. Correlations with fat-free mass were significant (p<0.05) for plasma 
glutamate and branched-chain amino acids, and that for WB MPB trended toward 
significance (p=0.07).  
 
Conclusions 
Cachexia in clinically stable patients with moderate COPD is characterized by increased 
WB MPB, which indicates that myofibrillar protein wasting is an important target for 
nutritional and pharmacological modulation.   
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Introduction 
Weight loss and muscle wasting are prevalent in patients with 
moderate-to-severe chronic obstructive pulmonary disease 
(COPD)1,2, a combination that is commonly referred to as pulmonary 
cachexia. Low fat-free mass (FFM), reflecting the amount of skeletal 
muscle mass, is associated with exercise intolerance3 related to 
reduced skeletal muscle strength4,5, impaired health status6 and 
shorter survival7. Experimental studies in acute disease models 
indicate that increased skeletal muscle protein breakdown (PB) is a 
typical feature of cachexia, and activation of the ubiquitine-
proteasome pathway has been identified as an important trigger of 
proteolysis8. Surprising little information is available about protein 
metabolism in relation to cachexia in clinically stable chronic disease 
states. In comparing underweight patients with emphysema with 
healthy control subjects, Morrison et al.9 found no difference in 
skeletal muscle PB but lower whole-body protein synthesis in the 
emphysema patients. This study was, however, limited by the facts 
that the control group was significantly younger than the COPD 
group (mean age: 45 and 62 yr, respectively) and that no 
noncachectic COPD patients were included. Recently, elevated 
concentrations of urinary pseudouridine, used as an indirect 
biomarker for cellular PB, were found in cachectic COPD patients 
than in noncachectic patients and healthy controls10. In addition, the 
noncachectic patients had higher urinary pseudouridine concen-
trations than did the controls. The plasma amino acid profile in 
cachectic COPD patients is more extensively investigated than is 
protein metabolism, and it consistently shows a low concentration of 
the branched-chain amino acids (BCAAs) leucine, isoleucine, and 
valine9,11,12.  
Measurements of whole-body (WB) protein metabolism do not 
necessarily reflect skeletal muscle metabolism. Vissers et al.13 
described a technique to measure the rate of myofibrillar PB (MPB) 
by using the primed constant and continuous infusion protocol with 
deuterated 3-methylhistidine. Although myofibrillar protein is also 
present in other tissue such as intestine and skin, it is mainly found 
in muscle. Therefore, WB MPB gives an indication for skeletal muscle 
PB. The current study is the first to measure the rate of WB MPB in 
humans. The main purpose of the current study was to investigate 
whether WB MPB is greater in cachectic COPD patients than in 
noncachectic COPD patients or healthy controls. The secondary 
purpose was to study whether WB MPB is reflected in WB PB. 
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Methods 
Study population 
In total, 16 clinically stable males with moderate-to-severe COPD14 
and seven age- and sex-matched healthy control subjects were 
studied. Each member of the healthy control group was matched for 
BMI with a member of the noncachectic COPD group (n=7; BMI: 
28±1 kg·m-2). The remaining COPD patients (n=9) were defined as 
the cachectic COPD group (BMI: 20±1 kg·m-2). Exclusion criteria for 
all subjects were malignancy, cardiac failure, distal arteriopathy, 
recent surgery, and severe endocrine, hepatic, or renal disorder. In 
addition, patients who were using systemic corticosteroids ≤3 
months before the study were excluded, because it has been shown 
that systemic corticosteroids may affect muscle protein 
metabolism15. The following pulmonary maintenance medications 
were being used by various proportions of the patients: inhaled 
short- and long-acting β2-adrenoceptor agonists, 56%; anti-
cholinergics by inhalation, 54%; combined inhalers of short-acting 
β2-adrenoceptor agonists and short-acting anticholinergics, 8%; 
inhalation corticosteroids, 19%; combined inhalers of sympathy-
comimetics and corticosteroids, 46%; xanthines, 31%; and oral N-
acetylcysteine, 23%. On the evening before the test day and the 
morning of the test day, the maintenance medication was suspended 
to avoid potential acute effects of these medications on substrate 
metabolism16, because glucose and glycerol metabolism were also 
measured in the study (data presented in chapter 7 and 8). 
Written informed consent was obtained from all subjects. The study 
was approved by the medical ethics committee of the University 
Hospital Maastricht.  
Pulmonary function tests 
Before the test day, all subjects underwent spirometry for 
measurement of forced expiratory volume in one second (FEV1) and 
forced vital capacity; the highest value from three technically 
acceptable maneuvers was then used. Total lung capacity, 
intrathoracic gas volume, and residual volume were assessed by 
using WB plethysmography (Masterlab; Jaeger, Wurzburg, 
Germany). Diffusion capacity for carbon monoxide was measured by 
using the single-breath method (Masterlab; Jaeger). All values 
obtained were related to a reference value and expressed as 
percentages of the predicted value17. On the morning of the lung 
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function measurements, the pulmonary maintenance medications 
were suspended. 
Experimental protocol 
Study design 
Subjects were in a supine position for 1.5 h. A catheter was placed in 
an antecubital vein of the arm for tracer infusion (at a rate of 
85 ml·h-1) according to a primed constant and continuous infusion 
protocol. The stable isotopes L-[ring-2H5]-phenylalanine (PHE), 
L-[ring-2H2]-tyrosine (TYR) were used to measure WB total protein 
turnover. L-[2H3]-3-methylhistidine (3MH) was infused to measure 
WB MPB. The following priming doses (PDs) and infusion rates (IRs) 
were used: L-[ring-2H5]-PHE: PD=2.19 μmol·kg-1, IR=3.20 
μmol·kgFFM-1·h-1, L-[ring-2H2]-TYR: PD=0.95 μmol·kgFFM-1, IR=0.77 
μmol·kgFFM-1·h-1, L-[2H3]-3MH: PD=0.09 μmol·kgFFM-1, IR=0.03 
μmol·kgFFM-1·h-1. Moreover, a bolus dose of L-[ring-2H4]-TYR was 
also given to prime the phenylalanine-derived plasma tyrosine pool 
(PD=0.31 μmol·kgFFM-1). The tracers were obtained from Cambridge 
Isotopic Laboratories (Woburn, MA, USA). After a baseline venous 
blood sample was collected, the PD was administrated intravenously. 
Subsequently, constant continuous tracer infusion was started until 
the end of the test day. A second catheter for arterialized venous 
blood sampling was placed in a superficial dorsal vein of the hand of 
the contralateral arm, which was placed in a thermostatically 
controlled hot box (internal temperature: 60°C), at least 20 minutes 
before the first blood sampling. The use of the hot box is a technique 
to mimic direct arterial sampling18. Three arterialized venous blood 
samples were taken between 80 and 90 minutes after the start of 
the infusion to measure enrichments [the ratio of tracer to tracee 
(TTR)] of the stable isotopes at plasma steady state level. 
Biochemical analyses  
Venous and arterialized venous blood samples were collected in a 
heparinized tube that was immediately put on ice and centrifuged 
(3120 x g, 4°C for 10 minutes) to obtain plasma. Subsequently, 
250 μl plasma was deproteinized with 20 mg sulfosalicylic acid to 
analyze plasma amino acid concentrations and enrichments. All 
samples were frozen in liquid nitrogen and stored at -80°C until 
analysis. Amino acid concentrations were analyzed from venous 
blood by high-performance liquid chromatography (HPLC) system19. 
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PHE, TYR, and 3MH enrichments were analyzed by using a liquid 
chromatography mass spectrometry system (LC-MS, Thermoquest, 
Veenendaal, The Netherlands)20.  
Calculations 
All metabolic data were determined under steady state conditions. 
Therefore, WB rate of appearance (Ra) of PHE represents WB PB. 
Because 3MH is released only from MPB, the WB Ra of 3MH gives an 
indication of WB MPB. The following calculation was used:  
 
WB Ra=I/TTR, 
 
where I represents the tracer infusion rate in plasma.  
Moreover, WB protein synthesis was calculated by subtracting the 
hydroxylation of PHE to TYR [WB Ra TYR x (TTR TYR4/TTR PHE5)] 
from WB PB21. WB net balance was calculated by subtracting WB 
protein synthesis from WB PB.  
WB FFM was measured in each subject by using bioelectrical 
impedance analysis to express metabolic data per kg FFM. The FFM 
of the COPD patients was calculated by using each patient’s specific 
regression equation22, while the FFM of the healthy control subjects 
was calculated by using a specific regression equation described by 
Dey et al.23. Body weight and height were measured to the nearest 
0.1 kg and 0.1 cm, respectively, while the subjects were standing 
and wearing light indoor clothing but no shoes.  
Statistical analyses 
Results are expressed as mean ± standard error of the mean (SEM). 
The mean values of the data obtained from the three arterialized 
venous blood samples were used as WB protein turnover and MPB in 
the postabsorptive state. All data were tested for normality with a 
normal probability plot. The one-way analysis of variance with the 
post hoc Scheffé test was used to test whether there were significant 
differences between the groups in general characteristics, lung 
function, amino acid concentration, and protein turnover. To increase 
the size of the noncachectic group, which will increase the statistical 
power for comparison, the control group and the noncachectic COPD 
patients were taken together (control + noncachectic COPD groups, 
n=14) to ascertain the effect of a change in body composition on 
protein metabolism by using the Scheffé test. The bivariate Pearson 
correlation coefficient was measured to test data for correlations. All 
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p values <0.05 were considered significant. SPSS for Windows 
software (version 11.0; SPSS Inc, Chicago, IL, USA) was used for 
data analysis. 
Results 
General characteristics 
General characteristics of the subjects are shown in Table 9.1. There 
were no significant differences in FFM, FFM index (FFMI: 
FFM·height-2), fat mass (FM), or FM index (FMI: FM·height-2) between 
the noncachectic COPD group and the BMI-matched healthy control 
group. Cachectic COPD patients had lower values for FFM, FFMI, and 
FM (all: p<0.01) and FMI (p<0.05) than did the noncachectic COPD 
group. 
 
Table 9.1 General characteristics of the study participants (mean ± SEM). 
 Control group(n=7) 
Noncachectic COPD group
(n=7) 
Cachectic COPD group 
(n=9) 
Age, yr  65 ± 2  64 ± 4  70 ± 3 
Weight, kg  86 ± 6  82 ± 3  59 ± 3 1,2 
BMI, kg·m-2  28 ± 1  28 ± 1  20 ± 1 1,2 
FFM, kg  63 ± 3  56 ± 2  45 ± 1 1,3 
FFMI, kg·m-2  21 ± 1  19 ± 1  16 ± 0 1,3 
FM, kg  25 ± 3  26 ± 3  14 ± 2 1,3 
FMI, kg·m-2  8 ± 1  9 ± 1  5 ± 1 3,4 
Lung function    
FEV1, % predicted  102 ± 4  53 ± 5  48 ± 4 3 
FVC, % predicted  109 ± 4  101 ± 6  109 ± 6 
ITGV, % predicted  104 ± 9  131 ± 10  167 ± 7 1,3 
RV, % predicted  111 ± 8  124 ± 10  170 ± 9 1,2 
DLCO, % predicted  113 ± 6  62 ± 7  59 ± 4 1 
TLC, % predicted  104 ± 5  105 ± 6  123 ± 5 3,4 
BMI: body mass index, FFM: fat free mass, FFMI: fat-free mass index, FM: fat mass, 
FMI: fat mass index, FEV1: forced expiratory volume in one second; FVC: forced vital 
capacity, ITGV: intrathoracic gas volume, RV: residual volume, DLCO: diffusing 
capacity for carbon monoxide, TLC: total lung capacity. 1,4 Significantly different from 
control group (one-way ANOVA and post hoc Scheffé test): 1 p<0.01, 4 p<0.05. 2,3 
Significantly different from noncachectic group (one-way ANOVA and post hoc Scheffé 
test): 2 p<0.01, 3 p<0.05. 
 
All COPD patients were characterized by lower values for FEV1 and 
diffusion capacity for carbon monoxide (p<0.01). The cachectic 
COPD group had higher values for residual volume (p<0.05) than did 
the control group. Moreover, the cachectic COPD group had 
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significantly higher intrathoracic gas volume and residual volume 
(both: p<0.01) and total lung capacity (p<0.05) than did the 
noncachectic COPD group, which indicated mild hyperinflation at 
rest.  
Whole-body protein turnover and myofibrillar protein 
breakdown 
Data on WB PB, synthesis, and net balance, shown in Table 9.2, did 
not differ significantly between the three groups. MPB (Figure 9.1) 
was significantly higher in the cachectic COPD group than in the 
control group (p<0.05). There was one outlier for MPB in the non-
cachectic COPD group (BMI: 32 kg·m-2; WB MPB: 24 
nmol·kgFFM-1·min-1). When the combined control and noncachectic 
COPD groups (n=14) were compared with the cachectic COPD group, 
WB MPB was significantly higher in the latter (p<0.05). Moreover, 
WB MPB tended to significantly correlate with FFM (r=-0.38, p=0.07; 
Figure 9.2). 
 
Table 9.2 Whole-body total protein turnover in the control and COPD groups (mean 
± SEM). 
 Control group (n=7) 
Noncachectic COPD group 
(n=7) 
Cachectic COPD group 
(n=9) 
 nmol·kgFFM-1·min-1 nmol·kgFFM-1·min-1 nmol·kgFFM-1·min-1 
WB PB  839 ± 45  769 ± 47  774 ± 28 
WB PS  772 ± 54  697 ± 46  708 ± 26 
WB NB  -63 ± 7  -59 ± 12  -62 ± 5 
WB PB: whole-body protein breakdown, WB PS: whole-body protein synthesis, WB 
NB: whole-body net balance. There were no significant differences in protein turnover 
between the groups (one-way ANOVA with post hoc Scheffé test). 
Plasma amino acid concentrations 
Plasma concentrations of glutamate were significantly (p<0.05) 
lower in the cachectic COPD group than in the control group or the 
noncachectic COPD group (Table 9.3). Plasma tyrosine, isoleucine, 
and BCAA concentrations were significantly lower in the cachectic 
group than in the noncachectic COPD group (p<0.05). When the 
cachectic COPD group was compared with the combined control and 
noncachectic COPD groups, we found that plasma tyrosine and 
glutamate (both: p<0.01), leucine, isoleucine, valine, and the sum of 
BCAAs (p<0.05) were significantly lower in the former group. Plasma 
glutamate concentrations were significantly correlated with BMI, 
FFM, and FFMI [BMI: r=0.67, p<0.01; FFM: r=0.70, p<0.01 (Figure 
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9.3); FFMI: r=0.59, p<0.01] but not with FMI. Plasma BCAA 
concentrations were significantly correlated with FFM and FFMI [FFM: 
r=0.55, p<0.01 (Figure 9.3); FFMI: r=0.52, p<0.01]. 
 
 
Figure 9.1 Box-whisker plot of myofibrillar protein breakdown (WB MPB) in the 
healthy control, noncachectic COPD, and cachectic COPD groups. Values 
indicate minimum, 25th percentile, mean, 75th percentile, maximum, and 
outlier. MPB differed significantly between the control group and the 
cachectic COPD group and between the combined control and 
noncachectic COPD groups and the cachectic COPD group, p<0.05 for 
both (one-way ANOVA and post hoc Scheffé test). FFM: fat-free mass. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.2 Scatter plot of whole-body myofibrillar protein breakdown (WB MPB) and 
fat-free mass (FFM) in the healthy control (closed triangles; n=7), 
noncachectic COPD (closed circles; n=7 with one outlier: grey circle), 
and cachectic COPD groups (open circles; n=9). Bivariate Pearson’s 
correlation coefficient was measured: r=-0.38, p=0.07. 
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Table 9.3 Plasma amino acid concentrations in the control group, the noncachectic 
COPD group and the cachectic COPD group (mean ± SEM).  
 Control group
 
(n=7) 
Noncachectic COPD 
Group 
(n=7) 
Cachectic COPD 
group 
(n=9) 
Phenylalanine, μmol·l-1  62 ± 1  64 ± 2  60 ± 2 
Tyrosine, μmol·l-1  68 ± 3  71 ± 4  58 ± 2 1,2 
Glutamate, μmol·l-1  84 ± 10  84 ± 4  52 ± 6 1-3 
Leucine, μmol·l-1  130 ± 7  82 ± 5  65 ± 1 4 
Isoleucine, μmol·l-1  78 ± 4  82 ± 5  65 ± 1 1,4 
Valine, μmol·l-1  229 ± 13  228 ± 11  201 ± 3 4 
BCAAs, μmol·l-1  435 ± 24  439 ± 19  380 ± 4 1,4 
BCAAs, branched-chain amino acids (the sum of leucine, isoleucine, and valine). 
1 Significantly different from the noncachectic COPD group, p<0.05 (one-way ANOVA 
and post hoc Scheffé test). 2,4 Significantly different from both noncachectic groups 
(one-way ANOVA and post hoc Scheffé test): 2 p<0.01, 4 p<0.05. 
3 Significantly different from the control group, p<0.05 (one-way ANOVA and post hoc 
Scheffé test).  
 
Figure 9.3 Scatter plots of plasma glutamate and branched-chain amino acid 
(BCAA) concentrations and fat-free mass (FFM) in the healthy control 
(closed triangles; n=7), noncachectic COPD (closed circles; n=7 with 
one outlier: grey circle), and cachectic COPD groups (open circles; n=9). 
Pearson’s correlation coefficient was 0.70 for plasma glutamate and 0.55 
for BCAA’s (both: p<0.01) 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
The current study shows that WB MPB is higher in clinically stable 
cachectic patients with moderate COPD than in noncachectic patients 
and control subjects. However, no difference in WB total protein 
turnover was found between the two groups. 
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Whole-body myofibrillar protein breakdown 
The greatest storage of protein in the body occurs in skeletal muscle. 
However, WB measurements of protein metabolism do not always 
reflect skeletal muscle protein metabolism24. 3MH is present solely in 
myofibrillar protein, and the proteolysis of myofibrils releases 3MH 
that cannot be reused. Therefore, measurement of the TTR of 3MH in 
plasma can be used as a valid method of measuring MPB. Because ≈ 
90% of the total body pool of 3MH is present in skeletal muscle25, 
MPB gives an indication of skeletal muscle PB. 
The finding in the current study that WB MPB did not differ 
significantly between noncachectic COPD patients and healthy control 
subjects is consistent with data from a previous study, in which the 
measurement of urinary concentrations of 3MH was used as a 
noninvasive method of measuring MPB26. However, when both 
methods of measuring MPB are compared, several practical 
disadvantages to the collection of urinary 3MH concentrations should 
be described. First, the amount of 3MH in the urine is dependent on 
the amount of meat intake of the subjects. Thus, it is necessary for 
subjects to follow a meat-restricted diet for 3 days before the 
measurement. Second, because the urine has to be collected for 24 
hours, the effect of acute stressors on MPB, such as feeding or 
exercise, cannot be measured. Both items are covered by measuring 
MPB by using the tracer technique.  
The most striking observation of the current study was that cachexia, 
characterized by low BMI, FFM, and FM, was associated with 
increased WB MPB in COPD patients. MPB in the cachectic COPD 
patients was significantly higher than that in the combined control 
and noncachectic COPD groups and tended to be higher than that in 
the noncachectic COPD patients if the outlier was excluded 
(p=0.062). This outlier had a BMI of 32 kg·m-2, which indicated an 
obese person. Whether the high MPB was related to the high BMI 
requires further investigation. The lack of significance between the 
noncachectic and cachectic COPD groups could also be due to the 
small study population. The degree of airflow limitation did not differ 
significantly between the noncachectic and the cachectic COPD 
patients. Until now, no available study has compared MPB in 
cachectic and noncachectic patients. 
The increased MPB was accompanied with low concentrations of 
glutamate and BCAA in plasma, and both plasma glutamate and 
BCAA concentrations were highly correlated with FFM and FFMI. In 
addition, lower plasma glutamate concentrations were found in FFM-
depleted COPD patients than in control subjects11,27. Moreover, lower 
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BCAA concentrations were shown in underweight COPD patients than 
in normal-weight COPD patients and control subjects28. In that study, 
the lower BCAA concentrations were associated with enhanced 
resting energy expenditure. BCAA and glutamate are amino acids 
whose transamination products can be further oxidized in the 
skeletal muscle or the liver. The results of the current study and of 
the study by Yoneda et al.28 suggest that the transamination of 
glutamate and BCAA from plasma and from MPB increases in skeletal 
muscle during wasting.  
The higher MPB in cachectic COPD patients is in line with the 
hypothesis of increased skeletal muscle PB in the muscle wasting 
syndrome. The underlying mechanism of muscle proteolysis is thus 
an important target for therapeutic intervention to prevent or reverse 
this process. The ubiquitine-proteasome pathway is assumed to 
provide most of the proteolytic activity required for the degradation 
of myofibrillar protein29. Recently, activation of nuclear factor-kappa 
B (NF-κB) in skeletal muscle was shown to result in muscle atrophy 
through increased muscle protein degradation by the ubiquitine-
proteasome pathway30. Recently, Agusti et al.31 showed increased 
NF-κB activation in underweight COPD patients. Tumour necrosis 
factor-α (TNF-α) activates NF-κB transcription32. Increased systemic 
levels of TNF-α or the soluble TNF-receptors have been consistently 
shown in COPD patients10 and were associated with systemic 
hypoxia33.  
This is the first study to measure WB MPB in humans. WB 
myofibrillar protein synthesis, however, was not measured. 
Consequently, no conclusions can yet be drawn about net myofibrillar 
protein balance in cachexia or about potential additional disturbances 
in skeletal muscle anabolism. 
Whole-body total protein turnover 
WB total protein turnover did not differ significantly between the 
control and COPD groups. This is in contrast with the findings of 
Engelen et al.21 who showed a higher WB PB and synthesis in 
normal-weight COPD patients than in healthy control subjects. Two 
factors may explain this discrepancy between the studies: first, in 
the study by Engelen et al., patients had more severe disease than 
did the subjects in the current study (FEV1: 37±12% and 50±3% of 
predicted, respectively). Second, patients in the current study did 
not take their maintenance medication on the evening before and on 
the morning of the test day, whereas the patients in the study by 
Engelen et al. continued their medication. In the past, an effect of 
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the use of inhalation medication on glucose metabolism was shown16, 
and therefore, the current study, the intake of the medication was 
stopped. No information is yet available on the acute effect of the 
withdrawal of medication on substrate metabolism. Theoretically, an 
acute effect on protein metabolism cannot be excluded.  
As mentioned earlier, Broekhuizen et al.10, in a recent large 
epidemiologic study, found significantly higher urinary pseudouridine 
concentrations in COPD patients than in healthy control subjects. 
That study also found significantly higher urinary pseudouridine 
concentrations in cachectic COPD patients than in noncachectic COPD 
patients or healthy control subjects. Urinary pseudouridine is a stable 
metabolite of RNA and consequently is used as a marker for cellular 
PB. As did those in the study by Engelen et al.21, patients in the 
study by Broekhuizen et al. continued taking their habitual 
medication; the same differences in WB PB were detected between 
COPD patients and control subjects in both studies. Caution in the 
comparison of these studies is necessary, however, because the 
measurement of urinary pseudouridine as a marker for PB has not 
yet been compared with isotopic protein turnover measurements. 
In the current study, WB MPB was not reflected by WB total PB. It is 
likely that a significant proportion of nonmyofibrillar protein 
degradation, possibly protein in the intestine or the liver, 
overwhelms the myofibrillar protein degradation. Assuming that 
muscle contributes to 25% of the WB protein turnover in humans24, 
an increase in MPB of 50% results in an increase in WB PB of 12%, a 
difference that may be too low to detect. 
In summary, cachectic COPD patients with moderate disease severity 
are characterized by higher WB MPB and lower plasma 
concentrations of glutamate and BCAAs than are those in the 
combined control and noncachectic COPD groups. Future studies are 
needed to relate MPB to proteolytic and regulatory markers in 
skeletal muscle biopsies so as to further unravel the pathogenesis of 
MPB in COPD and to identify relevant targets for nutritional and 
pharmacologic modulation. 
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Abstract 
Chronic obstructive pulmonary disease (COPD) and obesity are common and disabling 
chronic health conditions with increasing prevalence worldwide. A relationship between 
COPD and obesity is increasingly recognized, although the nature of this association 
remains unknown. This review focuses on the epidemiology of obesity in COPD and the 
impact of excessive fat mass on lung function, exercise capacity and prognosis. We 
also review the evidence for altered adipose tissue functions in obesity, including 
reduced lipid storage capacity, altered expression and secretion of inflammatory 
factors, adipose tissue hypoxia and macrophage infiltration in adipose tissue. We 
consider how these factors might be interrelated and contribute to the development of 
insulin resistance in obesity. We propose that in patients with COPD, reduced oxidative 
capacity and systemic hypoxia may amplify these disturbances, not only in obese 
patients but also in subjects with hidden loss of fat-free mass. The potential 
interaction between abnormal adipose tissue function, systemic inflammation and 
COPD may provide more insight in the pathogenesis and reversibility of systemic 
pathology in this disease. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) and obesity are major 
causes of morbidity and mortality worldwide and according to current 
estimates the global burden of these conditions will increase even 
further. While spirometry is used for diagnosis and gradation of 
COPD severity according to the Global initiative for chronic 
Obstructive Lung Disease (GOLD) guidelines1, classification of 
overweight and obesity is based on body mass index (BMI) as 
defined by the World Health Organization2.  
According to the Burden of Obstructive Lung Disease (BOLD) 
Initiative3, the estimated international prevalence of stage II or 
higher COPD is currently 10.1% in individuals aged 40 years and 
older. COPD was the fifth leading cause of mortality around the world 
in 2001 and will be the third most frequent cause of death by the 
year 20204. The prevalence of obesity, defined as a body mass index 
(BMI) ≥30 kg·m-2 2 has multiplied during the last decades and varies 
from 10 to 20% in most European countries to more than 32% in the 
population of the United States of America2. According to the most 
recent global WHO projections 400 million adults were obese in 2005 
and it is estimated that this number will exceed 700 million by the 
year 20155. Obesity plays a major role in the development of the 
metabolic syndrome and has been identified as an important risk 
factor for chronic diseases such as type 2 diabetes mellitus and 
cardiovascular disease. Obesity is linked to respiratory diseases such 
as obstructive sleep apnoea syndrome and obesity hypoventilation 
syndrome6 and accumulating evidence suggests an association 
between obesity and asthma7. A potential link between obesity and 
COPD is also increasingly recognized8 although very little is known 
about the mechanisms underlying this association. At least, the risk 
for development of obesity is increased in COPD as a result of a 
reduced level of physical activities in daily life in these patients 
compared to healthy age-matched controls9.  
Prevalence of obesity in COPD 
Steuten et al.10 studied the prevalence of obesity in a large primary 
care population of COPD patients in the Netherlands. The overall 
prevalence of obesity in this population was 18% with the highest 
prevalence in GOLD 1 and 2 (16–24%) and the lowest in GOLD 4 
(6%). For comparison, the current prevalence of obesity in the 
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general population in the Netherlands is 10% in adult men and 12% 
in adult females11. A much higher prevalence of obesity was reported 
by Eisner et al.12 in an adult multi-ethnic cohort of early stage COPD 
patients in Northern California, USA. Fifty-four percent of COPD 
patients had a BMI≥30 kg·m-2, which is considerably more than the 
20–24% of obese in the same US state reported by the Centres for 
Disease Control and Prevention using annual data from the 
Behavioural Risk Factor Surveillance System (www.cdc.gov/BRFSS/). 
Thus, available data suggest that obesity is more prevalent in COPD 
patients than in the general population, depending on the severity of 
chronic airflow limitation. Indeed, a study in moderately severe 
patients participating in cardiopulmonary rehabilitation showed that 
abdominal obesity measured by waist circumference was almost 
twice as common in COPD patients as in age and gender matched 
controls13. In addition, the occurrence of obesity might differ 
between various clinical phenotypes of COPD. The classical 
distinction of “pink puffers” and “blue bloaters” was based on 
anthropometric characteristics of patients with emphysema and 
chronic bronchitis respectively. By definition, “pink puffers” were thin 
in appearance with a frequent history of weight loss, while “blue 
bloaters” showed no marked weight loss and tended to be 
overweight14. In fact, a significantly increased prevalence of 
(pre)obesity (BMI≥28 kg·m-2) was reported in patients with chronic 
bronchitis (25%) compared to controls (16%) in the Tucson 
prospective cohort study15, while underweight was more prevalent in 
emphysema patients. 
There are no published studies on the prevalence of COPD in obesity. 
However, data from the 4th examination of The Copenhagen City 
Heart Study suggest that the prevalence of COPD among obese 
individuals is significantly lower than among the rest of the 
population (11.2% vs. 18.6%), due to a lower occurrence of mild 
and moderate disease (personal communication with Jørgen Vestbo, 
Department of Cardiology and Respiratory Medicine, Hvidovre 
Hospital, Copenhagen, Denmark).  
In addition to obesity characterized by an absolute abundance of fat 
mass in patients with COPD, it is well-recognized that alterations in 
body composition commonly occur in normal-weight COPD patients 
as well. Selective wasting of fat-free mass (FFM; i.e. muscle mass) 
occurs in 10–15% of normal-weight COPD patients16,17, resulting in a 
relative or absolute increase in fat mass18. This situation shows 
resemblance to the involuntary loss of muscle mass with advanced 
age, defined as sarcopenia19. 
Thesis Frits Franssen_08.pdf   198 21-11-2008   10:22:03
 Perspective: COPD and obesity⏐199 
Effect of obesity on respiratory function and 
exercise performance 
In any given individual, the effects of obesity on respiratory function 
depend on the mass and anatomical distribution of the excessive 
adipose tissue on the thorax and abdomen20,21. The nature of the 
physiological impairment induced by obesity will vary with its extent 
and will ultimately reflect integrated abnormalities of ventilatory 
mechanics/muscle function, pulmonary gas exchange, ventilatory 
control and cardiac performance20-37. These respiratory 
derangements are consistently accentuated upon adopting the supine 
posture. Common physiological abnormalities associated with 
eucapnic obesity (excluding obesity hypoventilation syndrome) are 
listed in Table 10.1. Restrictive mechanics are manifest by reduced 
expiratory reserve volume and functional residual capacity. Residual 
volume and total lung capacity are preserved except in extreme 
obesity. The forced expiratory volume in one second (FEV1)/forced 
vital capacity (FVC) ratio is preserved but tests of small airway 
function may be abnormal20-37. Diffusing capacity of the lung for 
carbon monoxide (DLCO) is in the normal range or increased; gas 
exchange is compromised in severe obesity particularly in the supine 
posture. Normative predictive equations for spirometric 
measurements, plethysmographic lung volumes and DLCO are 
generally not corrected for weight. This has implications for the 
clinical interpretation of pulmonary function tests in the overweight 
and obese who comprise an increasing proportion of those tested. 
 
Table 10.1 Respiratory function in eucapnic obesity. 
Decreased chest wall and lung compliance 
Small airway dysfunction and expiratory flow limitation 
Preservation of FEV1/FVC ratio  
Variable reduction of (or preserved) ventilatory muscle strength and endurance 
Increased work and oxygen cost of breathing 
Normal or increased diffusion capacity for carbon monoxide (DLCO) 
Abnormal ventilation/perfusion relations and arterial oxygen desaturation 
Normal or increased central respiratory drive 
 
Exercise performance 
Peak oxygen uptake (V& O2), corrected for weight, is surprisingly 
preserved in obesity, at least during weight-supported cycle 
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exercise26,38-40. When comparing oxygen uptake measurements 
during exercise in obese individuals with predictive normal values, 
underestimation in the former can be avoided by expressing V& O2 as 
a percentage of ideal body weight. Obese individuals have a higher 
metabolic demand at any given power output as a result of the high 
oxygen cost of lifting heavy limbs26,38-40. Pulmonary gas exchange is 
rarely critically compromised in obesity and arterial oxygen 
saturation may even improve during exercise, reflecting an 
improvement in V/Q relationships26,38-40. Patients with obesity may 
have expiratory flow limitation at rest which, when compounded by 
high ventilatory requirements, leads to significant air trapping and 
dynamic increase in EELV during exercise26,39,40 (Figure 10.1). Given 
the increase in ventilatory demand (secondary to increased 
metabolic loading) and the excessive intrinsic mechanical loading of 
the inspiratory muscles in obesity, the muscular effort required to 
support a given ventilation  is elevated at any given power output 
compared to normal-weight individuals40-42. Not surprisingly, the 
work and oxygen cost of breathing is also increased at rest and 
during exercise38,41,43,44. Exertional dyspnea intensity is uniformly 
increased for any given power output and rises sharply as ventilation 
(and therefore contractile muscle effort) approach maximal 
capacity26. In some patients, exercise performance is further 
compromised by attendant skeletal muscle deconditioning, peripheral 
muscle dysfunction and cardiac impairment (e.g., eccentric left 
ventricular hypertrophy of obesity)45,46.  
Combined deleterious effects of obesity and COPD 
The physiological derangements that occur at rest and during 
exercise in obesity and in COPD, when each is considered in 
isolation, are well understood. However, no mechanistic studies have 
explored the pathophysiological interactions that occur when both 
conditions coexist in the same individual, as is increasingly the case. 
Given the vast pathophysiological heterogeneity of COPD, the 
concomitant effects of aging and gender on physical performance, 
and the existence in many of serious comorbidities in conjunction 
with obesity, the mechanisms of exercise intolerance in obese COPD 
are necessarily complex. Clinical experience indicates that the 
combined restrictive/obstructive deficits evident in obese patients 
with COPD culminate in worsening symptomatology and activity 
limitation8,47,48.  
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Figure 10.1 Maximal and tidal flow-volume loops are shown for a series of age-
matched women: a lean woman with normal lung function, an obese 
woman with normal lung function, a lean woman with COPD (FEV1=46% 
predicted), and an obese woman with COPD (FEV1=45% predicted). 
Inner tidal loops are shown at rest (solid inner loops) and at ventilations 
of ~32 l·min-1 (dotted loops); the latter corresponding to the symptom-
limited peak of exercise for both women with COPD. While the healthy 
lean woman decreased her end-expiratory lung volume during exercise, 
the other women experienced dynamic pulmonary hyperinflation 
(leftward arrows). Additional flow and volume constraints on tidal volume 
expansion in the women with COPD limited the peak ventilation that 
could be attained during exercise. In women with COPD, a critically 
reduced inspiratory reserve volume (IRV) limited any further increase in 
tidal volume during exercise and resulted in severe exertional dyspnoea. 
Ratings of dyspnea intensity using the modified 10-point Borg scale are 
shown at comparable ventilations during exercise. BMI: body mass 
index. 
 
Obesity would be expected to amplify the abnormalities of dynamic 
ventilatory mechanics and ventilatory demand that characterize 
COPD. Thus, ventilatory requirements are predictably higher in obese 
COPD patients compared with normal-weight COPD patients as a 
result of the increase in chemostimulation that arises from the 
combination of increased metabolic loading, high fixed physiological 
deadspace and possibly earlier metabolic acidosis due to impairment 
in oxygen uptake from deconditioning or cardiac dysfunction. The 
increased recoil of the chest wall and lung in patients with central 
obesity may increase expiratory flow rates at a given operating lung 
volume compared with non-obese COPD patients. However, the 
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relatively reduced absolute EELV in obese COPD patients may worsen 
expiratory flow limitation and air trapping during exercise (Figure 
10.1), particularly in the setting of the relatively increased 
ventilatory requirement49,50. The net effect of these abnormalities is 
an earlier mechanical limitation of ventilation with greater dyspnoea 
and exercise curtailment in the obese COPD patient. The 
accompanying rapid shallow breathing pattern (at a relatively low 
power output and ventilation) may compromise dynamic inspiratory 
muscle function and deleteriously effect alveolar ventilation49-51. In 
obese COPD patients compared with their non-obese counterparts, 
the increased contractile muscle effort required to sustain ventilation 
during exercise in the face of serious mechanical constraints on tidal 
volume expansion would be expected to cause significant 
neuromechanical uncoupling of the respiratory system and lead to 
incapacitating dyspnoea earlier in exercise. 
Effects of body composition on exercise performance in 
obese COPD 
In addition to ventilatory limitations, alterations in body composition 
contribute to exercise intolerance in patients with COPD. It is well-
recognized that loss of FFM contributes to muscle weakness52 and 
reduced exercise capacity53 in patients with moderate-to-severe 
COPD. Available data in these patients suggest that the contribution 
of alterations in fat mass to exercise intolerance is limited in 
comparison to the impact of muscle wasting. The degree of physical 
impairment, assessed by 12 minute walking test, was greater in 
normal-weight patients with depleted FFM and relatively enhanced 
fat mass compared to underweight patients with preserved FFM16. 
Less is known about effects of obesity or relatively increased fat 
mass on physical performance in less severe COPD patients. In 
patients with early stage COPD, obesity, decreased lean-to-fat mass 
ratio and increased sagittal abdominal diameter were associated with 
functional limitation on the six minute walk test12. Particularly the 
accumulation of fat mass and not the loss of lean mass had a 
negative impact on performance. This observation is not unique for 
early stage COPD patients. In a cohort of elderly from the general 
population, high body fatness was associated with increased risk of 
self-reported mobility-related disability, while low FFM was not 
predictive of disability54. In another community-based cohort study 
of older persons, higher fat mass was related to increased risk of 
functional limitation assessed by walking speed55. Although absolute 
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lean mass was not related to physical performance, a higher ratio of 
lean mass-to-fat mass was predictive for walking speed. Thus, it 
seems that both absolute and relative accumulation of fat mass 
contribute to functional limitation in the elderly and early in the 
course of COPD, while the influence of muscle wasting on physical 
performance becomes apparent in more severe patients when FFM 
drops to very low levels16,56.  
The obesity paradox in COPD 
The prognostic value of nutritional status is well established in 
patients with COPD. Low BMI is associated with increased all-cause 
and COPD-related mortality, unrelated to disease severity57. Recent 
studies indicate that FFM-index is an even more important 
determinant of prognosis in moderate-to-severe COPD than BMI17,56. 
Fat mass index was not predictive for prognosis in moderate-to-
severe COPD56. Remarkably the relative risk for mortality seems 
decreased in overweight and obese COPD patients in GOLD stage 3-
4, while it is increased in GOLD 1-2 patients with (pre)obesity57. A 
possibly protective role for obesity in COPD was also observed in 
early studies on the association between body weight and 
mortality58, in the epidemiologic Copenhagen City Heart Study17 and 
in a population of severe COPD patients treated by long-term oxygen 
therapy59. This possible association between (pre)obesity and 
improved outcome in COPD contrasts with epidemiological data from 
the general population, where obesity is associated with a largely 
decreased life expectancy, independent of smoking status60. This 
phenomenon is referred to as a “reverse epidemiology of obesity” or 
the “obesity paradox” and was identified in several other chronic 
disease states such as end-stage chronic kidney disease, chronic 
heart failure and rheumatoid arthritis61. The pathophysiological 
mechanisms of the obesity paradox are yet to be unravelled. In 
obese men with COPD, the annual decline in FEV1 was significantly 
lower compared to men of normal BMI range while this effect was 
not seen in women62. This suggests a gender specific protective role 
for obesity in the progression of chronic airflow limitation. 
Furthermore, it is not yet clear whether excessive fat mass or muscle 
mass contributes to the survival advantage in chronic wasting 
diseases61. 
In apparent contradiction to the possible existence of a obesity 
paradox in COPD, it is well recognized that the risk of cardiovascular 
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mortality is increased in patients with chronic airflow limitation, 
independent of BMI63. Epidemiological studies indicated that low 
forced expiratory volume in one second (FEV1) is a risk factor for 
coronary heart disease in subjects without pulmonary disease64. 
Besides the presence of chronic airflow obstruction, low-grade 
systemic inflammation is one of the mechanisms that may be 
responsible for the increased rate of cardiovascular complications in 
COPD65. The role for smoking-related systemic inflammation is 
evident in COPD pathogenesis and led to the proposition of the term 
“chronic systemic inflammatory syndrome” complementary to the 
diagnosis of COPD66. Insulin resistance may also contribute to the 
increased cardiovascular mortality in COPD patients. It plays an 
important role in the pathogenesis of type II diabetes mellitus and it 
clusters with a variety of risk factors for cardiovascular disease, such 
as abdominal obesity, dyslipidemia and hypertension in the metabolic 
syndrome67. In a recent meta-analysis of longitudinal studies, the 
presence of the metabolic syndrome was strongly associated with 
cardiovascular morbidity and mortality68. Indeed, some studies 
suggest the presence of insulin resistance in COPD69, especially in 
normal-weight to obese70,71 and hypoxemic patients71. 
Based on the evidence outlined above, it can be hypothesized that 
obesity exerts divergent effects in subgroups of COPD with different 
severity of disease. Obesity may protect against mortality in 
advanced COPD patients, in which loss of FFM is a particularly 
important short-term risk factor for death. By contrast, in earlier 
stage COPD, the harmful long-term effects of obesity-related 
conditions such as low-grade systemic inflammation and insulin 
resistance may result in increased cardiovascular and all-cause 
mortality.  
In recent years, new insights in the functioning of adipose tissue in 
obesity have evolved that are reviewed in the next section and may 
be of importance to further unravel the clinical significance and 
pathophysiology of obesity in COPD.  
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Adipose tissue dysfunction in obesity and the 
influence of hypoxia 
The association between abdominal obesity, insulin resistance and 
cardiovascular disease is well-recognized72, but the underlying 
mechanisms are not yet fully understood. Adiposity is associated 
with insulin resistance even over relatively normal ranges of body 
fatness. There is strong evidence that altered adipose tissue function 
plays a crucial role in the pathogenesis of obesity-related insulin 
resistance and type 2 diabetes, as has recently been reviewed73. 
Lipid storage capacity of adipose tissue in obesity 
Adipose tissue is the main lipid storage depot in our body, and is of 
crucial importance in buffering the daily influx of dietary fat entering 
the circulation. One characteristic of adipose tissue in obesity is the 
enlargement of adipocytes, which may represent an impaired 
adipocyte differentiation. The hyperthrophic adipocytes of obese 
subjects are overloaded with stored triacylglycerol (TAG) and it is 
likely that the buffering capacity for further lipid storage in these 
adipocytes is decreased, especially in the postprandial state74. Non-
adipose tissues are therefore exposed to an excessive influx of lipids, 
which could lead to ectopic fat deposition when the oxidative 
capacity is insufficient. It is well-established that accumulation of 
lipids in skeletal muscle75-77, pancreatic islets78 and the liver79,80 play 
an important role in the development of insulin resistance and/or 
impaired insulin secretion in obese individuals. Another explanation 
for the observation that adipocyte hypertrophy is associated with 
insulin resistance and the development of type 2 diabetes relates to 
the endocrine function of adipose tissue. 
Adipose tissue as a source of inflammation in obesity 
Adipocytes express and secrete a variety of adipokines, including 
cytokines, growth factors, adiponectin, resistin, adipsin, leptin, 
acylation stimulating protein (ASP), plasminogen activator inhibitor-1 
(PAI-1), lipoprotein lipase (LPL), and components of the renin-
angiotensin system81-83, which may exert local and systemic effects. 
Chronic low-grade inflammation is a hallmark of obesity, insulin 
resistance and type 2 diabetes84-87. Importantly, inflammatory 
pathways play a prominent role in the mechanisms underlying insulin 
resistance and type 2 diabetes in cultured cells and animal 
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models88-92, and this may also be the case in humans. 
The inflammatory response that is often present in obesity appears 
to be triggered and to reside predominantly in the enlarged adipose 
tissue93-97. The expression and/or secretion of inflammatory 
molecules, including tumour necrosis factor-α (TNF-α) 95,98-100, 
interleukin (IL)-6 99-102, PAI-1 103,104 and leptin 100,105-107 are increased 
in adipose tissue of obese insulin resistant individuals. In contrast, 
the expression of the insulin-sensitizing factor adiponectin is reduced 
in obese and insulin resistant subjects 108-110. Interestingly, enlarged 
adipocytes seem to express pro-inflammatory and anti-inflammatory 
factors with a shift toward dominance of pro-inflammatory 
adipokines compared to smaller adipocytes111.  
Recent data indicate that adipose tissue of obese individuals is 
infiltrated by macrophages, which may be a major source of locally-
produced pro-inflammatory adipokines108,112,113. There seems to be 
cross-talk between adipocytes and macrophages within adipose 
tissue. For example, macrophage-secreted factors exert effects on 
adipocytes that may increase systemic inflammation and insulin 
resistance associated with obesity114,115. The mechanisms underlying 
the impaired adipokine secretion and macrophage infiltration in 
adipose tissue in obesity remain to be elucidated but there is 
evidence to support a major role for adipose tissue hypoxia in these 
events. 
Adipose tissue hypoxia in obesity 
Recently, evidence has emerged that adipose tissue hypoxia is 
present in obese mice116. Accordingly, it has been shown that 
weight-loss decreased adipose tissue expression of hypoxia-
responsive genes117. An alteration in oxygen pressure and/or oxygen 
content of the blood was not apparent in the obese animals116. Based 
on the above, it can be speculated that hypoxia in adipose tissue 
may contribute to obesity-related insulin resistance. 
Since adipose tissue blood flow (ATBF) per unit tissue mass is 
reduced in obese humans118-122 and rodents116,123, decreased blood 
supply to adipose tissue may explain adipose tissue hypoxia in 
obesity. Indeed, it has been suggested that the expansion of adipose 
tissue mass during the progressive development of obesity may lead 
to hypoxia in certain parts of adipose tissue, because angiogenesis is 
insufficient to maintain normoxia in the entire adipose tissue 
depot124. As a consequence, adipose tissue hypoxia may induce an 
increased secretion of inflammatory factors, acute phase proteins 
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and angiogenic factors by adipose tissue in order to increase blood 
flow and vascularization. The transcription factor hypoxia inducible 
factor-1 (HIF-1) is a key regulator in the response to alterations in 
oxygen tension and modulates the expression of genes that are 
involved in angiogenesis, erythropoiesis, inflammation and glucose 
metabolism124-130. 
Recent studies have demonstrated that adiponectin and PPARγ mRNA 
expression were decreased, whereas PAI-1 and visfatin mRNA 
expression were elevated in hypoxic 3T3-L1 adipocytes compared 
with normoxic control cells 116,131,132. Likewise, hypoxia altered the 
expression and secretion of inflammation-related adipokines in 
human adipocytes133. Furthermore, weight-loss led to improved 
oxygenation and reduced inflammation in dietary obese mice134. 
Secondly, severe hypoxia may induce adipocyte death. A hypoxic 
environment devoid of nutrients prevents the cell undergoing energy 
dependent apoptosis and cells become necrotic135. Subsequently, 
macrophages fuse and form syncytia that sequester and scavenge 
adipocyte debris136. Hypoxia-induced adipocyte death may thus 
evoke macrophage infiltration in adipose tissue of obese individuals. 
These data suggest that adipose tissue hypoxia modulates, either 
directly or indirectly via recruitment of macrophages, adipokine 
expression and secretion and may therefore provide an important 
link between obesity and insulin resistance73. Thirdly, hypoxia 
inhibits adipocyte differentiation137,138, which appears to be a 
precipitating factor in the development of type 2 diabetes as 
mentioned earlier139,140. Finally, unfolded protein response (UPR), a 
HIF-1-independent signalling pathway, contributes to cellular 
adaptation to hypoxia141. Many disturbances, including hypoxia, 
cause accumulation of unfolded proteins in the endoplasmatic 
reticulum (ER)141,142, leading to ER stress137,143. It has been 
demonstrated that ER stress is elevated in adipose tissue and liver of 
obese mice, which activates the inflammatory response, thereby 
contributing to insulin resistance144,145. In conclusion, adipose tissue 
hypoxia, possibly due to an impaired ATBF as a consequence of 
adipose tissue expansion, may be an important factor in the 
development of obesity-related insulin resistance via effects on 
adipokine expression and/or adipocyte differentiation73. 
In summary, evidence suggests that enlargement of adipocytes, 
impaired adipose tissue blood flow, adipose tissue hypoxia, local 
inflammation and macrophage infiltration in adipose tissue are 
interrelated in obesity and may lead to disturbances in adipokine 
secretion and excessive fat storage in non-adipose tissues, which 
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together may result in insulin resistance and ultimately type 2 
diabetes mellitus73. The following section will focus on the possible 
impact of altered adipose tissue function on skeletal muscle oxidative 
capacity, systemic inflammation and insulin sensitivity in COPD.  
Potential impact of adipose tissue dysfunction on 
the pathophysiology of COPD 
Adipose tissue and fat oxidative capacity in COPD 
There is a lack of studies on adipose tissue morphology in patients 
with COPD. While available evidence suggests an increased 
prevalence of abdominal obesity at the macroscopic level13, no 
microscopic data are available in COPD. As a consequence, possible 
alterations in size, differentiation and lipid buffering capacity of 
adipocytes remain unknown.  
If fatty acid delivery to skeletal muscle exceeds fat oxidation, lipids 
and lipid intermediates accumulate in skeletal muscle cells. 
Intramyocellular fat accumulation is closely related to the 
development of insulin resistance76. Reduced peripheral skeletal 
muscle fat oxidative capacity is consistently reported in patients with 
COPD146. It is reflected by a muscle fibre type shift from type I to II 
(or slow-twitch to fast-twitch) and reduced activities of enzymes 
involved in oxidative energy metabolism147. In the case of high non-
esterified fatty acid (FFA) release into the circulation in COPD, the 
reduced fat oxidative capacity would be a potential risk factor for 
development of metabolic syndrome. Since obesity is associated with 
increased exposure of skeletal muscle to TAG and FFA, obese COPD 
patients would be at particular risk. Indeed, increased fasting 
lipolytic rate and enhanced levels of circulatory FFA have been 
reported in hypoxemic COPD patients in comparison to controls148, 
although another study did not confirm this149. Also reduced 
intramyocellular triglyceride content (IMTG) was reported in a small 
group of normal-weight COPD patients. However, levels of oxidative 
enzymes were not reported in that study and no obese COPD 
patients were included. 
Adipose tissue as a source of inflammation in COPD 
In addition to pulmonary inflammation, persistent low-grade 
systemic inflammation is frequently demonstrated in patients with 
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COPD. Increased levels of pro-inflammatory cells and mediators have 
been reported in the circulation of COPD patients. Enhanced plasma 
concentrations of fibrinogen, C-reactive protein (CRP), TNF-α and 
circulating leukocytes have been consistently observed in stable 
COPD patients in comparison to healthy controls150, while raised 
levels of IL-6 70,151, IL-8 152, IL-10 70, IL-18 153 have also been shown. 
The presence of low-grade systemic inflammation was associated 
with several systemic consequences in patients with COPD, including 
reduced exercise capacity and worse health-related quality of life154. 
Also, increased circulatory levels of TNF-α, IL-6 and their soluble 
receptors were observed in FFM-depleted COPD patients in 
comparison to patients with preserved FFM, both in patients with low 
body weight as well as in COPD patients with normal BMI155. This 
suggests a role for systemic inflammation in COPD-related muscle 
wasting, even in patients without apparent weight loss such as 
subgroups of sarcopenic or obese patients. In addition, a link 
between systemic inflammation and markedly increased 
cardiovascular mortality in COPD was suggested65.  
Despite the growing awareness that systemic inflammation is a 
hallmark in the pathogenesis of COPD, remarkably little is known 
about the underlying mechanisms. Although it is often hypothesized 
that inflammation in the systemic compartment is the result of spill 
over of the inflammatory process in the airways, lung parenchyma 
and pulmonary vasculature, evidence from cross-sectional studies 
indicates no correlation between pulmonary and circulatory 
inflammatory markers in stable COPD152,156.  
Adipose tissue is another possible source of systemic inflammation. 
As discussed before, adipose tissue expresses several pro-
inflammatory mediators with potential systemic metabolic effects. 
The importance of these adipokines released from fat tissue in the 
pathogenesis of systemic inflammation in obesity is recognized. By 
measurements of arterio-venous concentration differences of 
cytokines, in combination with measurement of adipose tissue blood 
flow, release of IL-6 from abdominal subcutaneous adipose tissue 
into the systemic circulation has been demonstrated in healthy 
human subjects102. Furthermore, the rate of IL-6 release per unit 
abdominal subcutaneous adipose tissue has been shown to be equal 
or greater in obese subjects, depending on the degree of obesity157. 
Taken into consideration the absolute increased fat mass in the 
obese, these findings indicate that IL-6 release from abdominal 
subcutaneous adipose tissue is elevated at the whole-body level in 
these individuals. In another study in obese subjects, IL-6 
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concentrations in the portal vein, which drains the visceral fat, were 
significantly increased compared to IL-6 levels in peripheral arterial 
blood, demonstrating that visceral fat is an important source of IL-6 
in obesity158. Furthermore, portal vein IL-6 levels were related to 
arterial CRP concentrations, suggesting a mechanistic link between 
visceral fat mass and systemic inflammation in vivo.  
The role of adipose tissue in the pathogenesis of systemic 
inflammation in patients with COPD has not been studied. Also, the 
possible cross-talk between fat mass-derived inflammatory factors 
and loss of FFM in COPD is speculative. However, based on the 
foregoing it can be hypothesized that in early-stage COPD patients 
with obesity or relatively abundant fat mass, adipose tissue may act 
as additional source of inflammation (Figure 10.2). Since systemic 
inflammation is associated with loss of skeletal muscle in COPD155, 
this may contribute to loss of FFM and amplify alterations in body 
composition towards loss of lean body mass and preservation of fat 
mass. Additionally, excretion of adipokines by adipose tissue in COPD 
might be reinforced by the presence of chronic or intermittent 
hypoxia.  
 
Figure 10.2 Proposed mechanistic links between COPD, body composition, adipose 
tissue dysfunction, systemic inflammation and insulin resistance.   
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Adipose tissue hypoxia and insulin resistance  in COPD  
As mentioned earlier, there is evidence for adipose tissue hypoxia in 
obesity116. It has recently been demonstrated that hypoxia induces 
expression and secretion of several pro-inflammatory mediators 
including IL-6, leptin, PAI-1 and monocyte migration inhibitory factor 
(MIF) in human adipocytes133. As stated before, adipose tissue 
hypoxia might thus provide an important link between obesity and 
insulin resistance through secretion of inflammatory adipokines.  
In COPD patients with obesity or relatively abundant fat mass the 
link between adipose tissue hypoxia and systemic metabolic effects 
might be further enhanced by the presence of systemic hypoxemia in 
more advanced stages of disease, which does not occur in healthy 
obese. Although there are no studies that directly focussed on this 
issue, there is growing evidence for insulin resistance in COPD, 
especially in normal-to-overweight and hypoxic patients. Glucose 
intolerance was first reported in normal-weight chronic hypoxemic 
COPD patients on long-term oxygen therapy, although results might 
have been confounded by the use of systemic glucocorticosteroids159. 
More recently, the presence of insulin resistance was reported in 
normal-weight COPD patients with normal systemic oxygen 
saturation69. Interestingly, both BMI as well as systemic IL-6 
concentration were independent determinants of insulin resistance. 
In line with this observation, there is evidence for decreased insulin 
sensitivity in a large group of normal-weight COPD patients in 
comparison to underweight patients and normal-weight controls70. 
However, insulin sensitivity was not related to BMI in that study. 
Finally, supplemental oxygen resulted in increased glucose tolerance 
and insulin sensitivity in hypoxemic COPD patients, and this effect 
tended to be greater in obese than in lean subjects71.  
Potential mechanistic links between adipose tissue mass, local and 
systemic hypoxia, systemic inflammation and insulin resistance in 
patients with COPD offer challenging research opportunities not only 
in the field of the extrapulmonary manifestations of the disease, but 
also in the area of pathogenesis of obesity-related metabolic 
disturbances. 
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Inleiding 
COPD 
COPD is de afkorting van het Engelstalige “Chronic Obstructive 
Pulmonary Disease”, hetgeen staat voor chronisch obstructieve 
longziekten. Deze aandoening wordt gekenmerkt door een 
progressieve en niet volledig omkeerbare vernauwing van de 
luchtwegen. COPD omvat de ziektebeelden chronische bronchitis en 
longemfyseem. Kortademigheid, hoesten en vermindering van het 
inspanningsvermogen zijn de voornaamste klachten van patiënten 
met COPD en leiden tot ernstige beperkingen in het dagelijks 
functioneren. Roken is de belangrijkste risicofactor voor het 
ontwikkelen van COPD, hoewel minder dan een kwart van alle rokers 
deze aandoening krijgt. Volgens de huidige schattingen heeft 10 
procent van de volwassen wereldbevolking een matige tot zeer 
ernstige vorm van COPD; de verwachting is dat COPD in 2020 de 
derde meest voorkomende doodsoorzaak wereldwijd zal zijn.  
In de klassieke benadering werd COPD puur gezien als een 
longziekte, gebaseerd op de aanwezigheid van chronische 
luchtwegvernauwing. In de laatste decennia zijn er echter 
belangrijke manifestaties buiten de longen beschreven bij patiënten 
met COPD. Deze manifestaties worden ook wel aangeduid als de 
systemische effecten van COPD en omvatten onder andere 
veranderingen in de voedingstoestand en abnormaal functioneren 
van de skeletspieren. 
Voedingstoestand 
Verstoringen in de voedingstoestand komen regelmatig voor bij 
patiënten met COPD. Het totale lichaamsgewicht is opgebouwd uit 
vetmassa en vetvrije massa. Om een indruk te krijgen van de 
voedingstoestand van patiënten met COPD wordt naast gewicht en 
lengte, tegenwoordig ook in toenemende mate de vetvrije massa 
gemeten. De vetvrije massa van het lichaam bestaat uit celmassa 
(de eiwitten en mineralen van spieren, organen en botten) en water. 
De vetvrije massa wordt gebruikt als maat voor de hoeveelheid 
spiermassa. In de afgelopen decennia is duidelijk geworden dat 
veranderingen in de voedingstoestand belangrijke gevolgen hebben 
voor COPD patiënten. Hoewel uit eerder onderzoek al bekend was 
dat gewichtsverlies een negatieve invloed heeft op de overleving van 
deze patiënten, is nog niet zo lang geleden aangetoond dat vooral 
verlies van vetvrije massa de prognose van COPD patiënten nadelig 
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beïnvloedt. Daarnaast is verlies van vetvrije massa bij COPD 
patiënten, onafhankelijk van het lichaamsgewicht, een belangrijke 
oorzaak van spierzwakte, verminderd inspanningsvermogen en 
verlaagde kwaliteit van leven. 
Sarcopenie 
Het woord ‘sarcopenia’ is een samenvoegsel van het Griekse ‘sarco’ 
(vlees) en ‘penia’ (gebrek) en betekent in de letterlijke vertaling 
‘gebrek aan vlees’. De medische term ‘sarcopenie’ wordt gebruikt om 
het verlies aan spiermassa en spierfunctie op hoge leeftijd te 
beschrijven. Hoewel de afname van spiermassa deel uitmaakt van 
het natuurlijke verouderingsproces, is sarcopenie een belangrijke 
oorzaak van spierzwakte, verminderde mobiliteit en toenemende 
afhankelijkheid bij gezonde ouderen. Belangrijke factoren die 
bijdragen aan het ontstaan van sarcopenie zijn inactiviteit, afname 
van functioneren van het zenuwstelsel op hogere leeftijd en 
veranderingen in de eiwitstofwisseling.    
De verstoringen in de voedingstoestand die optreden bij een deel van 
de patiënten met COPD vertonen gelijkenis met sarcopenie. Er wordt 
gesproken over COPD patiënten met ‘sarcopene kenmerken’ indien 
er sprake is van een verminderde vetvrije massa (als maat voor de 
spiermassa) in combinatie met een normaal of zelfs toegenomen 
lichaamsgewicht. In de afgelopen jaren is duidelijk geworden dat 
vooral het verlies aan vetvrije massa nadelige gevolgen heeft voor 
het functioneren en de overlevingskans van patiënten met COPD. 
Skeletspieren 
Abnormaal functioneren van de skeletspieren is een tweede 
systemisch effect van COPD en leidt tot spierzwakte en verminderd 
inspanningsvermogen bij patiënten met deze aandoening. In de 
afgelopen decennia is er veel onderzoek gedaan naar de aard en 
oorzaak van het disfunctioneren van de skeletspieren van met name 
de onderste ledematen. Naast afname van de hoeveelheid 
spiermassa, zijn er bij COPD patiënten veranderingen in de 
samenstelling van de skeletspiervezels. Er is sprake van een 
verschuiving van zuurstofafhankelijke vezels met een groot 
uithoudingsvermogen (type I vezels) naar zuurstofonafhankelijke 
vezels (type II vezels). Deze laatste worden gekenmerkt door een 
snellere en grotere kracht, maar ook door een toegenomen 
vermoeibaarheid. Naast deze verschuiving in spiervezelsamenstelling 
is de energiestofwisseling van de skeletspieren van COPD patiënten 
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verstoord. De activiteit van enzymen die voedingsstoffen verbranden 
met behulp van zuurstof (oxidatieve enzymen) is verlaagd, waardoor 
de skeletspieren voor hun energievoorziening afhankelijker zijn van 
de afbraak van suikers in afwezigheid van zuurstof (glycolyse). De 
beschreven veranderingen leiden tot een verminderde kracht, 
uithoudingsvermogen en efficiëntie van de aangetaste skeletspieren. 
Overige systemische effecten 
Naast de verslechterde voedingstoestand en abnormaal functioneren 
van skeletspieren zijn er diverse andere systemische effecten 
beschreven bij patiënten met COPD. Hormonale verstoringen, 
veranderingen in de eiwitstofwisseling, botontkalking en angst en 
depressie komen frequent voor bij deze aandoening. Hoewel de lijst 
met systemische effecten steeds langer wordt, zijn de mechanismen 
die eraan ten grondslag liggen grotendeels onbekend. De afgelopen 
jaren is duidelijk geworden dat chronische ontstekingsreacties een 
belangrijke rol spelen bij het ontwikkelen van COPD. Naast een 
permanente ontsteking van de luchtwegen als gevolg van de 
inhalatie van sigarettenrook, is er sprake van chronische 
ontstekingsreacties in de bloedbaan. Hoewel de origine van deze 
systemische ontstekingsreacties nog grotendeels opgehelderd dient 
te worden, is de aanwezigheid van dergelijke chronische 
ontstekingsreacties bij patiënten met COPD geassocieerd met verlies 
aan spiermassa, verslechterde inspanningscapaciteit en verminderde 
kwaliteit van leven. Ook spelen deze chronische ontstekingsreacties 
mogelijk een rol bij het verhoogde risico op hart- en vaatziekten en 
bij de ontwikkeling van verminderde insuline gevoeligheid bij 
patiënten met COPD. Naast chronische ontstekingsreacties op 
lichaamsniveau spelen andere mechanismen een rol bij het ontstaan 
van de manifestaties van COPD buiten de longen. Gasuitwisse-
lingsstoornissen, inactiviteit, verminderde voedselinname en 
medicatiegebruik dragen in meer of mindere mate bij aan 
veranderingen in voedingstoestand, energiestofwisseling en 
functionaliteit. 
Behandeling 
Het groeiend besef dat COPD een longziekte is met manifestaties 
buiten het primair aangedane orgaan, heeft belangrijke gevolgen 
voor de medische praktijk. In aanvulling op de traditionele 
medicamenteuze behandeling van de chronische luchtwegvernauwing 
vraagt de hedendaagse behandeling van COPD om een holistische 
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benadering. Hierbij dient rekening te worden gehouden met de 
diverse aspecten van de aandoening. Aansluitend op de constatering 
dat verstoringen in de voedingstoestand en functioneren van 
skeletspieren belangrijke consequenties hebben voor deze patiënten, 
zijn er strategieën ontwikkeld om de nadelige veranderingen in 
lichaamssamenstelling en skeletspieren om te keren. Doel van deze 
nieuwe behandelingsmodaliteiten is het verlichten van symptomen 
en het verbeteren van overleving van COPD patiënten. 
Longrevalidatie, waarbij door middel van bijvoeding, 
inspanningstraining en gebruik van weefselopbouwende medicatie 
(zoals anabole steroïden) voedingstoestand en spierfunctie worden 
verbeterd, is uitgegroeid tot een essentiële component in de 
behandeling van patiënten met matig tot ernstig COPD. 
Doel van het onderzoek 
Het bestuderen van de verdeling van skeletspierdisfunctie tussen 
onderste en bovenste ledematen bij patiënten met COPD was het 
eerste doel van dit onderzoek. Met de verkregen resultaten wordt 
beoogd het inzicht in de oorzaak van abnormaal functioneren van de 
skeletspieren bij COPD patiënten te vergroten en de ontwikkeling van 
specifieke interventies gericht op het verbeteren van spierfunctie te 
bevorderen. De huidige kennis van skeletspieren van patiënten met 
COPD is grotendeels gebaseerd op resultaten van onderzoeken naar 
de onderste ledematen omdat er maar vrij weinig onderzoek gericht 
op de bovenste ledematen was. De resultaten van deze onderzoeken 
waren bovendien niet eenduidig. Verlaagde vetvrije massa en 
verstoringen in de energiestofwisseling dragen bij aan 
skeletspierdisfunctie. Heterogeniteit in de verdeling van deze 
factoren tussen verschillende spiergroepen kunnen leiden tot klinisch 
belangrijke verschillen in spierfunctie tussen onderste en bovenste 
extremiteiten. Derhalve worden in dit onderzoek diverse aspecten 
van skeletspierfunctie van onderste en bovenste ledematen gemeten 
en bestudeerd in relatie tot veranderingen in vetvrije massa. Naast 
kracht en uithoudingsvermogen van de skeletspieren wordt de 
mechanische efficiëntie bepaald. Dit is een maat voor energiegebruik 
van de spier per eenheid van geleverde arbeid.   
De invloed van verstoringen in het energiemetabolisme en de functie 
van de skeletspieren bij patiënten met COPD op de cellulaire 
(intermediaire) stofwisseling, waarbij voedingsstoffen worden 
omgezet in energie en bouwstoffen, is vooralsnog onbekend. 
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Bovendien dragen veranderingen in glucose (suiker) metabolisme, 
vetafbraak (lipolyse) en skeletspier-eiwitombouw mogelijk bij aan 
verstoringen in de voedingstoestand en in het bijzonder aan het 
verlies van vetvrije massa bij deze patiënten. Het tweede doel van 
dit onderzoek is dan ook het bestuderen van de 
substraatstofwisseling (glucose, vet en eiwit) in relatie tot 
veranderingen in de lichaamssamenstelling bij patiënten met COPD. 
Functionele gevolgen van sarcopenie in COPD 
In het eerste deel van dit proefschrift wordt de relatie tussen 
lichaamssamenstelling, spierfunctie en inspanningsvermogen 
bestudeerd. Hoofdstuk 2 bevat een systematische literatuurstudie 
naar de overeenkomsten in de veranderingen die optreden in de 
skeletspieren bij patiënten met chronisch orgaanfalen. Spierzwakte, 
verschuivingen in spiervezelsamenstelling en afname van de 
zuurstofafhankelijke energiestofwisseling zijn niet alleen kenmerken 
van patiënten met COPD, maar ook van patiënten met chronisch 
hartfalen of chronisch nierfalen. Hoofdstuk 2 onderzoekt tevens de 
potentiële invloed van enkele vaak voorkomende externe factoren op 
de relatie tussen het primair orgaanfalen en de veranderingen in de 
skeletspieren. Verminderde energie-inname komt vaak voor bij 
patiënten met COPD, mogelijk met gevolgen voor de skeletspieren. 
Anorexia nervosa is een ziektebeeld gekenmerkt door extreme en 
langdurige beperking van de energie-inname en deze aandoening 
leent zich daarom bij uitstek om de gevolgen van ondervoeding op 
de skeletspieren te bestuderen. Zoals beschreven in hoofdstuk 2 
worden patiënten met anorexia nervosa gekenmerkt door 
spierzwakte in combinatie met gemiddeld kleinere type II spiervezels 
en een afname van zuurstofafhankelijke en zuurstofonafhankelijke 
skeletspier-stofwisselingscapaciteit.  
Kortademigheid tijdens geringe inspanning leidt tot een vermindering 
van het niveau van dagelijkse activiteit bij veel patiënten met COPD. 
Afname van lichamelijke activiteit heeft grote invloed op het 
functioneren van skeletspieren en leidt tot een vermindering van het 
spiervezeloppervlakte en het percentage type I spiervezels en een 
verlies aan oxidatieve capaciteit.  
COPD is een aandoening die vooral bij ouderen voorkomt. Zoals 
eerder in dit hoofdstuk beschreven, treden er met het stijgen van de 
leeftijd veranderingen op in de skeletspieren. Deze veranderingen 
worden in detail bestudeerd in hoofdstuk 2; ze omvatten naast 
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verlies aan spiermassa en -functie onder andere vermindering van 
spiervezeloppervlakte van type II vezels, een verschuiving van type I 
naar type II skeletspiervezels en een verminderde oxidatieve 
capaciteit.  
De resultaten van de literatuurstudie in hoofdstuk 2 laten zien dat 
een vermindering van energie-inname en inactiviteit zeer 
waarschijnlijk bijdragen aan de geobserveerde veranderingen in de 
skeletspieren van patiënten met COPD. Hoewel er overeenkomsten 
bestaan tussen de veranderingen die optreden in de skeletspieren 
met het natuurlijk verouderingsproces en in de skeletspieren van 
COPD patiënten, is op dit moment onvoldoende onderzocht of 
leeftijdsgerelateerde veranderingen in versterkte mate of op jongere 
leeftijd optreden bij patiënten met COPD.    
De hoofdstukken 3 en 4 van dit proefschrift behandelen potentiële 
verschillen in spierfunctie en inspanningsvermogen tussen bovenste 
en onderste ledematen bij patiënten met COPD.  
Een verhoogd energiegebruik tijdens lichamelijke inspanning werd 
eerder gerapporteerd bij COPD patiënten; dit kan leiden tot een 
verstoorde energiebalans en gewichtsverlies. In overeenstemming 
met deze observatie werd eerder aangetoond dat het energiegebruik 
per eenheid verrichte inspanning van de beenspieren verhoogd is bij 
patiënten met COPD. Dit duidt op een verlaging van de mechanische 
efficiëntie van de onderste extremiteiten bij deze patiënten. In 
hoofdstuk 3 zijn de mechanische efficiëntie en de 
inspanningscapaciteit van de bovenste ledematen vergeleken met die 
van de onderste ledematen bij COPD patiënten en bij gezonde 
vrijwilligers. In tegenstelling tot de verminderde mechanische 
efficiëntie gedurende beeninspanning, is de mechanische efficiëntie 
van de bovenste extremiteiten van de COPD patiënten vergelijkbaar 
met die van gezonde vrijwilligers. Daarnaast is het 
inspanningsvermogen van de bovenste ledematen, in tegenstelling 
tot het inspanningsvermogen van de onderste extremiteiten, relatief 
behouden bij COPD patiënten.  
In hoofdstuk 4 van dit proefschrift worden de invloed van vetvrije 
massa en de effecten van inspanningstraining op spierfunctie van de 
bovenste en onderste extremiteiten bij patiënten met COPD 
onderzocht. Eerdere onderzoeken hadden vooral zwakte van de 
onderste ledematen aangetoond, terwijl spierfunctie van de bovenste 
extremiteiten onvoldoende was onderzocht. Ook de relatie tussen 
vetvrije massa enerzijds en kracht en uithoudingsvermogen van de 
skeletspier anderzijds was grotendeels onbekend. In deze studie 
worden beide facetten van spierfunctie gemeten op 
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gestandaardiseerde wijze en in een vergelijkbaar protocol voor 
spieren van de onderste (quadriceps spier) en de bovenste (biceps 
spier) ledematen. Binnen de COPD patiënten wordt er onderscheid 
gemaakt tussen een groep met een normale vetvrije massa en een 
groep met een verlaagde vetvrije massa. Spierkracht van de 
quadriceps en de biceps blijkt in dezelfde mate te zijn aangedaan bij 
de COPD patiënten, terwijl het verlies van uithoudingsvermogen van 
de spieren beperkt blijft tot de onderste ledematen. Het verlies van 
quadriceps-kracht is groter bij patiënten met een verminderde 
vetvrije massa dan bij patiënten met een normale vetvrije massa, 
terwijl biceps-kracht en het uithoudingsvermogen van onderste en 
bovenste extremiteiten vergelijkbaar zijn bij beide groepen. Na 
inspanningstraining als onderdeel van een longrevalidatieprogramma 
wordt er een toename in kracht en uithoudingsvermogen van de 
quadriceps-spier waargenomen, terwijl de spierfunctie van de biceps-
spier niet verandert. 
In de afgelopen jaren is duidelijk geworden dat een verlaging van 
vetvrije massa niet alleen nadelige gevolgen heeft voor de 
spierfunctie en overlevingskans van COPD patiënten met 
ondergewicht, maar ook van COPD patiënten met een normaal 
lichaamsgewicht. Toename van vetvrije massa bij patiënten met een 
sarcopene voedingstoestand heeft derhalve in theorie positieve 
effecten. In hoofdstuk 5 wordt het effect van een 
trainingprogramma met intensieve inspanning op de 
lichaamssamenstelling van patiënten met een normaal gewicht maar 
een verlaagde vetvrije massa onderzocht. Daarnaast wordt de relatie 
tussen veranderingen in voedingstoestand en veranderingen in 
spierfunctie en inspanningsvermogen bestudeerd. In de studie wordt 
een significante toename in lichaamsgewicht geobserveerd, welke 
wordt veroorzaakt door een toename van vetvrije massa. Hoewel de 
vetvrije massa een belangrijke determinant is van 
inspanningsvermogen en spierkracht in deze sarcopene 
patiëntengroep, blijkt de associatie tussen de veranderingen in 
voedingstoestand en functionele capaciteit gering. Daarnaast blijkt 
de leeftijd van patiënten mede voorspellend voor spierkracht en 
inspanningsvermogen, onafhankelijk van de vetvrije massa. 
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Substraatstofwisseling in relatie tot sarcopenie in 
COPD 
Het tweede deel van dit proefschrift bevat de studies naar potentiële 
verstoringen in de intermediaire stofwisseling bij patiënten met 
COPD in relatie tot veranderingen in voedingstoestand. De 
intermediaire stofwisseling wordt in deze onderzoeken gemeten door 
gebruik te maken van stabiele isotopen. Dit zijn natuurlijk 
voorkomende maar zeldzame varianten van atomen met een andere 
massa. Het verschil in gewicht is het gevolg van een verschillend 
aantal neutronen. Door dit massaverschil kunnen deze isotopen 
onderscheiden worden van de natuurlijk veel voorkomende atomen. 
Door moleculen met ingebouwde stabiele isotopen via de bloedbaan 
toe te dienen aan COPD patiënten, is het mogelijk om de 
stofwisseling van deze moleculen in detail te bestuderen. Dit gebeurt 
aan de hand van de verschijningssnelheid van deze moleculen tijdens 
infusie, aangezien de verhouding tussen deze verzwaarde moleculen 
en de natuurlijk in het lichaam voorkomende moleculen een maat is 
voor de stofwisselingssnelheid.  
In hoofdstuk 7 wordt de suikerstofwisseling bestudeerd. Door 
middel van een stabiel isotoop van glucose (suiker) worden 
potentiële verschillen in glucoseproductie van het lichaam gemeten 
tussen COPD patiënten en gezonde vrijwilligers. Op grond van de 
verminderde zuurstofafhankelijke skeletspierstofwisseling, chronisch 
zuurstofgebrek en veranderingen in de voedingstoestand werden er 
aanpassingen in glucosemetabolisme verwacht bij COPD-patiënten. 
De studie laat zien dat de basale glucoseproductie verhoogd is bij 
patiënten met COPD, in vergelijking met gezonde vrijwilligers. Deze 
verhoging is aanwezig in rusttoestand, maar wordt versterkt door 
lichamelijke inspanning. De veranderingen in glucoseproductie zijn 
het meest uitgesproken bij patiënten met ondergewicht, maar treden 
tijdens inspanning ook op bij patiënten met een normaal 
lichaamsgewicht. Daarnaast zijn er indirecte aanwijzingen voor 
verminderde insulinegevoeligheid bij de COPD patiënten met een 
normaal lichaamsgewicht.     
In de hoofdstukken 8 en 9 van dit proefschrift wordt de rol van 
potentiële verstoringen in vet- en spiereiwitafbraak onderzocht 
binnen de veranderingen in voedingstoestand die optreden bij 
sarcopene COPD patiënten.  
Op grond van eerder onderzoek waren er indirecte aanwijzingen dat 
een verminderde vetafbraak bijdraagt aan het ontstaan of 
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handhaven van een relatief grote vetmassa bij COPD patiënten met 
een sarcopene voedingstoestand. In hoofdstuk 8 wordt de 
vetafbraak van sarcopene COPD patiënten vergeleken met die van 
gezonde vrijwilligers met een vergelijkbare Quetelet-index (gewicht 
gedeeld door lengte in het kwadraat). Daarnaast worden mogelijke 
verschillen in vetafbraak gemeten tussen sarcopene patiënten en 
COPD patiënten met ondergewicht en een verlaagde vetmassa. 
Studies bij kankerpatiënten hebben immers aangetoond dat een 
verhoogde vetafbraak een oorzaak kan zijn van verlies aan vetmassa 
en gewichtsverlies. In de huidige studie wordt de vetafbraak 
gemeten met behulp van een stabiele isotoop van glycerol. 
Vetafbraak en concentraties van hormonen betrokken bij de 
vetafbraak (catecholamines, insuline) worden gemeten in rust en 
tijdens stimulatie door middel van een submaximale fietsinspanning. 
Uit het onderzoek blijkt dat de basale en inspanningsgeïnduceerde 
vetafbraak van sarcopene COPD patiënten vergelijkbaar is met de 
vetafbraak van gezonde vrijwilligers. Daarnaast is de vetafbraak van 
COPD patiënten met ondergewicht niet verschillend van de andere 
twee groepen. Desondanks blijken er significante verschillen te 
bestaan in concentraties van hormonen betrokken bij de vetafbraak. 
De resultaten van dit onderzoek suggereren dat verstoringen in de 
vetafbraak niet bijdragen aan verstoringen in de voedingstoestand 
bij patiënten met COPD. Waarschijnlijk is niet het behoud van 
vetmassa maar het selectieve verlies aan vetvrije massa een 
belangrijk mechanisme in het ontstaan van een sarcopene 
voedingstoestand bij patiënten met COPD. Deze hypothese wordt 
onderzocht in hoofdstuk 9, waarin eiwitafbraak en eiwitstofwisseling 
van de skeletspier op het hele lichaamsniveau worden gemeten bij 
COPD patiënten met ondergewicht en een verlaagde vetvrije massa. 
Deze worden vergeleken met de eiwitafbraak en -stofwisseling van 
COPD patiënten en gezonde vrijwilligers met een normaal gewicht en 
vetvrije massa. In de studie wordt een stabiele isotoop van het 
aminozuur 3-methylhistidine gebruikt om de afbraaksnelheid van 
spiereiwit te bepalen. Er wordt geen verschil gevonden in 
eiwitstofwisseling op heel lichaamsniveau tussen de verschillende 
groepen. De skeletspier-eiwitafbraak van patiënten met 
ondergewicht en een verlaagde vetvrije massa blijkt echter duidelijk 
verhoogd ten opzichte van patiënten en gezonde vrijwilligers met 
een normaal gewicht en vetvrije massa. De resultaten van dit 
onderzoek suggereren dat selectief verlies van skeletspiermassa een 
belangrijke rol speelt bij de afname van vetvrije massa en bijdraagt 
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aan het ontstaan van een sarcopene lichaamssamenstelling bij een 
subgroep van COPD-patiënten.  
Naast de groep van sarcopene COPD patiënten (gekenmerkt door 
een verlaagde vetvrije massa in combinatie met een behouden 
vetmassa en lichaamsgewicht) komt er ook vetzucht (obesitas) voor 
bij patiënten met COPD. Mensen met obesitas hebben een sterk 
verhoogd lichaamsgewicht, hetgeen vooral het gevolg is van 
toegenomen vetmassa. Er zijn steeds meer aanwijzingen voor een 
verband tussen COPD en vetzucht, hoewel de aard hiervan 
vooralsnog onbekend is. Hoofdstuk 10 van dit proefschrift biedt een 
perspectief op deze associatie en richt zich vooral op de potentiële 
bijdrage van vetzucht aan de systemische ontstekingsreacties en het 
ontstaan van insuline resistentie binnen COPD. Net als patiënten met 
COPD worden personen met obesitas gekenmerkt door chronische 
ontstekingsreacties op lichaamsniveau; deze dragen bij aan de 
ontwikkeling van verminderde gevoeligheid voor insuline en 
uiteindelijk zelfs aan diabetes mellitus type 2 (ouderdomssuiker). Het 
wordt steeds duidelijker dat chronische ontstekingsreacties bij 
mensen met vetzucht het gevolg zijn van abnormaal functioneren 
van de vetcellen. Deze zijn vergroot en bevatten grote aantallen 
ontstekingscellen, vooral macrofagen. Daarnaast is de afgelopen 
jaren bekend geworden dat vetcellen ontstekingsstoffen (adipokines) 
produceren en uitscheiden. Lokaal zuurstoftekort ten gevolge van 
verminderde doorbloeding van de vergrote vetcellen draagt 
waarschijnlijk bij hieraan. 
COPD patiënten met een relatief of absoluut toegenomen vetmassa 
hebben in theorie een verhoogde kans op abnormale vetcelfunctie. 
De verminderde capaciteit van de skeletspieren om vetten te 
verbranden in combinatie met het verhoogde aanbod van vetten 
vanuit het overtollige vetweefsel leidt tot een verhoogde kans op 
vetstapeling in de skeletspieren. Deze vetstapeling is gerelateerd aan 
het ontstaan van verminderde insuline gevoeligheid. Daarnaast 
treedt er bij patiënten met ernstig COPD regelmatig zuurstoftekort 
op lichaamsniveau op, hetgeen niet het geval is bij gezonde 
personen met vetzucht. Dit systemische zuurstoftekort kan in theorie 
het gebrek aan zuurstof in de vergrote vetcellen van COPD patiënten 
met overmatige vetmassa versterken. Daarmee kan het vrijkomen 
van ontstekingsstoffen uit de vetcellen in de bloedbaan worden 
gestimuleerd en kunnen de chronische ontstekingsreacties in stand 
worden gehouden. Zoals reeds beschreven worden deze chronische 
ontstekingsreacties gezien als een belangrijke factor in het verlies 
van vetvrije massa bij patiënten met COPD en in het ontstaan van 
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een verminderde gevoeligheid voor insuline. Onderzoek naar het 
functioneren van vetcellen in relatie tot zuurstofgebrek en chronische 
ontstekingsreacties op lichaamsniveau bij patiënten met COPD is een 
uitdaging voor de nabije toekomst; mogelijk geeft dit meer inzicht in 
de ontwikkeling van systemische effecten van de aandoening, zoals 
verlies aan vetvrije massa. 
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Dankwoord 
Nadat u de inhoud van de voorgaande tien hoofdstukken en de 
samenvatting aandachtig heeft doorgenomen, is het nu tijd voor een 
luchtiger hoofdstuk. Hierin wil ik de personen bedanken die mij 
gedurende het lange promotietraject hebben geholpen. Hoewel mijn 
naam de kaft van dit proefschrift siert, was de voltoo ng hiervan 
onmogelijk geweest zonder de bijdrage en steun van deze personen. 
 
Allereerst uiteraard dank aan mijn promotoren, prof. dr. ir. Annemie 
Schols en prof. dr. Emiel Wouters. Beste Annemie, bedankt dat je mij 
betrokken hebt bij de prachtige onderzoekslijn die jij samen met 
prof. dr. Wouters in de afgelopen decennia vorm hebt gegeven en die 
inmiddels zoveel waardevolle resultaten heeft opgeleverd. Als geen 
ander weet jij onderzoekers met diverse achtergronden en 
aandachtsgebieden met elkaar aan tafel en vervolgens aan het werk 
te krijgen. Daarbij houd je niet alleen de individuele belangen van de 
betrokkenen op korte termijn in het oog, maar heb je ook altijd een 
duidelijke visie op wetenschappelijke ontwikkelingen en samenwer-
kingsverbanden op de langere termijn. Je enthousiasme en 
creativiteit binnen het onderzoek, ervaring en onvoorwaardelijke 
steun die ik altijd van jou heb gevoeld, waardeer ik enorm. Hoewel 
mijn promotietraject veel langer heeft geduurd dan gepland, toonde 
je altijd begrip voor de opgelopen vertraging ten gevolge van mijn 
opleiding of privé aangelegenheden. Naast je promotorschap, heb ik 
ook genoten van je fanatisme op de squash- en tennisbaan. De boog 
kan immers niet altijd gespannen staan…  
Prof. dr. Wouters, ik wil u hartelijk danken voor de kansen die u mij 
in de afgelopen jaren heeft geboden. Zonder u als promotor, opleider 
en voorbeeld, was ik niet waar ik nu ben. Als wetenschapper voert u 
al jaren de frontlinie van het internationale COPD onderzoek aan, 
waarbij uw lezingen, publicaties en visie immer toonaangevend en 
richtinggevend zijn voor collega’s. Uw kritische en altijd waardevolle 
begeleiding van mijn onderzoek heb ik bijzonder gewaardeerd. Ook 
bent u ondanks uw ontelbare bezigheden nauw betrokken geweest 
bij de dagelijkse praktijk van mijn opleiding in het azM. Tenslotte wil 
ik u bedanken voor de geboden gelegenheid om mij op internationaal 
niveau te presenteren en ontwikkelen.  
 
De leden van de beoordelingscommissie bedank ik voor de kritische 
beoordeling en goedkeuring van het manuscript. Naast voorzitter 
prof. dr. ir. R.P. Mensink bestond de commissie uit prof. dr. S.D. 
Anker (Campus Virchow-Klinikum, Berlijn, Duitsland), prof. dr. M.P. 
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Van Dieijen-Visser, prof. dr. M.I. Polkey (Royal Brompton Hospital, 
London, Verenigd Koninkrijk) en prof. dr. C.D.A. Stehouwer.  
 
Klinisch onderzoek is mensenwerk. Graag wil ik dan ook de COPD 
patiënten en gezonde vrijwilligers bedanken die hebben 
deelgenomen aan de studies die beschreven zijn in dit proefschift. 
 
Graag wil ik ook mijn collega onderzoekers van de afdeling 
Longziekten bedanken. Toen ik in 2000 begon aan mijn 
promotieonderzoek, was ik als jonge dokter een vreemde eend in de 
bijt in de onderzoekerskamer aan het Peter Debyeplein, waar 
onderzoekers met diverse achtergronden verschillende systemische 
aspecten van COPD probeerden te ontrafelen. Door de uiteenlopende 
expertise en vaardigheden van de diverse onderzoekers had ik al 
snel het gevoel deel uit te maken van een team, waarbinnen 
iedereen zich optimaal kon ontplooien zonder steeds opnieuw het 
wetenschappelijke wiel te hoeven uitvinden. Naast Eva Creutzberg, 
Mieke Dentener, Mariëlle Engelen, Ramon Langen, Jos van Der 
Velden, Marja Vermeeren en Juanita Vernooij wil ik in het bijzonder 
Erica Baarends en Roelinka Broekhuizen bedanken. Met behulp van 
data verkregen door hun inspanningen, kreeg mijn onderzoek een 
snelle start. Speciale dank ook voor Erica Rutten, die mij hielp bij de 
opzet en uitvoering van de metabole studies.  
 
Prof. dr. Hans Sauerwein (Academisch Medisch Centrum, 
Amsterdam) dank ik voor zijn bijdrage aan de metabole studies en 
introductie in het onderzoek met stabiele isotopen. Mariette 
Ackermans wil ik bedanken voor de analyse van de bloedmonsters. 
 
Mijn collega arts-assistenten van de afdeling Longziekten (Jaclyn, 
Karin, Khaled, Lowie, Mariana, Michiel, Robert, Ruud, Selene, 
Tamara, Vivian, Xiang) bedank ik voor de mogelijkheid om zo nu en 
dan een stapje terug te doen uit de hectiek van de dagelijkse zorg 
om tijd te besteden aan mijn promotieonderzoek. En bedankt voor 
de dagelijkse gezelligheid natuurlijk. De stafleden, verpleging en 
longfunktie laboranten van de afdeling Longziekten wil ik bedanken 
voor de prettige sfeer waarin mijn opleiding heeft plaatsgevonden en 
voor de plezierige samenwerking in de afgelopen jaren. Daarnaast 
bedank ik de dames van het secretariaat voor hun ondersteuning. 
 
De medewerkers van CIRO Horn, in het bijzonder de afdelingen 
fysiotherapie/bewegingsagogiek en diëtetiek, wil ik bedanken voor 
hun hulp bij het verzamelen van de gegevens over spierfunktie, 
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uithoudingsvermogen en lichaamssamenstelling in het kader van 
mijn onderzoek.  
 
Een speciaal woord van dank gaat uit naar mijn paranimfen, Jeroen 
Jansen en Harry Gosker. Ik heb lang zitten denken over mogelijke 
overeenkomsten tussen jullie, omdat het me leuk leek daar iets over 
te schrijven. Ik moet echter tot de conclusie komen dat jullie 
significant verschillend zijn. Waar Jeroen bekendheid verwierf als 
onderwerp van een artikel in een lokale krant getiteld ‘Inbreker blijkt 
uitbreker’, heeft Harry vele wetenschappelijke artikelen gepubli-
ceerd. Terwijl Harry jaren geleden op de squashbaan bijna 
gereanimeerd diende te worden, wint Jeroen al jaren elke denkbare 
sportactiviteit met ogenschijnlijk minimale inspanning. Jeroen, de 
vraag of jij mijn paranimf wilde zijn, heb je al jaren geleden (na een 
paar pilsjes?) beantwoord. Ik ben blij dat je deze rol wilt vervullen. 
Pas je op dat ik niet struikel tijdens mijn verdediging of ander 
gestuntel uithaal? Harry, als kamergenoot aan het begin van mijn 
promotieonderzoek heb ik veel van je kunnen afkijken en hebben we 
veel lol gehad. Naast overeenkomsten in het COPD onderzoek, 
bleken we allebei van dezelfde slechte films en sportieve activiteiten 
te houden. Help je me ook weer als mijn computer crashed tijdens 
het lekenpraatje?    
 
Groot is mijn dank richting mijn ouders. Pa en ma, jullie hebben mij 
altijd de ruimte hebben gegeven om mijn keuzes op gebied van prive 
en opleidingen tot een succes te maken. Op alle mogelijke manieren 
staan jullie altijd onvoorwaardelijk voor mij klaar. Zonder mij ooit in 
een bepaalde richting te hebben gedwongen, weet ik dat jullie trots 
zijn op de afronding van mijn proefschrift en specialisatie. Zonder 
jullie hulp en liefde was het onmogelijke geweest de graad van 
Doctor te behalen. 
 
Tenslotte wil ik mijn liefje bedanken. Lieve Mara, door de combinatie 
van een hectische opleiding met onregelmatige werktijden en een 
promotie-onderzoek was er heel weinig tijd voor jou. Vaak stond je 
er alleen voor. Bij herhaling heb je ondervonden dat een artikel 
weliswaar ‘klaar’ was, maar dat dat niet betekende dat het ook 
‘gereed’, ‘af’ of ‘voltooid’ was. Er leek nooit een einde te komen aan 
mijn promotie-onderzoek en vaak ging mijn wetenschappelijk 
ambitie ten koste van jou. Je zult het bijna niet geloven, maar nu 
ben ik ECHT klaar! Bedankt voor je liefde, steun en trouw. Ik ben 
gelukkig met jou en Marijn (en Luna en Jet). Laten we iets leuks gaan 
doen!           
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Curriculum vitae 
Frits Franssen werd geboren op 19 november 1973 in Heerlen. In 
1992 behaalde hij zijn Gymnasium-ß diploma aan het Bernardinus 
College in Heerlen. In hetzelfde jaar begon hij aan de studie 
Gezondheidswetenschappen aan de Universiteit Maastricht. Na het 
behalen van de propedeuse, koos hij in 1993 voor de afstudeer-
richting Milieugezondheidkunde. In 1994 werd hij toegelaten tot de 
Geneeskunde opleiding aan de Universiteit Maastricht. Tijdens zijn 
studie was hij actief lid van O.M.S.G. Plutarchus en vervulde hij 
verscheidene bestuursfunkties. Een onderzoeksstage op de afdeling 
Longziekten resulteerde in een abstract voor het congres van de 
European Respiratory Society in 2000 met als titel Isokinetic muscle 
performance and 12 minute walking distance predict daily activity 
pattern in patients with COPD .  Na het behalen van zijn artsdiploma, 
startte Frits in september 2000 met zijn promotieonderzoek onder 
begeleiding van prof. dr. ir. A.M.W.J. Schols en prof. dr. E.F.M. 
Wouters. In februari 2002 begon hij aan de opleiding tot longarts in 
het academisch ziekenhuis Maastricht. Daarnaast neemt hij sinds 
2005 deel aan een Europees netwerk van jonge onderzoekers op het 
gebied van COPD en asthma. Ook was hij enkele jaren actief binnen 
het bestuur van de arts-assistentenvereniging van het academisch 
ziekenhuis Maastricht, waarvan de laatste tijd als voorzitter. Tevens 
is hij lid van Junior Chamber International regio Maastricht. In 2007 
trouwde Frits met Mara Crombach en zij hebben 1 zoon, Marijn 
(2008). Hobbies van Frits zijn muziek luisteren, hardlopen, squashen 
en backpacken.  
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